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Summary
The membrane attack complex (MAC) has been implicated in the pathology associated with 
several immune-mediated diseases and clinical interventions. However, there are currently no 
drugs available that specifically inhibit MAC assembly. The aim of this thesis was to generate 
and characterise agents that inhibit the activity of C6, a component of the MAC, with a view to 
testing them in models in which the development of pathology is mediated by MAC formation. 
Two approaches were taken in generating agents that recognise C6: firstly, phage display was 
used to identify C6 inhibitory peptides. Several C6 inhibitory phage-peptides were identified and, 
whilst the synthetic peptide analogues bound C6, their inhibitory properties were not retained. 
However, motifs within each identified peptide had sequence homology with either C5b or C7, 
two other components of the MAC that bind to C6. This technique may be more useful in 
determining the domains of C5b and C7 that interact with C6 to form the MAC.
For the second approach, monoclonal antibodies were raised against rabbit, rat, mouse and 
human C6. The two most interesting antibodies were raised against human C6 and inhibited 
complement-mediated haemolysis in a cell-based assay. Both of these antibodies were species 
specific, excluding the possibility of testing their therapeutic properties in animal models of 
complement-mediated disease. Instead, an ex vivo model of cardiopulmonary bypass was 
established and used to test the ability of these antibodies to block soluble C5b-9 formation. 
Neither antibody inhibited soluble C5b-9 formation, suggesting that they might be interfering with 
the insertion of C6 into the cell membrane during MAC assembly. Nevertheless, the agents 
described in this thesis demonstrate that it is possible to specifically inhibit MAC formation and 
the reagents are now in place to test the proof-of-concept for therapeutic targeting of C6 in 
complement mediated disease.
1Chapter 1: General Introduction
1.1. The Complement System
Complement (C) is so-called as it was originally discovered as a heat-labile component of normal 
plasma that was able to augment the opsonization of bacteria by antibodies1. Thus it was said to 
‘complement’ the adaptive immune system2.
C plays a central role in innate immune defence against invading pathogens through C fixation and 
opsonization, and by triggering local acute inflammation. It is involved in the induction of antibody 
responses linking innate and adaptive immunity and also in the clearance of immune complexes 
and inflammatory products6. This suggests that aspects of the C system pre-date the adaptive 
immune system in evolutionary terms, although it is likely that both systems have evolved together.
The effects of C are mediated through three activating enzymatic cascades: the classical, alternative 
and mannose-binding lectin (MBL) pathways. All of these cascades activate a common non-enzymatic 
cascade, the terminal pathway, which results in the assembly of the membrane attack complex (MAC), 
the insertion of which into the cell membrane leads to the formation of a transmembrane pore7'15. If 
sufficient numbers of MAC are present in the cell membrane, then cell death occurs due to lysis16. In 
order to prevent inappropriate C activation, the C cascade is highly regulated by a number of regulatory 
proteins (C regulators), acting at multiple levels of the system.
If C activation occurs over a sustained period of time and the C regulators fail to adequately control 
this, then C-mediated damage can occur to tissues and organs. Examples of the development of such 
pathologies include rheumatoid arthritis (RA), multiple sclerosis (MS) and glomerulonephritis. In these 
situations, intervention with therapies that specifically inhibit C activity and thus subsequent C-mediated 
damage are clinically beneficial. Although anti-C therapies are in development, these tend to target the 
activating pathways, even though it is likely that the activity of the MAC is responsible for most of the 
tissue damage. The purpose of this thesis is to investigate strategies for inhibiting the activity of one of 
the MAC components, C6, thereby preventing MAC formation. To help with understanding the 
rationale behind this approach, this chapter describes the C system and the various attempts to make 
C inhibitors so far.
1.1.1. The C Activating Pathways
Although the activating pathways of C are triggered by different stimuli, the consequences of them are 
all the same. That is, to enzymatically activate C3 to C3b, which then binds to the surface membranes 
of microorganisms so that they are targeted to cells expressing C3 receptors (C3R), such as
i
2phagocytic cells17. In addition, the activation pathways cleave C5, releasing a soluble peptide, C5a 
and creating C5b. C5a activates phagocytic cells, mast cells and basophils, resulting in the recruitment 
of more plasma proteins and phagocytic cells to the site of C activation18. C5b is the first component 
of the terminal pathway, which results in MAC formation and consequently, cell lysis19. Further 
information about the characteristics of the C proteins is presented in Table 1.1.
1.1.1.1. The Classical Pathway
The Classical pathway is triggered by the binding of C1, a multimolecular complex, to the Fc (constant 
fragment) regions of IgG or IgM antibodies that are complexed with antigen (immune complex) 2°-22. C1 
comprises the recognition protein C1q and a catalytic subunit, C1r2C1s2 that is a calcium-dependent 
tetramer containing two molecules each of the serine proteinase proenzymes C1r and C1s23-24. C1q is 
a member of the collectin family (collagenous lectins) and is a large protein (460 kDa), comprising a 
bundle of six collagen-like triple helices, each ending in a C-terminal globular domain, so that the 
complex resembles a bunch of six tulips 25-27. It is these globular domains that recognise the Fc regions 
of IgM and IgG and bind to the antigen-antibody complex. The catalytic subunit C1r2C1S2 spatially 
traverses the tulip structure of C1q 28-29 and the binding of a minimum of two of the globular domains of 
C1q to Fc domains is required to bring about the conformational change of C1q so that it binds 
C1r2C1S2more tightly, resulting in the autoactivation of C1r, which in turn enzymatically activates C1s 
28. Activation requires the participation of at least two IgG molecules, or one pentameric IgM molecule 
30. Therefore, IgM molecules are more effective in activating the C system than are IgG molecules; 
further, the human IgG subclasses differ in their efficiency for binding and activating C1q, such that 
they can be ranked in the order lgG3>lgG1>lgG2; lgG4 has no activating ability31. Various 
substances, such as bacterial lipopolysaccharide, viral membranes, man-made liposomes, nucleic 
acids and components of damaged cells are also capable of activating C1 in an antibody-independent 
manner. Such activators may also be of physiological and pathological significance32.
Activated C1s catalyses cleavage of C4 at a single site in the a chain, resulting in the release of C4a (a 
small soluble peptide with no defined function) and C4b, within which a labile intramolecular thioester 
bond becomes exposed. The thioester bond enables C4b to covalently bind to a hydroxyl or amino 
group on the cell surface33 in close proximity to C1q. The membrane bound C4b, in the presence of 
Mg2+ions, binds C2 near its amino terminus and presents it for cleavage by C1s, yielding C2a and C2b 
34'36. C2a remains bound to C4b, forming C4b2a, a complex with proteolytic activity for C3 and known 
as C3 convertase36. The C3 convertase cleaves C3 into two fragments: a small soluble peptide, C3a, 
that is an anaphylatoxin and C3b. A labile thioester bond becomes exposed in C3b42, through which it
3Table 1.1 The component proteins of the complement system
Component Structure Plasma
concentration
mg/l
Molecular
weight
(kDa)
Gene location 
Chromosome (Chr)
Classical pathway:
C1 3 subunits:C1q 180 460 C1q A, B and C
C1qr2S2 C1r 80 chains; Chr 1p34-36:
C1s 80 C1r, C1s; Chr 12p13
C4 3 chainsia 600 97 2 genes (C4A and
P 75 C4B) in Major
Y 33 Histocompatability
Complex (MHC) Chr 6
C2 Single chain 20 102 MHC Chr 6
Alternative pathway:
Factor B Single chain 210 93 MHC Chr 6
Factor D Single chain 2 24 Chr 19
Properdin Oligomers of 
identical chains
5 53 (each chain) X chromosome
Mannose Binding Lectin pathway
MBL Oligomers (1-6) 
oftrimersof 
identical chains
150 (varies) 75 (each trimer) Chr 10
MASP-1 2 chains: A, B 6 91 Chr 3q27
MASP-2 2 chains: A, B ? 78 Chr 1p36.23-31
MASP-3 2 chains: A, B 101.5 Chr 3q27
Common
C3 2 chains: a 1300 110 Chr 19
3 75
Terminal pathway
C5 2 chains 70 115
75
Chr 9
C6 Single chain 65 120 Chr 5
C7 Single chain 55 110 Chr 5
C8 3 chains:a 55 65 a,P; Chr 1: y; Chr 9
P 65
Y 22
C9 Single chain 60 69 Chr 5
Table adapted from Complement Regulatory Proteins, Morgan BP and Harris CL, page 3 37; 
additional information from Contemporary Immunology: Therapeutic Interventions in the 
Complement System, Chapter 1: Complement as a regulatory and effector pathway in human 
diseases, page 3 38, Stover et a l39, Presanis et a l40 and Mullighan et a/.41.
4can bind covalently either to cell membranes in the same way as C4, or to the activating C4b2a 
complex to form the C5 convertase (C4b2a3b)4346. C5 can then bind non-covalently to a site on C3b 
in the C5 convertase and be cleaved by C2a within the convertase complex. This results in the release 
of C5a, a soluble molecule with potent chemoattractant and anaphylatoxic properties. C5b, the first 
component of the terminal pathway, is also generated, but remains attached to C3b on the cell surface 
during the early stages of MAC assembly. This is shown in Figure 1.1.
Although C3, C4 and C5 share structural similarities and are likely to have evolved from a common 
ancestor 33,42,47,48 C5b does not contain a labile thioester bond47, but instead contains a labile 
hydrophobic surface binding site and a site for binding C6 that become exposed following the cleavage 
of C5 21.
1.1.1.2. The Mannose-Binding Lectin (MBL) Pathway
The MBL pathway is the most recently discovered activation pathway49'52. MBL is a member of the 
collectin family; its structure is homologous to C1q — multimeric molecules with globular binding regions 
and collagenous stalks. MBL acts in the same way as C1q, but instead of binding antibodies, it binds 
to arrays of terminal mannose groups s3-54 and N-acetyl glucosamine residues, which are present in 
large quantities on viral surfaces and bacterial cell walls. MBL is an oligomer of structural subunits, 
each of which comprises three identical 32 kDa polypeptides 55-56. Several sizes of MBL oligomer have 
been identified57. Like C1q, MBL is associated with serine protease proenzymes: MBL-associated 
serine proteases (MASPs) and the overall structure of these resemble those of C1r and C1s5U0. Two 
have been described, designated MASP-1 and -2 58-61. MASP-1 can be alternatively spliced, resulting 
in MASP-357 and a truncated form of MASP-2 has been identified - a non-protease, small MBL- 
associated protein (sMAP or Map19) 62-63. Two MASPs will associate with MBL in a similar manner to 
the interaction between C1q, C1r and C1s. The association of the MASPs with MBL is dependent on 
the MBL oligomer size57. The detailed molecular events of this activation pathway are yet to be 
elucidated, although it is known that the binding of MBL to microbial carbohydrates activates the 
MASPs 64-65. MASP-2, like C1s, cleaves and activates C4 and C2 to form the classical pathway C3 
convertase, C4b2a 58.6M9, whilst MASP-1 directly cleaves C3 57-66'70'71, resulting in the activation of the 
alternative pathway70. This is shown in Figure 1.1.
1.1.1.3. The Alternative Pathway
The alternative pathway is another antibody-independent C activating pathway, but distinct from both 
the classical and MBL-activating pathways. It is initiated by C3b, which can either be present in the 
fluid or bound through its thioester bond to an activating surface. Factor B (fB), which is functionally 
analogous to C2 and shares a 40% sequence homology, binds C3b in a Mg2+-dependent manner. fB
Figure 1.1 The Activation pathways of the Complement system 
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5is then cleaved by the serine protease, factor D (fD), yielding C3bBb, where Bb now has an exposed 
serine protease domain and a smaller fragment, Ba, is released72. C3bBb is also a C3 convertase, 
which is equivalent to, but distinct from, that of the classical pathway, although they both cleave C3 at 
the same site, producing C3b. This C3b molecule can bind in close proximity to the C3bBb complex 
and together, these form the C5 convertase (C3bBbC3b), although most C3b doesn’t become part of 
the convertase. This newly bound C3b molecule then binds to C5, allowing Bb in the adjacent C3bBb 
complex to cleave it. This is shown in Figure 1.1. The site of cleavage in C5 is identical to that 
exploited by C2a in the classical pathway C5 convertase (C4b2a3b). C5a is released and labile 
membrane- and C6-binding sites are exposed on C5b as described above for the classical pathway. 
The origin of the initiating C3b of the alternative pathway can be as a product of the classical, MBL or 
alternative pathways so that an amplification loop is generated 73>74. However, in biological fluids, C3 
continually undergoes slow, spontaneous hydrolysis of its intramolecular thioester bond, a process 
termed ‘tickover1 47>74-76 inducing a conformational change in the protein to yield a C3b-Iike molecule, 
C3(H20), which binds fB to undergo cleavage by fD as described above 73-74. Alternatively, the 
thioester bond of C3 can be directly attacked by a hydroxyl group on the other surface rather than by 
water, resulting in covalent binding of C3b-like C3 to the surface.
‘Tickover’ deposition of C3b occurs on all host cells exposed to C but does not result in continued 
activation because the surface features do not favour efficient binding of fB and any bound C3b is 
rapidly degraded. The surfaces of many microorganisms and foreign cells do favour binding of fB, due, 
for example, to the presence of lipopolysaccharides of gram-negative bacteria (endotoxins) and cell 
wall techoic acids from gram-positive bacteria. Following the binding of fB to such surfaces, C3b can 
be rapidly generated and deposited on these surfaces, thereby amplifying C activation. In this way, it is 
thought that the alternative pathway acts as an effective defence against invading microorganisms 
before an immune response against them can be mounted.
The effectiveness of the alternative pathway is further improved by properdin, a basic oligomeric 
glycoprotein, generally consisting of between two and four monomers77. Each monomer comprises six 
tandem repeats of thrombospondin repeat (TSR) modules78 that form oligomers through non-covalent 
interactions. Properdin protects C3b from degradation by the regulatory proteins factor I (fl) and H (fH), 
and also inhibits the dissociation of C3b and Bb, thereby prolonging the half-life of the C3 convertase
79,80.
61.1.2. The Terminal Pathway
All the terminal complex components; C6, C7, C8 and C9 are hydrophilic plasma proteins and comprise 
a single chain, apart from C8, which is composed of three chains, designated a, p and y. C6, C7, the a 
and p chains of C8, as well as C9, share a structural homology81. C8y is covalently linked with C8a, 
but is not homologous with any other C components82. The modular structures of these proteins are 
depicted in Figure 1.2, along with the C5a’-chain, the region of C5b that interacts with C6 and 01. 
Whilst still attached to C3b in the C5 convertase, C5b binds to circulating C6 at the cell surface through 
a ‘metastable’ binding site that is not accessible in intact C521. However, the precise sites of C5b, C6 
and 01 that interact with each other are not yet fully characterised. The FIMs (factor I module) 
domains of C6 and 01 can bind to the C345C domain of C5b reversibly s3-84, although the FIMs 
domains enhance, but are not essential for the activity of C684 This has lead to the suggestion that 
during MAC formation the FIMs in C6 form an important but not crucial bond with C5b, and another 
domain of C6 binds to a metastable binding site within C5b. The FIMs domains of 01 then displace the 
FIMs domains of C6, so that 01 is incorporated into the complex 83>85. When circulating 01 binds to 
C5b-6, two changes occur simultaneously. The C5b-7 complex is released from the C5 convertase to 
the fluid phase and a further conformational change in the complex is induce^, exposing an unstable 
membrane binding site in the C5b-7 intermediate86. The membrane-binding site is prone to rapid 
decay, either by hydrolysis or through the interaction with a C regulatory protein, unless it binds to a 
membrane. In addition to the target cell membrane, it is possible for the C5b-7 complex to bind to an 
adjacent host cell membrane, which can result in the damage or lysis of the cell if the MAC forms; this 
is referred to as ‘bystander lysis’ 10-87-88. Studies show that MAC formation is very inefficient in 
comparison to the formation of other C products89. C8 then binds to 01 in the C5b-7 complex through 
its p chain. This results in the complex C5b-8 embedding further into the membrane to form small 
pores, causing the cell to become ‘slightly leaky’ 90. Finally, a molecule of C9 enters the C5b-8 
complex and binds to the a  chain of C8. Binding occurs via the MAC/perforin (MACPF) domain, 
together with the N-terminal thrombospondin-1 (TSP-1) and low-density lipoprotein receptor class A 
(LDLRA) domains of C991. The C9 molecule then unfolds, elongating from a globular, hydrophilic form 
to an amphipathic form that traverses the cell membrane, causing the membrane to leak even more. At 
the same time, multiple binding sites for C9 become exposed within the molecule, enabling further C9 
molecules to bind, unfold and insert into the membrane. As more C9 molecules insert into the C5b-8 
complex, the lesion becomes larger and a transmembrane pore forms, known as the membrane attack 
complex (MAC)11-12-19*88. This is shown in Figure 1.3.
Figure 1.2 Schematic modular structures of C5a’-chain, C6, C7, C8 and C9
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Figure 1.3 The Terminal Pathway of the Complement System
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7There is debate over the mechanism by which the MAC causes cell lysis. One theory is that the MAC 
forms a rigid ring around a stable transmembrane pore and this in some way is borne out by in vitro 
studies; when C9 molecules were incubated in the presence of Zn2+ ions, detergent-resistant 
aggregates of 12 or more C9 molecules formed in ring-like structures resembling the MAC lesion seen 
in the cell membranes of C iysed cells 11.12,88,92. Another theory is that the MAC induces areas of lipid 
perturbation in the membrane, demonstrated as ‘leaky patches’ 93. This is supported by the 
observation that the C5b-8 complex induces membrane leakiness, as described above, and also that a 
functional transmembrane pore can be formed when just one or two C9 molecules bind to the C5b-8 
complex 8-94-95. Nevertheless, it is through these physical or functional transmembrane pores that ions 
and small molecules pass and the cell ultimately lyses, due to osmotic swelling 96-97.
Nucleated cells are able to evade cell death by removing the membrane-inserted MAC and restoring 
the integrity of the cell membrane, a process termed recovery 98-i°°. This can be achieved either 
through endocytosis and subsequent degradation, or by shedding on membrane vesicles i°i-i°3.
Human neutrophils can shed approximately 25,000 MACs from their cell membranes without lysing, 
and this is temperature and Ca2+-dependent 98,104,105.
The MAC is able to exert nonlytic effects on many cell types, most notably inducing cell activation 
events, including the release of inflammatory mediators, secretion of cytokines, proliferation and many 
other proinflammatory responses i°6-107. The specific signalling pathways that are initiated by the MAC 
in order to exert these effects remain to be elucidated. It is increasingly clear that these vary between 
cell types and other conditions, such as the number of MACs on the cell surface may be important as 
well. For example, it is thought that the changes in intracellular Ca2+ levels during pore formation in the 
cell membrane could be a key trigger in some cell types. Others have shown that sublytic doses of the 
MAC exert its effects through nuclear factor-kappaB (NF-kB) activation in endothelial cellsi08. Studies 
indicate that in addition to sublytic doses of C5b-9, membrane-inserted complexes of C5b-7, C5b-8 are 
also able to induce cell cycle activation through signal transduction of the mitogen-activation protein 
kinase (MAPK) pathways in several cell types 109*113. The induction of signal transduction pathways by 
sublytic doses of MAC continues to be a focus of research and could well prove to play an important 
role in the progression or resolution of C-mediated pathologies in addition to the cell lysis that 
undoubtedly occurs.
1.2. C Receptors
The C system plays a central role in innate immune defence against invading pathogens through C 
fixation, opsonization, by triggering local acute inflammation and its involvement in the induction of
8antibody responses These effects are mediated by the products of C activation through their 
interaction with C receptors, which are expressed on a variety of cells. These include several receptors 
for C1q, and receptors for the large and small fragments Of cleaved C3, C4 and C5 (Table 1.2).
1.2.1. C1q receptors
There are four putative receptors for C1q114: calreticulin (CRT; formerly known as collagenous C1q 
receptor (cC1qR)1i5-121, C1q receptor for phagocytosis enhancement (C1qRp; formerly known as 
cC1qR100) 122f binding protein for the globular head of C1q (gC1q-R) 123-124 and C Receptor 1 (CR1 or 
CD35)125, a multifunctional receptor.
CRT and C1qRp bind C1q through the collagen tail, but will also bind other collectins (collagenous 
lectins) in this way126, including MBL and pulmonary surfactant protein A (SPA), which are both 
involved in host defence5S. CRT is a multifunctional protein and is primarily an intracellular protein that 
Is involved in glycoprotein quality control in the endoplasmic reticulum. The expression of C1qRp is 
restricted to neutrophils and monocytes 127-128.
gC1q-R binds C1q through the globular head of C1q and is a highly charged, acidic glycoprotein 
expressed on leukocytes, platelets and endothelial cells with a putative molecular weight of 33 kDa129- 
133. Further studies demonstrated that gC1q-R was only detectable on healthy cultured cells following 
permeabilization of the cell membrane, indicating that it was an intracellular protein134 Subsequently, 
it was shown that the leader sequence of gC1q-R is a mitochondrial targeting sequence and that it is 
expressed in mitochondrial compartments13S. However, confusion over the full in vivo functions of 
gC1q-R remain, as it has been shown that some C1q-mediated events, such as the enhanced 
expression of P-selectin by platelets, as well as chemotaxis by mast cells are inhibited by anti-gC1q-R 
antibodies136.
1.2.2. C Receptor 1 (CR1, CD35), a receptor for C1q, C3b and C4b
CR1 is a membrane bound molecule, comprising three domains, a cytoplasmic domain, a 
transmembrane region and an extracellular domain and is expressed on B-lymphocytes, monocytes 
and neutrophils. It binds to the collagen tails of C1q via long homologous repeat (LHR-) D. It has also 
been shown to be a receptor for MBL137 and acts as receptors for C3b and C4b, discussed below. 
Although these receptors for C1q have been identified, it is likely that there are further C1q receptors. 
Their roles in C1q-mediated cell activation and other events remain to be elucidated fully.
CR1 is also a receptor for both C3b and C4b, which bind at different sites of the molecule138. Its major 
function as a receptor is to enable the transportation of immune complexes (coated in C3b and C4b) on
Table 1.2 Receptors for C components, fragments and complexes
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Receptor Ligand Characteristics Distribution
Calreticulin C1q, collagenous region 70 kDa Broad
C1qRp C1q, collagenous region 100kDa, acidic glycoprotein Monocytes,
neutrophils
gCIqbp C1q, globular heads 33 kDa, 80 kDa Leukocytes, platelets
FHR factor H Not determined Broad
CR1
(CD35)
C1q, C3b, C4b 180-220 kDa, single chain, 
transmembrane, approximately 
30 short consensus repeats 
(SCRs)
Erythrocytes, B cells,
neutrophils,
monocytes.
CR2
(CD21)
C3d (and EBV) 145 kDa, single chain, 
transmembrane, 15-16 SCRs
B cells, follicular 
dendritic cells, 
epithelia, glia.
CR3
(CD11b/18)
iC3b (and matrix) Heterodimer Myeloid and natural 
killer cells.
CR4
(CD11c/18)
iC3b, C3dg Heterodimer Myeloid,
macrophages.
C5aR
(CD88)
C5a 40 kDa, 7 transmembrane 
spanning
Neutrophils, 
macrophages, mast 
cells, muscle.
C3aR C3a Approximately 60 kDa, 7 
transmembrane spanning
Neutrophils, 
macrophages, mast 
cells, muscle.
Taken from The Complement System: a brief overview from Complement Regulatory Proteins by 
Morgan and Hams, p1937.
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erythrocytes through the circulation to the spleen and liver, where they are cleared by mononuclear 
cells17. CR1 is also a C regulator and this is discussed later.
1.2.3. C Receptor 2 (CR2, CD21)
CR2 is highly homologous to CR1, although it does not have any C regulatory activity. It is the receptor 
for C3d, produced when C3b is cleaved by fl and serum proteases139. Although the role of CR2 is 
unclear on most cell types, on B cells it is known to be involved in the induction of antibody responses
139,140,
1.2.4. C Receptors 3(CR3, CD11b/CD18) and 4(CR4, CD11c/CD18)
CR3 and CR 4 are both members of the p2 integrin family of cell adhesion molecules141*144. CR3 is 
the receptor for iC3b and various extracellular matrix proteins, enabling myeloid and natural killer cells 
to bind to matrix and to C-opsonized surfaces. CR4 is the receptor for iC3b and C3dg and is thought to 
function in a similar manner to CR3.
1.2.5. The C3a (C3aR) and C5a (C5aR, CD88) receptors
The C3aR145 and C5aR146 are receptors for C3a and C5a respectively. They are both members of the 
7-transmembrane-spanning receptor family and are highly homologous with each other. It is through 
the C5aR that C5a exerts its powerful effects of inducing migration and chemotaxis of neutrophils147. 
C5a, acting via C5aR, can also upregulate neutrophil surface expression of CR1 and CR3148>149, 
resulting in the recruitment of phagocytic cells in inflammation and rendering them fully active in 
phagocytosis.
1.3. C Regulation
There is the potential for host cells to be attacked by C products that could lead to the C-mediated 
destruction of host tissues. Therefore, the C system is strictly regulated through the inactivation of its 
activated components by C regulatory (C reg) proteins. Some are bound to the cell membrane on 
which C is activated, whilst others are in the fluid phase. C regs can be further divided into two groups; 
those that are encoded within the Regulators of C Activation (RCA) gene cluster, on the short arm of 
chromosome 1, and those that are not 15°.
Proteins of the RCA cluster share a structural homology with each other -  they are either partly or 
entirely made up of repeating domains called short consensus repeats (SCRs). Each SCR has a loop 
structure held in place by disulfide bonds between the conserved cysteines-1 and -3, and -2 and -4 
151. The SCR motif and variations of it are common to many C proteins as well as a large number of 
non-C proteins28. RCA cluster proteins all bind and/or regulate C3 and C4 activation products152,
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suggesting a common evolutionary ancestor153. All the C regulators are summarised in Table 1.3 and 
are described in the following discussion in the order in which they act on the C pathway.
1.3.1. Inhibitors of C Activating Pathways
1.3.1.1. C1-inhibitor
C1-inhibitor (C1inh) is a serine protease inhibitor (serpin) present in the plasma that inhibits the 
activated C1 complex 154-155. It binds strongly to the activated C1s and C1r subunits of C1 156-157, 
resulting in their dissociation from C1q, thereby inactivating C1 158-159. It also prevents the spontaneous 
autoactivation of the classical pathway by forming a stable complex with native C1 in plasma 16°.
1.3.1.2. Factor I (fl)
fl is a plasma serine protease that is dependent on the presence of specific cofactors to catalyse its 
cleavage of C3b and C4b in the convertases of the classical and alternative pathways. It is not 
encoded for in the RCA cluster, but all of its four cofactors are. Two of these cofactors are present in 
plasma: factor H (fH) and C4b binding protein (C4bp); and two are membrane bound: membrane 
cofactor protein (MCP, CD46) and the C receptor, CR1.
1.3.1.3. fH, an alternative pathway fluid phase cofactor for fI
fH binds C3b in the C3 and C5 convertases of the alternative pathway and catalyses the cleavage of 
C3b by f l 161, resulting in the formation of inactive iC3b and the release of C3f162.
1.3.1.4. C4bp, a classical pathway fluid phase cofactor for fl
C4bp binds C4b in the classical pathway C3 convertase and catalyses the cleavage of C4b by fl, which 
results in the release of inactive C4c163. Interestingly, the C and coagulation systems are linked 
through C4bp. The p chain of C4bp (sometimes present - see Table 1.3) enables it to bind protein S 
(not to be confused with S-protein!) a component of the coagulation system164.
1.3.1.5. fH and C4bp are decay accelerators
fH and C4bp also inhibit the C activating pathways independently of fl, by accelerating the dissociation 
of the components of the convertases from each other and this is termed decay acceleration 28-165. 
When the convertases form during C activation, the components they comprise spontaneously 
dissociate from each other over several minutes. By binding tightly to C3b166 in the AP convertases, 
fH displaces the enzymatic component of the complex, Bb or fB. fH also binds C3b in the fluid phase, 
thereby preventing it binding to fB. Likewise, C4bp binds C4b in the fluid phase, preventing C3 
convertase formation and also to C4b in the C3 convertase, displacing C2a.
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Table 1.3 Complement regulatory proteins
Molecule Structure Serum
concentration
(mg/l)
Molecular
Weight
(kDa)
Gene
Location
Target
Plasma.
C1 inhibitor 
(C1 inh)
Single chain 200 76 11 C1
Factor H Single chain 450 150 1 (RCA) C3/C5
convertase
Factor I 2 chains 35 50
38
4 C3/C5
convertase
C4bp 6 or 7 a  chains 
1 or 0 p chain
250 70
45
1 (RCA) 
1 (RCA)
Classical 
pathway C3 
convertase
S protein Single chain 500 83 17q C5b-7
Clusterin 2 chains: 
a
P
50
35
38
8p C5b-7
Carboxypeptidase 
N (CPN)
Dimeric
heterodimer
30 290 ? C3a, C4a, C5a
Membrane
Membrane 
Cofactor Protein 
(MCP) CD46
Single chain 
TM
60 1 (RCA) C3/C5
convertase
Decay
Accelerating 
Factor (DAF) 
CD55
Single chain 
GPI
65 1 (RCA) C3/C5
convertase
C Receptor 1 
(CR1)CD35
Single chain 
TM
- 200 1 (RCA) C3/C5
convertase
CD59 Single chain 
GPI
- 20 11 C5b-8/C5b-9
Table adapted from Complement Regu atory Proteins, Morgan BP and Harris CL, page 3337
TM -  transmembrane; GPI -  glycosyl phosphatidylinositol; RCA -  regulators of complement 
activation gene cluster
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1.3.1.6. MCP, a membrane bound activation pathway cofactor for fl
MCP is a membrane bound regulator that binds to C3b and C4b deposited on host cell membranes, 
which can then be degraded by fl, producing iC3b, C4c and C4d 167«168. Therefore, MCP regulates both 
the classical and alternative pathways. Unlike fH and C4bp, it does not have decay acceleration 
properties. In addition to four amino-terminal SCR domains, MCP comprises a heavily glycosylated 
Ser/Thr/Pro (STP) rich region, a transmembrane and a cytoplasmic domain169. Soluble forms of MCP, 
with C regulatory activity, have been detected in reproductive tract fluids, tears and plasma170-171. 
Studies suggest that MCP is also involved in events unrelated to C regulation, such as sperm-egg 
fusion 172*175.
1.3.1.7. CR1, a membrane bound activation pathway cofactor for Factor I
In addition to being a C receptor for C1q125, C3b and C4b138, CR1 is also a C regulator. It binds C3b 
and C4b within the C3 and C5 convertases from the classical and alternative pathway and acts as a 
cofactor for fl, resulting in the degradation of C3b to iC3b and C4b to C4c and C4d 176-177. The iC3b 
can be further cleaved by fl, with CR1 acting as cofactor to C3c and C3dg 178-180.
1.3.1.8. CR1 is a decay accelerator
CR1 is able to accelerate the decay of the CP and AP convertases in the same way as fH and C4bp, 
by binding to C3b and C4b, thereby displacing C2a and Bb from the convertases. Once it has 
disrupted the convertase it is associated with, it is released from the complex, enabling it to bind and 
inhibit other convertases on the membrane.
1.3.1.9. Decay Accelerating Factor (DAF, CD55)
DAF is a member of the RCA cluster family of proteins. Like MCP, it is membrane bound, but is 
attached to the cell membrane through a glycosyl phosphatidylinositol (GPI) anchor near its C-terminus 
181-182. DAF is not a cofactor for fl, but accelerates the decay of the CP and AP convertases by binding 
C4b and C3b, thereby displacing C2a or Bb respectively 183-185.
1.3.1.10. Carboxypeptidase-N (CPN)
CPN is a plasma zinc metalloprotease comprising two small enzymatically active subunits (CPN1) and 
two large subunits (CPN2) that prevent the enzyme being degraded186. It is a member of a large 
family of carboxypeptidases, where the active site is highly conserved and many of these proteins, like 
CPN, cleave arginine and lysine residues from various peptides. In the case of CPN, it cleaves 
carboxy-terminal (C-terminal) argninine (Arg) and lysine (Lys) residues of peptides found in plasma, 
including inflammatory kinins, creatine kinase MM and the C anaphylatoxins, C3a and C5a187. CPN
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cleaves Arg residues of C3a and C5a, yielding C3adesArg and C5adesArg 188>189, respectively. These 
molecules are largely inactive, although C5a desArg is able to stimulate neutrophils and basophils to 
some degree 19°.
1.3.2. Inhibitors of the Terminal Pathway
There are fluid phase and membrane bound terminal pathway inhibitors.
1.3.2.1. Fluid-phase Inhibitors
1.3.2.1.1. Hydrolysis of the C5b-7 membrane binding site
In the first instance, the C5b-7 complex in the fluid phase is subject to spontaneous decay due to the 
unstable nature of its membrane binding site which is susceptible to hydrolysis86. This significantly 
decreases the amount of complex depositing on the cell surface that can go on and form MAC and 
therefore represents an important means of C regulation.
1.3.2.1.2. C8
Plasma C8 is able to bind the C5b-7 complex in the fluid phase. This blocks the membrane binding site 
in the C5b-7 complex, thus preventing it binding to the cell surface191.
1.3.2.1.3. S-protein (vitronectin)
S-protein 192-193 and vitronectin 194>195 were discovered independently of each other, but it was 
subsequently shown that they were the same molecule 196-197. S-protein has a molecular weight of 
approximately 80 kDa and is widely distributed in biological fluids and tissues 194-198. It binds the fluid- 
phase C5b-7 complex 193>199 at or near the metastable membrane binding site in C5b-7, thereby 
preventing the association of the complex with the membrane 193.199.200, The resulting SC5b-7 complex 
is still able to bind C8 and multiple copies of C9, forming SC5b-9, also known as the terminal C 
complex (TCC) 201-203. Conformational changes in C9 occur exposing neoepitopes identical to those in 
the MAC, although the structure formed does not physically resemble the MAC. This has enabled the 
development of specific assays to monitor the level of C activation in vivo 204-205.
v. >
S-protein binds perforin, a T cell lytic protein and terminal C components, which all share structural 
homology, through its heparin binding domain 206. However, S-protein is primarily an adhesion 
molecule i98-207 and interacts with integrin receptors through its RGD domain 207-209. The multifunctional 
activities of this molecule, together with its high plasma concentration (up to 10 pM)2i0, make it an 
unsuitable candidate for modification as a potential therapeutic.
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1.3.2.1.4. Clusterin
Human clusterin is a heterodimeric serum glycoprotein comprising two subunits, designated a and p 
respectively, each with a molecular weight of approximately 40 kDa211. The two chains are linked by 
disulfidetonds and are heavily glycosylated. Clusterin binds the C5b-7 complex in the fluid phase, 
preventing it binding to the cell membrane212-213. C8, C9 and S-protein are then incorporated, 
generating an inactive fluid-phase SC5b-9 complex identical to that described in the previous section. 
However, there is little evidence that inhibition of C by clusterin is physiologically relevant.
Clusterin is widely expressed in tissues, plasma and seminal plasma and its expression is elevated 
after cell injury or death214-217. This and other evidence has led to suggestions of its involvement in 
lipid transport in the circulation218, male reproduction 219-220, and the neutralization of toxic debris 
released by dead and dying cells214-215. For these reasons, clusterin is an unsuitable candidate for an 
anti-C therapy.
1.3.2.2. Membrane bound regulators
1.3.2.2.1. CD59 (Homologous Restriction Factor-20, HRF-20)
CD59 is a GPI-anchored protein, with a molecular weight of approximately 20 kDa and was originally 
isolated from human erythrocyte cell membranes and discovered independently by various groups221- 
228. As well as being expressed on erythrocytes, CD59 is present on other circulating cells, endothelia, 
epithelia and most organs 225-228. CD59 inhibits MAC formation by binding to the C5b-8 complex 
through the C8a chain. One molecule of C9 can still bind the CD59/C5b-8 complex through the C- 
terminal p domain of C9, but the recruitment of further moiecules of C9 to the complex is blocked 229-231. 
CD59 has been isolated from rats 232, mice 233, pigs 234, sheep 235 and non-human primates 236-237.
The C system is subject to strict control by regulatory proteins. Potentially, these could be modified 
and administered for use as therapies in order to control C activation in disease. Several of these, 
such as C4bp, clusterin and S-protein have important functions outside of the C system and make 
unsuitable candidates. Others, such as CR1 and CD59 are only involved in the C system and are 
therefore much better candidates for modification for drug development.
1.4. Deficiencies in C Components
The study of C component deficiencies has provided many insights into the physiological function of C 
proteins and the roles of C pathways in vivo. This is particularly useful in drug design, when
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considering which part of the C system to target in an attempt to reduce the pathology caused by 
inappropriate C activity.
Inherited deficiencies of all the C proteins and most of the C regulatory proteins have been described 
23®-240. These provide information about the precise functions of particular C components, as their 
deficiency is often associated with the development of a specific pathology. These are summarised in 
Table 1.4.
1.4.1. Deficiencies in Classical Pathway Components
Patients deficient in classical pathway components, i.e. C1, C4 or C2, are predisposed to immune 
complex diseases241, most commonly manifested as Systemic Lupus Erythematosus (SLE) and 
glomerulonephritis, as well as to severe and recurrent pyogenic infections, for example, with 
Streptococcus and Staphylococcus. This emphasises the central roles the classical pathway plays in 
mediating the killing of invading bacteria and in the solubilizing immune complexes 239-240. This is 
probably because the main ways of combating infection by these organisms is by phagocytosis 
followed by intracellular killing. Therefore, any disruption in the pathways that lead to intracellular 
killing, i.e. antibody deficiency, C deficiency or phagocyte function will lead to an increased 
susceptibility to this type of infection 24°.
1.4.2. Deficiencies in Alternative Pathway Components
Deficiencies in the alternative pathway components have been described, but until recently, were 
thought to be rare 242. Homozygous deficiencies in fH are associated with renal disease, 
membranoproliferative glomerulonephritis and atypical haemolytic uraemic syndrome (HUS) 243. 
Heterozygous fH deficiencies are also associated with renal disease, most frequently, atypical HUS243. 
The fact that alternative pathway deficiencies are rarely detected suggests either that these 
deficiencies are most often mild and hence go undetected, or else the consequences are fatal and 
therefore not detected, highlighting the importance of the alternative pathway.
1.4.3. Deficiencies in Terminal Pathway Components
Terminal C component deficient patients often present with recurrent Neisserial infections, most often 
meningococcal infections, but are usually otherwise healthy 147>244. This observation has lead to the 
suggestion that extracellular cytolysis by MAC has evolved as a means of host defence specifically for 
this type of infection 24°.
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Table 1.4 Complement Component Deficiencies
Component Incidence Disease associations
Classical pathway:
C1q > 40 cases described Majority have SLE, predisposition to 
pyogenic infections, e.g. meningitis
C1r/C1s Rare:»10 cases described, 
deficiencies tend to occur 
together
Majority have SLE, predisposition to 
pyogenic infections, e.g. meningitis
C4 Homozygous (C4A + C4B) 
deficiency rare; *  40% of 
the population have 
heterozygous (C4A or C4B) 
deficiency
Homozygous deficiency associated 
with SLE; C4A deficients have 
increased predisposition to SLE; 
tendency for pyogenic infections
C2 Most common homozygous 
C deficiency in Caucasoids; 
1:10 000-1:30 000
Predisposition to SLE, susceptibility to 
pyogenic infections; at least 25% of C2 
deficient patients apparently healthy
Alternative pathway:
Factor D Very rare Neisserial infection
Properdin Not uncommon; inheritance 
is X-linked
Neisserial infection
Activation pathways:
C3 Rare Severe recurrent pyogenic infections; 
glomerulonephritis; SLE
Factor I Very rare -  results in a 
severe acquired C3 
deficiency
Severe recurrent pyogenic infections; 
glomerulonephritis; SLE
Factor H Very rare -  results in a 
severe acquired C3 
deficiency
Severe recurrent pyogenic infections; 
glomerulonephritis; SLE; haemolytic 
uraemic syndrome
Terminal pathway:
C5 Rare Neisserial infections; rarely SLE
C6 Second most common 
complement deficiency; 
1:60000
Neisserial infections; rarely SLE; at 
least 25% of homozygous individuals 
healthy
C7 1:25 000 in Japanese Neisserial infections; rarely SLE
C8 Less rare Neisserial infections; rarely SLE
C9 Rare in Caucasians; 1:1000 
in Japanese
Neisserial infections in Caucasians; 
weak association with neisserial 
infections in Japanese
C Reg Proteins
C1 inhibitor 1:150 000; autosomal 
dominant inheritance
Hereditary angiodema (HAE)
CR3/CR4 Severe immunodeficiency
DAF No associated disease
CD59 Very rare Paroxysomal nocturnal 
haemoglobinuria (PNH)-like disease
Table adapted from Morgan and Walport in Immunology Today240.
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The study of C deficient individuals has demonstrated that whilst all deficiencies have important clinical 
consequences for the individual, some deficiencies result in more severe diseases or a greater 
susceptibility to certain types of infection than others. Therefore, this must be taken into account when 
designing therapies that inhibit C activity, so that the potential for causing more disease is minimised. 
For example, inhibiting the classical pathway could result in the patient developing immune complex 
disease or having an increased susceptibility to pyogenic infections. On the other hand, inhibiting a 
terminal pathway component might lead to an increased susceptibility to Neisserial infections, but is 
less likely to lead to the development of immune complex disease and allows opsonisation and the 
solubilisation of immune complexes to occur, so that many infections can be overcome.
1.5. Complement and disease
The main physiological role of the C system is to overcome infection by invading pathogens, through 
the mechanisms described above. Nevertheless, it is clear that many infectious agents are able to 
hijack the C system and use it to advantage, potentially leading to the development of C-mediated 
pathologies. For example, parasitic infections, such as Schistosomiasis, Leishmaniasis and 
Trypanosomiasis are often long lasting, leading to the development of equilibrium between parasite and 
host, ensuring the survival of both host and parasite. In order for this to be achieved, such parasites 
are resistant to C activation at some point during their lifecycle and often, this is during the adult 
morphological blood-borne form. However, parasites continually release foreign antigen into the host 
circulation, resulting in circulating immune complexes, so that C activation occurs, followed by 
pathology. Furthermore, because continual C activation is occurring, many infected individuals are C 
depleted, so that they are more susceptible to other infections 245.
In recent years it has become apparent that although viruses are eliminated or controlled by the C 
system, some viruses are able to manipulate the C system to their own advantage, leading to their 
enhanced ability to infect the host or evade elimination by the C system. Viruses have developed 
various C evasion mechanisms. For example, Human Immunodeficiency virus (HIV) and Human 
Cytomegalovirus (HCMV) are able to incorporate C regulatory proteins into their viral envelope as they 
bud from the cell surface 246-247. Many of the larger DNA viruses, such as the herpesviruses and 
poxviruses encode their ownC regulatory proteins. These can share homology with cellular C 
regulatory proteins, as in the case of Kaposi’s sarcoma-associated virus (KSHV), which codes for a 
protein, KSHV C control protein (KCP) that exhibits homology to DAF 248-249. Alternatively, they can 
have no homology at all to cellular proteins, such as the herpes simplex virus-1 (HSV-1) and HSV-2 
glycoproteins. Both of these evasion mechanisms protect the viruses from C attack. Furthermore,
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some viruses enter host cells via C receptors or C regulatory proteins. For example, Epstein-Barr virus 
(EBV) infects B cells and endothelial cells through interactions between viral gp350/220 proteins and 
CR2, whilst the measles virus infects cells via interactions with MCP 250.
The activating pathways of C have been shown to be critical in host defence against bacterial 
infections. Gram-negative bacteria possess an outer cell wall, a major component of which is 
lipopoiysaccharide (LPS), that contains Lipid A and this binds and activates C1, thus activating the 
classical pathway. Gram-positive bacteria are unlikely to directly activate the classical pathway, as 
their cell walls are up to 150 nm thick and consist predominantly of peptidoglycan and techoic acid. 
Therefore, they are more likely to activate C via the alternative pathway. Due to the cell wall thickness, 
gram-positive bacteria are resistant to C-mediated lysis and so C activation serves only to enhance 
phagocytosis of these bacteria by phagocytes.
1.6. Complement and Autoimmune Diseases
Inappropriate C activation is the driving force behind the development of pathology in many diseases, 
including inflammatory conditions such as RA and MS, as a consequence of ischaemia -  reperfusion 
injury, as well as due to therapeutic intervention, for instance, extracorporeal circulation251. In such 
situations, the same protective C components that defend the patient against invading pathogens 
become chronically activated, leading to the sustained production of C3a and C5a which drive 
inflammation by recruiting and activating neutrophils, and MAC which may kill or injure cells.
RA is an autoimmune disorder, affecting 1-2 % of the worlds’ population. It is characterised by 
inflammation of the synovial tissues, joint swelling, stiffness and pain that can progress to joint erosion 
252. Excessive C activation has been implicated in the pathogenesis of RA 253, as demonstrated by the 
detection of soluble C activation products in inflammatory joint synovial fluid 254-257 and the deposition of 
MAC within rheumatoid synovium in vivo 258>259.
The precipitating factors that result in the development of MS are complex and remain to be fully 
elucidated, but the presence of CD8+ T cells and antibodies have been implicated in axonal damage. 
The presence of antibodies further implies a role for the C system in disease progression 26°. However, 
the involvement of C activation in the progression of MS is proving increasingly complicated to 
understand, as recent clinical trails with anti-inflammatory agents did not yield the expected results, 
suggesting the possibility that the inflammation observed in MS may be of benefit to the patient261. 
Extracorporeal circulation as happens in cardiopulmonary bypass (CPB) is a necessary part of most 
types of cardiac surgery, but postoperative complications may occur, including respiratoryfailure, renal 
dysfunction, bleeding disorders, neurologic dysfunction and altered liver function. In turn, these can
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result in multiple organ failure (MOF) and ultimately the death of the patient 262-266. These 
complications arise due to a complex inflammatory response, initiated by neutrophil and C activation 
267, which leads to platelet and leukocyte activation, resulting in widespread inflammation throughout 
the body268. Elevated levels of C3a have been detected both during and following CPB 267,269-271 anc| 
raised levels of SC5b-9 272>273 have also been recorded. The levels of C3a and SC5b-9 are not 
elevated in patients who have undergone cardiac or other major surgery not requiring CPB 267-272.
Targeting the terminal pathway as a potential therapy is becoming an increasingly attractive prospect, 
as it has been implicated in the development of various pathologies. In a rat model of 
glomerulonephritis, limited apoptosis was detected in rats deficient in C6, a component of MAC, 
whereas in C6-sufficient rats, a high degree of apoptosis was observed 274. A similar degree of 
apoptosis to that detected in C-sufficient rats was observed in C6 deficient rats treated with human C6, 
to reconstitute the deficiency. This strongly emphasises the role of MAC in the early stages of this 
disease model274. Moreover, a major advantage of a terminal pathway inhibitor is that the functions of 
the activation cascades, such as immune complex opsonisation and clearance of C3b coated bacteria, 
remain intact. The sole deficit in patients deficient in terminal complex components is susceptibility to 
infections with organisms of the genus Neisseria275, which, although a serious condition, is preventable 
with the prophylactic use of antibiotics. Therefore, inhibition of MAC may be safer to use as a long­
term therapy compared to activation pathway inhibitors.
C activation is a common feature in the progression of all the pathologies discussed above, even 
though the factors causing the activation are diverse. Theoretically, these diseases could be resolved 
by the therapeutic inhibition of C.
1.7. Complement-mediated disease and treatments
The traditional treatment of RA is to manage the patients’ symptoms with nonsteroidal anti­
inflammatory drugs (NSAIDs), corticosteroids and disease-modifying antirheumatic drugs (DMARDs) 
for example, methotrexate. The effectiveness of these drugs varies from patient to patient and there is 
a significant risk of toxicity when these drugs are used over the long term 252-276. New types of drugs, 
biological response modifiers (BRMs) are beginning to be used, generally in patients in whom the use 
of traditional drugs is ineffective or contra-indicated. BRMs block the biological effects of inflammatory 
cytokines 252>277. These include monoclonal antibodies against TNF-a such as Infliximab™, soluble 
TNF receptors, for example Etanercept™, and receptor antagonists to interleukin (ILJ-1, e.g.
Anakinra™. These drugs are more effective than the traditional treatments, as they alter the 
progression of joint erosion and also attenuate many associated symptoms. However, they are
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expensive and also have adverse effects, for example anti-TNF-a therapies may be associated with an 
increased risk of infections, sepsis and demyelination disorders 252.
Corticosteroids are also used for the symptomatic relief of conditions arising as a result of MS, such as 
true vertigo, which 20% of MS patients suffer from 278. Interferon-p (IFN-p) is often used as a treatment 
for MS; unfortunately, up to 35% of these patients develop neutralizing anti-IFN-p antibodies within 2 
years of starting this therapy. These antibodies reduce or abolish the biologic effects and limit the 
clinical efficacy of IFN-p 279. Glatiramer acetate, a collection of immunomodulatory synthetic 
polypeptides is also used to treat MS and like IFN-p, the patients remain relapse-free and the 
development of new lesions is reduced. However, it is limited in its effectiveness and there have been 
reports of adverse effects and toxicity issues 28°. Therefore, investigations are continuing into 
developing more effective treatments, including T-cell vaccination281, inhibitors of matrix 
metalloproteinase-9 (MMP-9), the upregulation of which has been implicated in MS 282, gene therapy 
283, and other immune-based therapies 284.
1.8. The Development of anti-Complement therapeutics
As inappropriate C activation is the driving force behind the development of pathology in many 
diseases, a sensible approach is to develop C inhibitors for therapeutic use. This section examines the 
various approaches that have been adopted from a historical perspective through to current 
developments.
1.8.1. Cobra Venom Factor (CVF)
Investigations with cobra venom gave one of the earliest indications that manipulating the C system 
may be of therapeutic benefit. The first decomplementation studies with cobra venom on animal sera 
were performed 100 years ago 285, although the active component, cobra venom factor (CVF) was not 
isolated until nearly 70 years later [Cochrane, 1970 #19; Gewurz, 1967 #598; 286‘290. CVF is a form of 
Cobra C3b [Alper, 1976 #602] and depletes C via the alternative pathway. CVF binds plasma fB, the 
fB is cleaved by fD and a stable C3 convertase (CVFBb), with a half-life of several hours in plasma, is 
formed. CVFBb is also resistant to the fluid phase regulators291, so that it is able to cleave C3 in an 
unregulated manner, leading to the release of large amounts of C3a and C3b. This results in the 
systemic depletion of C3 292 and thus C activity, for between 24 and 72 hours in experimental animals. 
By administering CVF repeatedly, systemic decomplementation can be maintained for up to a week251; 
after this time it becomes ineffective, due to a strong immune response and the subsequent generation 
of neutralising antibodies by the recipient285. In addition, large amounts of active C fragments are 
produced, resulting in shock, including circulatory collapse, metabolic acidosis and hypotension 293.
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For these reasons, the use of CVF in humans would not be beneficial. Cobra venom has been used to 
treat RA, with little success 294>295. Nonetheless, CVF has been very successful in treating many animal 
models involving uncontrolled inflammation, including transplantation 296-299, ischemia-reperfusion injury 
300 and various autoimmune diseases301’307. This set the precedents that (1) C is involved in the 
development of a wide range of pathologies and (2) the C system can be manipulated for therapeutic 
benefit.
1.8.2. Heparin and other polyionic molecules
Heparin is a polyanionic glycosaminoglycan routinely used as an anticoagulant, including in patients 
with shock syndromes 308. Its beneficial effect in such patients may in part be due to its ability to inhibit 
C, which has been demonstrated in vitro 309. Heparin acts on the classical, alternative and terminal 
pathways by binding and inactivating C1, inhibiting the assembly of the C3 convertases and disrupting 
MAC formation 31°-313. Little has been done to determine the efficacy of heparin as an anti-C agent in 
vivo, probably because of its lack of specificity. It is used extensively to coat extra-corporeal circuits in 
(CPB) and renal dialysis, to reduce coagulation and C activation within the circuit314-315.
Many other polyanionic molecules also have C inhibitory properties in vitro, including dextran sulphate, 
polyvinyl sulphate, polylysine and suramin316. In animal models, it has been demonstrated that 
suramin inhibits C and suppresses some components of the Arthus reaction and xenotransplant 
rejection317-318, whilst in man it has been used with limited success to treat attacks of hereditary 
angiodema319.
1.8.3. Serine protease inhibitors
Aprotinin is a non-specific serine protease inhibitor that is extracted from bovine lung and has been 
used to treat a variety of conditions over the last fifty years, including acute pancreatitis, septic and 
haemorrhagic shock and adult respiratory distress syndrome (ARDS) 32°. In the early 1980s, it was 
administered to patients in conjunction with heparin during CPB. At high doses, this was successful, 
particularly in reducing neutrophil activation321. However, it emerged that aprotinin increased the risk 
of patients suffering myocardial infarction during cardiac surgery, as well as other complications, such 
as acute renal failure and anaphylactic shock 32°.
Hereditary angioedema (HAE) is caused by a deficiency in C1-lnhibitor (C1-lnh) 322, the serine protease 
inhibitor and sole inhibitor of C1. Morbidity in C1-lnh deficient patients is high following surgical 
procedures. This condition became the first to be treated therapeutically using a C regulator in 1975, 
when patients with HAE were transfused with fresh frozen human plasma prior to dental surgery as a 
prophylactic measure 323. This treatment decreased the severity of complications following surgery; 
more specifically the precipitation of an attack of HAE was avoided 323. Subsequently, patients with
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acute attacks of HAE have been successfully treated with purified C1-lnh 324 Purified, pasteurised 
human C1-lnh has been used as a treatment for acute episodes of HAE and prophylatically for 
example, prior to surgery since the early 1980s with few adverse effects 325-330 and clinical trials have 
shown this is a safe and effective treatment in controlling HAE331. Surprisingly, C1-lnh is not widely 
used as a C inhibitor in other conditions. This may be due the fact that its activity is specific for the 
classical pathway, so that immune complex clearance and opsonisation may not occur. Nonetheless, 
the use of C1-lnh highlights the potential of native C regulators as therapeutics.
1.8.4. Small molecule inhibitors
There are many examples of synthetic and naturally occurring molecules that have C inhibitory activity 
in vitro. For example, K-76COOH, a xenobiotic isolated from the fungus Stachybotrys complement/, 
inhibits the cleavage of C5 in in vitro studies 332. In several C-mediated models of disease in guinea 
pigs and mice, K-76COOH inhibited disease development333. Rosmarinic acid, a polyphenolic 
phytochemical with antioxidant activity is extracted from the herb Rosemary. It covalently binds 
activated C3b in the forming convertase 334-335. An extract of the Chinese medicinal herb, Ephedra, 
inhibited C in the activation and terminal pathways but the active component was not well characterised
336,
Nafamastat mesilate (FUT-175) is a synthetic molecule and protease inhibitor that was originally 
developed as an anticoagulant and inhibits proteases from many systems 337. FUT-175 affects the C 
system at many levels, inhibiting C1r, C1s, fD and the C3/C5 convertase, but it also interferes with 
many other plasma protease systems 338-339. In animal models, FUT-175 has been shown to be 
effective against C-mediated disease when administered singularly340 and in combination with K- 
76COOH 341-342. In human patients, FUT-175 is an effective treatment for glomerulonephritis 343-344. 
However, as FUT-175 is such a powerful non-specific protease inhibitor, its use in humans is potentially 
harmful and so more specific and efficient C inhibitors, based upon FUT-175 are being generated 345.
1.8.5. The Development of Peptide Inhibitors
Initially, small peptides were identified as being able to inhibit C activity in vitro, such as the 
commonly used serine protease inhibitor, leupeptin 245. Peptide inhibitors of C activation were 
also designed, which mimicked the sequence around the sites at which components are cleaved 
during activation. For example, peptides derived from the sequences of C3 around the site of 
cleavage by C2 and also the sequence of Factor B around the site of cleavage by Factor D were 
shown to be potent competitive inhibitors of activation in vitro245. However, the development of . 
bacteriophage display technology has enabled the rapid identification and development of 
peptides with therapeutic potential.
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The surface (coat) of a bacteriophage (phage) comprises various proteins that are gene products 
of the phage genome. In phage display technology this is exploited by fusing a sequence coding 
a peptide or protein to a gene encoding a coat protein, so that the peptide is expressed 
(displayed) with the coat protein on the phage surface The advantage of this technique is that 
the phenotype of a bacteriophage surface-displayed peptide is linked with the genotype encoding 
that peptide, packaged within the same phage particle (virion) 346-347. This enables a high number 
of peptides to be rapidly screened and to identify peptides that bind any given protein without 
needing to know the sequence of the protein 348‘350. A library of 107-109 random peptides is 
quickly generated from inserted sequences through site-directed mutagenesis using degenerate 
oligodeoxynucleotides351 >352. Phage-plasmid derivatives of F-pilus dependent filamentous (Ff) 
Escherichia coli (E. coil) phage such as fd or M13 are most frequently used for phage display 
because these are able to accommodate quite large insertions of cDNA segments relative to the 
size of the phage genome 353-354.
Phage display libraries have been used to identify possible therapeutic candidates in a diverse 
range of fields for example neutrophil elastase inhibitors 355-356, inhibitors of anti-FVIII antibodies 
357, potential candidates for tumour vaccination 358 and C inhibitors 359-363. DX-890 (previously 
known as EPI-HNE-4) was originally discovered using a phage display library that displayed 
protease inhibitory domains because it was created from wild-type bovine pancreatic trypsin 
inhibitor355. It is a specific and potent inhibitor of human neutrophil elastase (NE). NE degrades 
many of the components of the pulmonary extracellular matrix; it may be involved in the induction 
of inflammation and when present in excess, actively participates in the destruction of lung 
structures 356. Excessive accumulation of NE occurs in the pulmonary fluid and tissues of 
patients suffering from cystic fibrosis (CF) 364-366, |n in vitro studies DX-890 inhibited the high 
levels of active NE present in 60% of sputum samples collected from children with CF and almost 
completely blocked (91%) the N-formyl-methionine-leucine-phenylalanine-induced migration of 
purified human neutrophils across a Matrigel basement membrane. In vivo, DX-890 protected rat 
lungs dose-dependently from haemorrhage, serum albumin leakage, residual active NE and 
discrete neutrophil influx in air spaces for up to 4 hours 356. DX-890 is currently in phase II clinical 
trials for the treatment of CF 367.
Twenty-five percent of haemophilia A patients develop functionally inhibitory anti-FVIII antibodies 
following the therapeutic administration of FVIII. Phage display has been used to identify 
peptides that neutralise the activities of these anti-FVIII antibodies. In vitro, one of the identified 
peptides, peptide 107, inhibited the activity of the human anti-FVIII monoclonal antibody, Bo2C11 
and restored normal haemostasis in a mouse model of haemophilia 357.
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Tumour antigens have been identified using phage display in patients with colorectal cancer 
(CRC) 358. This is a relatively new approach 368-369 and is a less time-consuming process than the 
current standard method that uses recombinant cDNA expression cloning (SEREX) 37°. It has 
been difficult to detect tumour specific antigens for solid tumour types of epithelial origin, in 
particular CRC 37°. These identified antigens may be potential candidates for tumour vaccination 
or may have a use as markers, either for diagnosis or prognosis353 
Phage display has also been used to identify C inhibitory peptides including ‘peptide 2J’ and 
compstatin. Peptide 2J was originally discovered along with 41 other peptides to bind C1q 359. 
Further characterisation demonstrated that peptide 2J was the only one to bind to the globular 
head of C1q with high affinity and specifically inhibit C1q haemolytic activity 36°. It is cross­
reactive with primate and rodent C1q and its activity is dependent on its cyclical structure. These 
results suggest that peptide 2J has therapeutic potential.
Compstatin is a cyclic 13-mer peptide that was originally screened against C3b361. Subsequent 
experiments demonstrated that it binds C3, C3b and C3c, but not C3d, suggesting that it binds to 
the C3c region of C3. The binding of compstatin to C3 is reversible and it inhibits both the 
classical and alternative pathways of C activation. It is only cross-reactive with primate C3 and its 
activity is dependent on its cyclic conformation. Experiments to determine the mechanism of 
inhibition by compstatin indicated that it interacts with C3 to inhibit its cleavage. Compstatin 
inhibited the generation of C3a, soluble C5b-9 and leukocyte activation in in vitro models of CPB 
362. Similar results were observed in an ex wVo xenograft model, in which pig kidneys were 
perfused with fresh human blood. Compstatin inhibited the generation of C3 activation products 
and soluble C5b-9 in a statistically significant manner and xenograft survival was prolonged by 
compstatin 363. These results demonstrate that the inhibition of C3 cleavage by compstatin stops 
additional C activation and inflammation and highlights its potential as a therapeutic agent. 
However, a major drawback of compstatin is its very short half-life, which means that it needs to 
be continuously infused in order to work. In addition, it is not cross-reactive with rodent C3, so 
that its therapeutic potential cannot be determined using the common rodent models of C- 
mediated disease. For these reasons, the likelihood of compstatin being further developed is 
limited, even though it is a potent inhibitor of C3 cleavage.
An added disadvantage of both compstatin and peptide 2J is that they both act at early stages in 
the C pathway. This eliminates the important opsonisation and pro-inflammatory effects 
mediated by cascade products. Potentially, this might increase the predisposition to bacterial 
infections and immune complex disease, especially if used as a long-term therapy82.
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1.8.6. The Modification of Native C Regulators
Native C regulators (CReg) allow the host to discern self from foreign cells and tissue371. By modifying 
these C inhibitors it may be possible to develop a potential therapy for use in conditions where C 
activation is unwanted.
1.8.6.1. First generation inhibitors
The therapeutic potential of soluble forms of membrane bound C regulators was first demonstrated 
when a soluble recombinant version of human CR1 (sCR1), consisting of the extracellular domain only 
was produced. This retained all the known functions of native CR1 in vitro i.e. it inhibited the formation 
of the C3 and C5 convertases, preventing C3b opsonisation, C5a generation and MAC formation 372-373. 
In a rat model of ischemia/reperfusion injury, sCR1 reduced myocardial size by 44%, minimised the 
accumulation of neutrophils within the infarcted area and attenuated MAC deposition 372-373. The 
protective effects of sCR1 have been confirmed in other animal models of ischemia/reperfusion injury
374-377_
Soluble CR1 was also used to treat rat models of human RA 378 379, as excessive C activation has been 
implicated in the pathogenesis of RA 253-259. Rats treated with sCR1 prior to disease induction had a 
delayed onset of disease and their disease was less severe. This suggested that the activating 
pathways were important in the development of disease in these models. However, the treatment of 
rats with sCR1 following disease onset failed to inhibit disease progression. This indicated that either 
the C activating pathways play a less important role in disease progression once it is established or that 
the sCR1 was not retained at the inflammatory site for long enough to have a therapeutic effect. This 
latter hypothesis was supported by the observation that sCR1 had no inhibitory effect in the Antigen 
Induce Arthritis (AIA) model when administered systemically378, as it was free to travel in the 
circulation, but it was inhibitory when administered locally378
Clinical trials have been conducted in humans using sCR1 to treat adult respiratory distress syndrome 
and the side-effects of CPB 380-381. These studies established that sCR1 is safe, but its efficacy was 
poor in terms of treating disease. For these reasons, it was not developed further251.
Soluble recombinant forms of the membrane-bound C regulators MCP and DAF have also been made. 
These are effective in blocking C activation in vitro as well as in animal models of C-mediated 
pathologies 382'384. In contrast, a recombinant soluble form of CD59 proved to be a poor C inhibitor in 
serum; this is perhaps not surprising, as it inhibits MAC formation that is occurring within the cell 
membrane, in vivo it was cleared from the circulation by filtration in the kidney 385, probably due to its 
small size.
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1.8.6.2. Second generation inhibitors
Various approaches have been taken to alter or improve the therapeutic efficacy of sCR1 in vivo. For 
example, sCR1[desLHR-A] lacks the seven amino-terminal SCR of full-length sCR1 and this confers 
alternative pathway specific inhibitory activity upon the molecule 386. The advantages of such a 
molecule are clear; immune complex clearance and classical pathway activation are allowed to occur, 
whilst amplification of C3b formation is not. sCR1 has also been modified by adding sialyl Lewisx (sLex) 
tetrasaccharide groups at Asn residues of sCR1, referred to as sCR1sLex. This enables the molecule 
to bind P-, E- and L-selectins, thus targeting it to sites of inflammation 387. In addition, it inhibits 
selectin-dependent leukocyte adhesion at these sites, making it a potent anti-inflammatory agent388. In 
a stroke model, sCR1sLex had greater neuroprotective effects than unmodified sCR1 389.
One of the most successful examples of modifying sCR1 is that of the drug APT070. This comprises 
the first three SCRs of CR1 390 attached to a membrane-targeting anchor consisting of two sequentially- 
linked outer cell membrane ligands (‘addressins’) to tether it at the site of injection391. The therapeutic 
efficacy of APT070 was demonstrated in an experimental arthritis model, Antigen Induced Arthritis 
(AIA) 392. Animals treated with APT070 had a significantly milder clinical and histological disease in 
comparison to untreated controls or animals treated with full-length sCR1 and this effect was dose- 
dependent. Moreover, APT070 was retained on cell surface membranes within the normal joint up to 
48 hours post intra-articular injection. Similar beneficial effects were observed in a model of renal 
transplantation 393. These data demonstrate that by modifying sCR1 so that it could be retained at the 
inflammatory site for longer, the therapeutic benefits of administering a soluble C regulator were far 
greater. A phase I clinical trial established that the administration of APT070 was tolerated by healthy 
volunteers 394. A phase IIA trial is currently being conducted to determine the effects of intra-articular 
APT070 upon clinical and biochemical markers in RA patients 395.
APT070 satisfies many of the requirements for a C inhibitory drug -  the sCR1 component is bacterially 
expressed and then the addressin is added chemically, making it ‘relatively’ cheap to produce, it is a 
small molecule, with a molecular weight of approximately 23 kDa, thereby minimising the potential for it 
to be immunogenic, and gets around the problem of being cleared rapidly from the site of 
administration due to the presence of the adressin tag. However, CR1 has a dual role in the C system, 
as a C regulator and receptor, and is not expressed on normal synoviocytes 396-397. Although it seems 
to stop C activation, in disease, MAC is deposited on the surface of the synovium, implicating it in the 
development of pathology. Therefore, it may be more appropriate to modify CD59, to inhibit MAC 
formation. To this end, a similar membrane-targeting moiety has been attached to soluble CD59, 
improving its activity in vitro 398-399.
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1.8.7. The potential of antibody-CReg hybrid molecules as therapeutics
This is a new area of research and so far, two types of antibody-CReg hybrids have been described. In 
the first type, the CReg is attached to the antibody Fab arms, which targets the molecule to a specific 
site. Zhang et a/400-401 made fusion proteins of either CD59 or DAF attached to anti-dansyl antibody 
fragments. When exposed to dansylated target cells, the CReg hybrid conferred protection against 
lysis by C. This needs to be tested further in vivo. In the second type, the CReg replaces the Fab arm, 
so that it is directly attached to the Fc portion of the antibody, giving the hybrid molecule a long half-life 
402. This has been done with the murine homologue of human CR1, C receptor-1-related gene/protein 
y (Crry) 403 and rat DAF and CD59404 In all cases, when tested in vivo, these agents had a prolonged 
half-life and made effective therapeutics 404>405. During the development of these molecules, Harris et 
alm  noted that some of these fusion proteins were significantly less active than the free CReg, but that 
cleaving the CReg from the Fc with papain restored this activity. Therefore, by introducing cleavage 
sequences that are recognised by matrix metalloproteinases and/or aggrecanases between the Fc 
region and the CReg, the molecule can be targeted to become active at sites of inflammation where 
such enzymes are in abundance. This would create a drug with little or no systemic anti-C activity, that 
would become active only when required, but that would have a long half-life in vivo m .
1.8.8. The development of monoclonal antibodies against C components
Another strategy to inhibit the progression of C-mediated disease has been to develop function- 
blocking monoclonal antibodies (mAbs) against C components. There are four advantages to this 
approach. Firstly, the mAbs raised are highly specific for the antigen of interest only. This will increase 
the efficacy of the drug. Secondly, mAbs have a high affinity for the antigen in comparison to other 
agents such as peptides and it is possible to select mAbs that block antigen activity. Thirdly, mAbs 
have a long half-life in the circulation -  approximately four weeks. Lastly, a mAb can be ‘humanised’ -  
i.e. it can be manipulated to be more human-like, decreasing its antigenic potential. Numerous 
monoclonal antibodies have been licensed for clinical use and have been shown to be both safe and 
effective.
Rituximab™ was the first monoclonal antibody to be approved for clinical use as an anti-cancer 
therapy, specifically in treating indolent B-cell non-Hodgkin’s lymphoma (NHL). It binds CD20, a 
transmembrane marker protein present on the surface of maturing B cells 406 and also present on the 
surface of most B-cell NHL407. Although CD20 is a pan-B cell marker, it was deemed an appropriate 
therapeutic target because it is expressed at high levels on the NHL cell surface, is not down-regulated 
after antibody binding and is not shed or secreted into the circulation, thereby increasing its efficacy as 
a therapeutic target408. Rituximab™ is a chimeric ‘humanised’ antibody comprising the anti-human
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CD20-binding Fab regions of the original murine antibody and a human lgG1 Fc portion m . The 
reasons for making a chimeric antibody are threefold. Firstly, the patient develops human anti-mouse 
antibodies (HAMA) to murine antibodies when they are repeatedly administered409411. The likelihood 
of this is greatly reduced if the murine lgG1 Fc portion is replaced with the human homologue412414 
The human Fc region binds the neonatal Fc receptor (FcRn) and recycles the antibody thereby 
prolonging its half-life in the circulation 415«416. Finally, whilst the murine mAb binds the antigen, it is 
through the Fc region that the effector aspects of the molecule are exerted. The human Fc is more 
effective in activating these effectors in patients than a murine Fc region would be. As CD20 is a pan- 
B-cell marker, treatment with Rituximab™ leads to the depletion of both normal B cells and lymphoma 
cells, resulting in the clearance of normal B cells for approximately 6 months. Surprisingly, there is 
neither an increased risk of infection nor decrease in IgG levels in the patient417. Rituximab™ is 
believed to deplete B cells in three ways: firstly, by antibody dependent cell mediated cytotoxicity 
(ADCC), in which natural killer cells, macrophages, and monocytes are recruited through their Fey 
receptors, to bind the Fey portion of Rituximab™ which is bound to surface CD20, inducing CD20+ B 
cell lysis 418>419. Secondly, through C dependent cytotoxicity induced when circulating C1q binds to 
Rituximab™ that is bound to surface CD20. The C cascade becomes activated, ending in MAC 
formation in the cell membrane causing CD20+ B cell lysis408 Thirdly, Rituximab™ promotes CD20+
B cell apoptosis 420. It is also thought to sensitise lymphoma cells to the cytotoxic activity of 
chemotherapy421-422. Rituximab™ has been tested for use in other haematological malignancies with 
varying degrees of success 422. Studies show that Rituximab™ is well tolerated by patients 422 and that 
most adverse events are infusion-related reactions, consisting mainly of fever and chills, in more than 
50% patients. These usually occur within 30-120 minutes of the first infusion and are milder with 
subsequent infusions423. Fatal infusion reactions have occurred, although these are rare and risk 
factors identified include a high tumour burden and cardiopulmonary disease424 Patients have been 
monitored for the development of HAMA and human anti-chimeric antibodies (HACA) 422. No HAMA 
responses were observed and 1.1% of patients were positive for HACA, demonstrating that the 
rationale of humanising therapeutic antibodies works and that repeated Rituximab™ exposure does not 
lead to the development of immune resistance in the majority of patients.
The therapeutic potential of Rituximab™ is now being tested in other conditions in which the 
involvement of B-cells is implicated 425, including RA 424-426-430) idiopathic thrombocytopenic purpura431, 
type II mixed cryoglobulinaemia 432 IgM antibody associated neuropathies 433 and SLE434436. In RA 
patients, interim results are encouraging, with significant clinical improvement and only mild to 
moderate adverse events reported424
/
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Campath-1H™ (Alemtuzumab) was licensed for clinical use in the treatment of patients with B-cell 
chronic lymphocytic leukaemia (CLL) who had not responded to other therapies in July 2001. It is a 
humanized monoclonal antibody raised against CD52, a GPI-anchored protein that is expressed on all 
mature lymphocytes, and in particularly high levels on malignant B lymphocytes 437, but is not 
expressed on haematopoietic stem cells 438. The function of CD52 remains unknown, although signal 
transduction, via the T cell receptor has been induced in cross-linking studies439. Like Rituximab™, 
Campath-1H™ is thought to act on target cells and cause cell death by C activation 44°, ADCC441 ■442 
and apoptosis443. Campath-1H™ has also been approved by the FDA to treat MS 444>445.
Mylotarg™ (Gemtuzumab Ozogamicin (GO)) was given conditional approval by the FDA in May 2000 
for use as a single-agent therapy for first recurrence of CD33 positive AML in patients over 60 years old 
who were not considered suitable for treatment with cytotoxic chemotherapy446. Mylotarg™ is a 
chemotherapeutic agent comprising a humanised anti-CD33 antibody covalently linked to a derivative 
of a potent cytotoxic enediyne antibiotic, calicheamicin 447. CD33 is a 67 kDa glycosylated 
transmembrane protein of unknown function, is expressed on most haematopoietic stem cells; on both 
mature and immature myeloid cells, and on erythroid, megakaryocytic, and multipotent progenitors448. 
CD33 is also found on leukaemic blasts from most AML and myelodysplastic syndrome (MDS) patients. 
CD33 was considered an attractive target for a mAb-based therapy in AML patients as it has little 
expression outside the hematopoietic system. Mylotarg™ is rapidly internalised into the target cell 
following binding to CD33449. This is an attractive therapeutic approach, as the chemotherapeutic 
agent is specifically targeted to the malignant cell, rather than to many different cell types. Once 
Mylotarg™ binds to CD33, it is endocytosed 450 and cleaved inside lysosomes by acid hydrolysis, 
releasing calicheamicin. This is further processed making a reactive intermediate 451-454 that cleaves 
DNA phosphodiester bonds455-456. In vitro studies demonstrate that cell lines that are not resistant to 
the active agent are induced into G2 arrest and this can be followed by apoptosis 457.
Many groups have focussed on generating mAbs that bind to C5 in such a way that is unable to 
be cleaved into its active components, C5a and C5b. Wiirzner et a/458 generated the anti-human 
C5 monoclonal antibody, N19/8. It was shown to bind human C5 and prevent its cleavage by 
either the classical or alternative pathway C5 convertases438-439, thereby inhibiting the generation 
of C5a and soluble C5b-9 and blocking serum C haemolytic activity. It also inhibited C-mediated 
damage in an ex vivo model of xenotransplantation 459 and blocked both leukocyte and platelet 
activation in an ex vivo model of CPB 46°. Experiments using the N19/8 Fab fragments alone 
demonstrated that the C inhibitory properties of the intact antibody were retained, indicating that 
the observed properties of the antibody were dependent on the variable regions of N19/8 and not 
on the intact N19/8 antibody structure461. To improve the therapeutic properties of this mAb, the
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N19/8 antibody was used to make a recombinant single chain antibody (scFv) directed against 
human C5. Single chain antibodies comprise the light and heavy variable chain regions of an 
antibody fused together to make a single tandem polypeptide. The binding specificity462-463 and 
affinities464-465 of the scFv molecule are often similar to that of the parent mAb, as the folded 
structure of an scFV is virtually identical to the variable region structure of the parental antibody 
466. The scFv molecule does not possess any effector functions, which is ideal for an antl-C 
therapy, but may still retain the ability to block the function of its target protein. scFv antibodies 
have greater therapeutic potential than intact mAbs as the possibility of the patient developing a 
HAMA response is significantly reduced, they quickly penetrate tissues467 and can be rapidly 
produced in large quantities using E.coli464-465. Although the scFv N19/8 antibody bound human 
C5 with a high affinity and was as potent as N19/8 at reducing MAC formation, its ability to inhibit 
C5a generation was not significantly reduced, suggesting that it bound to the C5b region of intact 
C5468. Like the intact mAb, the N19/8 scFv provided protection against C-mediated damage in 
an ex vivo model of xenotransplantation468 The discrepancy between the activities of the 
original antibody and the scFv variant might be due to steric hindrance as the original mAb was 
much larger than the scFv variant and may have inhibited C5a generation due to its size.
However, the N19/8 scFv antibody was not developed further.
A more successful example of making scFv antibodies is that of mAb 5G1.1, an antibody that 
also recognises human C5 and inhibits cleavage of C5, thereby preventing the generation of the 
pro-inflammatory products, C5a and MAC. mAb 5G1.1 was humanised and scFv molecules were 
also produced by grafting the complementarity determining regions of 5G1.1 onto human 
framework regions 469. Further investigations demonstrated that the intact humanised h5G1.1 
antibody had identical inhibitory activity to the original murine monoclonal antibody in C lysis 
assays. In addition, humanised Fab and scFv molecules blocked C-mediated haemolysis and the 
humanised h5G1.1 scFv was also able to block C5a generation 469.
As the humanised h5G1.1 scFv (from now on referred to as h5G1.1-scFv) inhibits C5a generation 
and C-mediated lysis, its activity was tested in Phase I and II clinical trials to determine whether 
h5G1.1-scFv could prevent C activation occurring as a result of CPB 47°. This demonstrated that 
at the highest dose administered, h5G1.1-scFv was able to inhibit C haemolytic activity for up to 
14 hours. There was a 40% reduction in myocardial injury, as measured by creatine kinase-MB 
release and there was a reduction in new cognitive deficits post CPB. At the two highest doses 
administered, leukocyte activation, as measured by surface expression of CD11b was reduced 
and also, there was a reduction in post-operative blood loss. Moreover, the generation of SC5b-9 
was inhibited in a dose-dependent manner. A phase III clinical trial is underway and phase II
i
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trials for the treatment of acute myocardial infarction are also being conducted471. H5G1.1-scFv 
is now designated the name Pexelizumab™ and the developers, Alexion, were granted Fast 
Track status for Pexelizumab™ by the US FDA471. The humanised mAb 5G1.1 is known as 
Eculizumab™ and was recently used in a pilot study to treat patients suffering from paroxysmal 
nocturnal hemoglobinuria (PNH) 472. Patients suffering from this condition make blood cells 
without GPI-linked proteins on the cell surface, including DAF and CD59, rendering them 
susceptible to lysis by the C system. Treatment with Eculizumab™ was safe and well tolerated 
and reduced the incidence of intravascular haemolysis and haemoglobinuria. Patients required 
fewer blood transfusions and their quality of life improved. The FDA granted Eculizumab™ 
orphan drug status for the treatment of idiopathic membranous nephritis in May 2001 and for the 
treatment of PNH in August 2003.
Phage display technology can also be used to develop human mAbs473. Antibody proteins are 
produced on the phage coat of phagemid vectors instead of random peptides. Phage antibody 
libraries are made by cloning variable regions of human antibody genes, derived from naive, 
immunized or synthetic antibody repertoires, into the phage coat-protein genes of phagemid 
vectors. Libraries containing greater than 1011 different variants have been constructed474 
Antibody variable regions can then be selected for by biopanning against the target molecule in 
exactly the same way as random peptides are. The gene of an antibody variable region of 
interest can subsequently be made into a single chain recombinant antibody by grafting it onto 
human antibody constant regions475. Cambridge Antibody Technology together with Abbott 
developed an anti-TNF-a antibody using this technology. HUMIRA™ was the first human mAb 
produced in this way to be licensed by the FDA for the treatment of RA in December 2002. 
Clinical trials showed that it was safe and well tolerated at the doses used 476. HUMIRA™ is also 
being tested in phase II clinical trials for the treatment of juvenile RA and Crohn’s disease. 
Another way of reducing the potential for HAMA responses is to create transgenic mice that are 
able to make human antibodies 444>445. The mice are engineered to suppress their own antibody 
production and regions of the human antibody heavy and light chain loci are then transferred into 
these animals. The human antibody genes are functional in the context of the mouse machinery 
for antibody recombination and expression. Following immunisation protocols, the B cells 
secreting human antibodies can be collected from these mice and used to generate human 
monoclonal hybridoma cell lines. Two antibody-based drugs are currently in phase II trials 
developed using this technology. One is HuMAX-CD4, an anti-CD4 antibody being used to treat 
psoriasis, developed by Genmab and EISAI. The other developed by Genmab and Medarex is
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HuMax-IL15, an anti-IL-15 antibody being used to treat RA and psoriasis. To date, no significant 
allergic reactions have been observed 475.
1.9. Aims and Objectives: The generation of agents that inhibit MAC formation
Although great advances have been made in the development of agents that block C activation, 
much of the damage caused by unregulated C activation is mediated by MAC formation. 
Therefore, it makes sense to develop inhibitors of MAC formation that do not interfere with the 
early C activating pathways so that immune complex opsonisation, clearance and 
chemoattraction of inflammatory ceils to sites of injury or infection are able to occur in an 
appropriate manner. Thus, the aim of this project is to develop agents capable of specifically 
inhibiting MAC formation. We have chosen to generate reagents that act on C6, a central 
component of the terminal pathway that forms an integral part of the C5b-8 complex, which binds 
multiple molecules of C9, to form the MAC. No other roles for C6 have been described and it 
therefore provides an ideal and highly specific means of preventing MAC formation.
Two approaches will be used to produce reagents that bind C6 and inhibit its activity in MAC 
formation. One will be to generate anti-C6 function blocking cross-species reactive mAbs and the 
other will be to identify peptide sequences that functionally block C6 activity. In the first instance, 
mAbs will be raised against rat, mouse and human C6 in strains of spontaneously C6 deficient 
rats and mice. These will be characterised for their C6 inhibitory activity and also for their activity 
against other species of C6. The desired mAb will have an IgG isotype and functionally block 
human C6 activity and additionally mouse C6 or rat C6 activity, making it possible to evaluate the 
efficacies of these mAbs as therapies in in vivo models of C-mediated disease. For the second 
approach, bacteriophage display technology (phage display) will be used. A complex library of 
phage-peptides expressing 7-mer peptide sequences will be ‘panned’ against purified human C6. 
Those that bind C6 will be selected and their functional blocking activity for C6 determined. 
Phage-peptides with the greatest C6 inhibitory activity will be sequenced. The peptide will be 
characterised for its ability to bind C6 and block its functional activity in vitro and in vivo.
Arresting the C cascade at an earlier stage may not be the most clinically useful point to prevent 
TCC formation because both activation pathways as well as cleavage of C5 by injured tissue- 
released enzymes 477 or C5 activation by oxygen radicals 478 would have to be blocked. Arresting 
the C cascade at a later stage, as shown with anti-C8 mAbs 479-480, will neither inhibit membrane 
insertion of the terminal complement complex nor C5a liberation.
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Although C8, S-protein, SP40 and CD59 are all involved in regulating C5b-9 formation, they do 
not make good therapeutic candidates. Therefore, various groups have sought to inhibit C5b-9 
formation by generating antibodies against components of the C5b-9 complex that block its 
formation. The biological functions of the TCC are controlled by C8481.
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Chapter 2: Materials and Methods 
Materials
All chemicals, except where stated, were obtained from either Fisher Scientific UK 
(Loughborough, Leicestershire, UK) or Sigma (Poole, Dorset, UK) and were of analytical grade.
Methods
2.1. General Protein Techniques
Table 2.1 General Antibodies Used
Name Conjugate Used in Company Catalogue
Number
Goat anti-mouse IgG 
(heavy and light chain)
Horseradish
peroxidase
(HRPO)
ELISA,
Western
Bio-Rad, Hercules, 
California, USA
172-1011
Goat anti-mouse IgG Fey 
fragment specific
HRPO ELISA Jackson ImmunoResearch 
Laboratories, West Grove, 
Pennsylvania, USA
115-035-
008
Rabbit anti-rat IgG HRPO ELISA Sigma, Poole, Dorset, UK
Mouse anti-rat lgG1, 
Clone RG11/39.4
Biotin ELISA BD Biosciences 
Pharmingen, San Diego, 
California, USA
553890
Mouse anti-rat lgG2a, 
Clone RG7/1.3
Biotin ELISA BD Biosciences 
Pharmingen
553894
Mouse anti-rat lgG2b, 
Clone RG7/11.1
Biotin ELISA BD Biosciences 
Pharmingen
553898
ExtrAvidin HRPO Dot Blot, 
Wesetrn
Sigma, Poole, Dorset, UK E2886
Goat anti-mouse IgM (p- 
chain specific)
HRPO Dot Blot, 
Western
Sigma, Poole, Dorset, UK A8786
2.1.1. Dialysis of proteins to exchange buffers
Dialysis tubing (Medicell International Ltd., London, UK) with a 12-14 kDa molecular weight cut off 
was boiled in deionised water for 5 minutes. The tubing was then tied securely at one end and 
about half-filled with the protein-containing solution to be dialysed. Air was expelled from the 
tubing that was then tied at the other end. The tubing was placed in an appropriately sized 
beaker containing the buffer (dialysis buffer) to be exchanged and stirred overnight at 4#C. To 
ensure full buffer exchange, dialysis was against 1000-fold the sample volume of dialysis buffer. 
The dialysis buffer was changed during dialysis in order to achieve this as necessary.
36
2.1.2. Concentrating proteins using ultrafiltration
Proteins were concentrated using the Amicon stirred cell 8000 series protein concentration 
system (Millipore, Bedford, Massachusetts, USA). Filter discs of appropriate cut-off size (either 
30 kDa or 100 kDa) were soaked in deionised water for 5 minutes and then assembled into the 
apparatus. The protein containing solution was placed in the apparatus and concentrated under 
pressure. This forced the fluid through the filter membrane while proteins of molecular mass 
greater than the cut-off were retained and concentrated. The filter discs were stored in PBS 
containing 0.1% Nalvb and reused for the same proteins only.
2.1.3. Coomassie Assay
This assay was primarily used in a semi-quantitative manner to detect the presence of protein. 
Fifty microlitres of Coomassie Protein Assay Reagent (Ready-to-use Coomassie Blue G-250 
based reagent; Pierce, Rockford, Illinois, USA) was added to 50 pi sample in a 96-well plate. The 
Coomassie reagent changed colour from brown to blue in the presence of protein. The intensity 
of the colour change was directly proportional to the amount of protein present. When the 
concentration of protein in the sample was being determined, a standard curve was generated (1 
-  20 pg/ml) using stock bovine serum albumin (BSA) solution diluted in the same diluent as the 
test samples were in. The absorbance of the wells was determined at 595 nm on a BioRad 
Microplate Reader (Model 3550-UV). A standard curve was plotted and the concentrations of the 
test samples calculated. The test sample was diluted to obtain values on the standard curve and 
the concentration of protein in the original sample calculated.
2.1.4. Micro BCA Protein Assay
This assay was used to accurately determine the protein concentration of a sample. The assay 
was supplied as a kit and the manufacturer’s protocol was followed. The BCA reagent was made 
up by mixing 50 parts Reagent MA, 48 parts Reagent MB together with 2 parts Reagent MC.
This was stable for one day at room temperature. A set of protein standards (1 -  20 pg/ml) was 
prepared by diluting the stock BSA solution provided in the same diluent as the test samples were 
in. One hundred microlitre aliquots of each standard, blank (diluent only) or test sample were 
pipetted into the appropriate microtitre plate wells and 100 pi of BCA reagent was added to each 
well. The plate was covered, the samples mixed on a plate shaker for 30 seconds, and then 
incubated for 2 hours at 37’C. The absorbance of the wells was measured at 570 nm on a Bio-
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Rad Microplate Reader. A standard curve was plotted and the concentrations of the test samples 
calculated. The sample was diluted to obtain values on the standard curve and the concentration 
of protein in the original sample calculated.
2.1.5. Determination of protein concentration by measuring A280
The approximate concentration of purified protein samples was determined by measuring the 
absorbance of the solution at 280 nm (A280) in a UV spectrophotometer (GeneQuant II, GE 
Healthcare). A blank reading was taken as a reference using the buffer that the sample was 
diluted in. The solution was then placed in the same quartz cuvette and the absorbance 
measured. If the sample absorbance was greater than 2.0 then the sample was diluted in the 
same buffer and the A280 measured again. The protein concentration of the sample was 
calculated according to Beer-Lambert’s Law:
Protein Concentration (mg/ml) = ((A280 x dilution factor)/ protein extinction coefficient).
2.1.6. Biotin conjugation of antibodies
The antibody was taken into 0.1 M carbonate buffer (0.1 M sodium hydrogen carbonate, 0.1 M 
sodium carbonate, pH 8.4) by dialysis overnight at 4°C. The protein concentration was adjusted 
to 1 mg/ml. One hundred and twenty microlitres of N-hydroxysuccinimidobiotin (Sigma H-1759) 
freshly dissolved in dimethylsulphoxide (DMSO) (1 mg/ml) per milligram of antibody to be 
biotinylated was added to the antibody and mixed. The mixture was incubated for 4 hours at 
room temperature. Unbound biotin was removed by dialysis of the mixture into phosphate 
buffered saline (PBS) (8.1 mM Na2HP04, 1.5 mM KH2PO4 , 137 mM NaCI, pH7.4) overnight. To 
determine whether biotinylation had been successful, the biotinylated antibody was tested in a dot 
blot.
2.1.7. Dot Blotting
Buffer Composition
Blocking buffer 5% non-fat milk/0.1% Tween-20/PBS
Washing buffer 0.1% Tween-20/PBS
To test the successful biotinylation of an antibody, doubling dilutions of the antibody were made 
and 1 pi aliquots of each of these dilutions were spotted onto nitrocellulose and allowed to dry in
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a 37°C oven. The nitrocellulose was blocked with blocking buffer for 30 minutes, washed once 
for 5 minutes with washing buffer and incubated for 1 hour at room temperature on a roller with 
HRPO-ExtrAvidin, diluted 1 in 1000 in washing buffer. The blot was washed five times by 
incubating in washing buffer for five minutes each and developed by incubation in SuperSignal® 
West Pico Chemiluminescent Substrate (Catalogue number 34080, Pierce, Rockford, Illinois, 
USA). This is a kit, comprising two solutions: SuperSignal® West Pico Luminol/Enhancer 
Solution and SuperSignal® West Pico Stable Peroxide Solution. Immediately prior to developing 
the blot, 1ml of the luminol/enhancer solution was mixed with 1ml of the stable peroxide solution, 
to make ECL substrate. The blot was then allowed to develop in this mixture for 1 minute.
Excess moisture was removed, and the blot was placed in a plastic bag and exposed to 
autoradiograph X-OMAT UV film (Kodak, Rochester, New York, USA). The exposed film was 
developed in a Compact X2 developer (X-Ograph Ltd.).
Dot blotting was also used to detect a specific protein within a heterogeneous solution, for 
example, to screen fractions during protein purification. This was done in the same way as 
described above, except that after blocking and washing, the blot was incubated in antibody to 
the protein of interest (primary antibody) diluted in washing buffer for 1 hour at room temperature. 
After washing as described, HRPO-conjugated anti-immunoglobulins (raised against the species 
of animal the primary antibody was raised in)(secondary antibody), diluted in washing buffer, was 
incubated with the blot for 1 hour at room temperature, washed and developed as above.
2.1.8. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SDS -  polyacrylamide gel electrophoresis (SDS-PAGE) was used to detect proteins of interest 
according to modifications of the method of Laemmli482. The BioRad Mini Protean II or Hoefer 
Mighty Small gel running apparatus were used. A 4% (v/v) acrylamide stacking gel was poured 
on top of a 7.5% acrylamide resolving gel to make discontinuous gels.
The following recipes were sufficient for four 0.75 mm thick gels:
4% Stacking gel (ml) 7.5% Resolving gel 
(ml)
Stacking buffer (0.5 M Tris, 0.4% SDS, pH 6.8) 1.2 -
Resolving buffer (1.5 M Tris, 0.4% SDS, pH 
8.8)
- 3.75
40% acrylamide 0.506 2.8
Deionised water (dH20) 3.2 8.2
10% ammonium persulphate .05 .15
TEMED .005 .015
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Buffers Composition
Non-reducing loading buffer 0.1 M Tris, 10% glycerol, 2% SDS, bromophenol blue, pH 6.8
Reducing loading buffer Non-reducing loading buffer + 0.625% 3-mercaptoethanol
Running buffer 25mM Tris, 191 mM glycine, 1% SDS
Proteins were prepared for loading by dilution 2:1 in either non-reducing loading buffer or 
reducing loading buffer and boiled for 5 minutes before loading. If complex mixtures of proteins 
such as serum were being run, then the incubation was for 30 minutes at room temperature, as 
the samples precipitated if boiled. Molecular weight markers were loaded onto each gel for 
accurate determination of protein size. Markers used included Gibco, SeeBlue +2, NBL markers 
and BioRad broad range markers. The gels were run in running buffer at 200 V for approximately 
45 minutes, until the dye-front had reached the bottom of the gel. Electrophoresed proteins were 
then visualised by staining the gel with Coomassie Brilliant Blue R250, silver stain or subject to 
western blot.
2.1.9. Coomassie Blue Staining of Electrophoresed Gels
The detection limit of this technique was 2 pg of protein in a band on an SDS gel.
Solution Composition
Coomassie Blue 
stain
0.2% w/v Coomassie Brilliant Blue R250 in 45% v/v methanol, 10 % v/v 
acetic acid in dH2 0
Destain solution 45% v/v methanol, 10% v/v acetic acid in dH20
Gel drying buffer 4% v/v glycerol, 20% v/v methanol in dH20
Following electrophoresis, the gels were immediately immersed in Coomassie Blue stain for 
between 1 hour to overnight on a rocker-table at room temperature. When the gels were stained, 
the staining buffer was removed; the gels rinsed in dH2 0  and placed in destain solution until the 
protein bands were clearly visible and the background reduced. Following the transfer of proteins 
from gels to nitrocellulose (section 2.1.12), these gels were also stained and destained, to confirm 
the transfer had been successful.
For a permanent record, the stained gels were equilibrated for 5 minutes in gel drying buffer and 
sandwiched between two sheets of acetate gel drying film (Promega) pre-soaked in gel drying 
buffer and stretched within a gel drying frame overnight at room temperature.
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2.1.10. Silver Staining of Electrophoresed Gels
The detection limit of this technique was 200 ng (0.2 pg) of protein in a band on an SDS gel483. 
The following incubation steps were for 20 minutes (unless stated) and were performed on a 
rocker-table at room temperature.
Solution Composition
Silver stain solution 1 50% v/v methanol, 10% v/v acetic acid in 6 H2O
Silver stain solution 2 5% v/v methanol, 7% v/v acetic acid in dFhO
Glutaraldehyde solution 5% v/v glutaraldehyde in dH20
Oxidising solution 5 Mg/ml DTT(dithiothretol) in dhbO
Silver stain 0.1 % w/v AgN03 in dhbO
Developing solution 0.002% v/v formaldehyde, 3% w/v Na2C03 in dhbO
Following electrophoresis, the gels were sequentially incubated in silver stain solution 1, silver 
stain solution 2, briefly rinsed with dFkO and incubated in glutaraldehyde solution. The gels were 
washed three times in dFbO, for 15 minutes each and then incubated in oxidising solution, rinsed 
with dhfcO, incubated in silver stain; rinsed with dhbO, then with 3% (w/v) Na2C03 in dhbO and 
developed in developing solution. When the protein bands had developed sufficiently, the 
reaction was stopped by the addition of citric acid (1 g per 50 ml developing solution used). For a 
permanent record, the stained gels were equilibrated for 5 minutes in gel drying buffer and dried 
as described in section 2.1.9.
2.1.11. Western Blotting
Western blot analysis was used to identify specific proteins from complex mixtures and to 
characterise mAbs.
Buffer Composition
Transfer buffer 25 mM Tris, 191 mM glycine, 20% v/v methanol in dH20
Blocking buffer 5% w/v non-fat dried milk/0.1 % Tween-20/PBS
Wash buffer 0.1% v/v Tween-20/PBS
Following SDS-PAGE, the gel was immediately equilibrated in transfer buffer for 10 minutes. The 
gel was placed on a sheet of nitrocellulose and further sandwiched between two sheets of filter 
paper, all of which had been pre-soaked in transfer buffer. The blotting apparatus was 
assembled according to the manufacturer’s instructions with the gel to the anode side and the 
nitrocellulose to the cathode. The proteins were then transferred onto the nitrocellulose at 100 V 
for 1 hour at room temperature, in a tank filled with cooled transfer buffer. After this, the 
nitrocellulose blots were blocked for 1 hour in blocking buffer at room temperature with constant
/
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mixing. The blots were rinsed with wash buffer and incubated with antibody raised against the 
antigen of interest (primary antibody), typically diluted to 1 pg/ml in wash buffer on a roller and 
incubated for 1 hour at room temperature or overnight at 4’C with constant mixing. The blots 
were washed in wash buffer five times for five minutes each at room temperature with constant 
mixing. Secondary antibody or HRPO-conjugated Extravidin (if the primary antibody was 
biotinylated), diluted 1/1000 -1/10,000 (depending on the agent) in wash buffer was incubated 
with the blots for 1 hour at room temperature with constant mixing. The blots were washed five 
times as described. The blots were developed and exposed in the same way as described in 
section 2.1.7.
2.1.12. EUSAs
Various ELISAs, developed in house, were used in the course of this work. All incubations were 
for 1 hour at 37°C, all wash steps comprised three washes (200 pi per well) with wash buffer. All 
dilutions were in blocking buffer (50 pi per well), except where stated. The buffer recipes are 
detailed below.
Buffer Composition
ELISA coating buffer 0.1 M NaHC03/Na2C03, pH9.6
Wash buffer 0.1% (v/v) Tween-20/PBS
Blocking buffer 1% (w/v) BSA/0.1% (v/v) Tween-20/PBS
ELISA developing solution 4 orthophenylenediamine (OPD) tablets (Dako) dissolved in 12 ml 
dH20 plus 5 pi of 30% H20 2.
Quenching solution 10 % (v/v) H2S04 in dH20.
2.1.12.1. Screening for anti-C6 mAbs by ELISA
Serum from immunised mice or supernatant from individual fusion wells were screened by an 
ELISA adapted for the purpose m . Ninety-six-well microtitre plates were coated with 1 pg/ml 
human C6 (Quidel Corporation, San Diego, USA -  or purified in house) (50 pi per well) in ELISA 
coating buffer. After washing, the plates were blocked with blocking buffer (200 pi per well). The 
blocking agent was removed, the plates washed and 50 pi of test sample was added to each well. 
A control antibody against human C6 was included to demonstrate the assay was working 
correctly (WU 6.4, a gift from Professor Reinhardt Wurzner, University of Innsbruck, Austria).
After washing, peroxidase conjugated anti-mouse IgG (H & L chains) immunoglobulin or 
peroxidase conjugated anti-mouse IgG FcY immunoglobulin was placed in each well, or for the rat 
anti-rat C6 hybridomas, HRPO-conjugated anti-rat immunoglobulin antibody was used. The plate 
was washed as described and the assay developed with ELISA developing solution (50 pi per
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well). Colour development was stopped with quenching solution (50 pi per well) when the 
positive control had developed sufficiently so that it was highly positive and the negative control 
had not developed. Typically, this was within 5 minutes, but could be incubated for up to 1 hour. 
The absorbance of each well was measured at 490 nm. Cells from wells with the greatest colour 
development were taken forward.
2.1.12.2. Rat mAb Isotype ELISA
Ninety-six well microtitre plates were coated with 100 pi of hybridoma supernatant to be tested. 
After washing, the plates were blocked with 150 pi blocking buffer per well. The blocking agent 
was removed, the plate washed three times with washing buffer and 100 pi of biotinylated anti-rat 
isotype specific secondary antibodies (Table 2.1) were added in duplicate to individual wells at a 
concentration of 1 pg/ml. The plates were washed, 100 pi HRPO-Extravidin was added to each 
well and incubated at 37°C for 1 hour. After washing, the plate was developed with the addition 
of 100 pi per wll of developing solution for up to 1 hour. Colour development was stopped by 
adding 50 pi of quenching solution to each well and the absorbance of each well was measured 
at490nm.
2.1.13. Isotyping of Mouse mAbs
Mouse mAbs were isotyped using the IsoStrip mouse monoclonal antibody isotyping kit, 
according to manufacturer’s protocols (Catalogue number 1 493 027; Boehringer-Mannheim, 
Roche Applied Science, Indianapolis, USA). This kit comprises a development tube containing 
lyophilised latex beads conjugated to anti-mouse light chain antibodies, and an isotyping strip 
(IsoStrip). The IsoStrip bears immobilised bands of goat anti-mouse antibodies corresponding to 
the mouse antibody isotypes IgGi, lgG2a, lgG2t>, IgG3, IgM and IgA heavy chains and to the kappa 
and lambda light chains. Both sides of the strip also bear a positive control band, which indicates 
that the antibody-coated beads have travelled up the strip. When the latex beads are 
resuspended in the tissue culture medium being tested and an Isostrip is placed in the mixture, 
the latex beads move up the strip by capillary flow. The complex continues to flow up the strip 
until it binds the band of immobilised goat anti-mouse antibody specific for the monoclonal’s 
isotype and also the band of immobilised antibody specfic for the monoclonal’s light chain. This 
is visualised by the appearance of a blue band corresponding to the monoclonal’s heavy and light 
isotype.
To do the test, conditioned medium was collected from the antibody-secreting clones and diluted 
1 in 10 with PBS. One hundred and fifty microlitres of this freshly diluted sample was added to
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each development tube and incubated for 30 seconds at room temperature. Each development 
tube was vortexed for 5 seconds to ensure the latex beads were completely resuspended. An 
IsoStrip was then added to each tube and allowed to soak up the liquid for between 5 and 10 
minutes. Development of the strip was complete when the positive control band on each side of 
the strip burned blue, which is between 5 and 10 minutes. After this time, the IsoStrips were 
examined and the antibody isotype interpreted. For a permanent record, the IsoStrips were dried.
2.1.14. Purification of Immunoglobulins
2.1.14.1. Partial purification of rabbit immunoglobulins
Solid polyethylene glycol (PEG)-6000 (15% (w/v)) was added to rabbit serum and stirred for 30 
minutes at 4°C. The Ig were precipitated by centrifugation at 12,000 g for 30 minutes at 4°C and 
resuspended in PBS, quantified by BCA assay and stored at -20°C.
2.1.14.2. Purification of Mouse IgM
Salt precipitation and ion exchange chromatography was used to purify mouse IgM isotype mAbs. 
To antibody-containing tissue culture supernatant, ammonium sulphate was added to 45% 
saturation, stirred continuously for 30 minutes at 4#C and centrifuged at 24000 g for 20 minutes. 
The supernatant was discarded and the pellet resuspended in 0.02 M K2HPO4/O.0 2  M KH2PO4, 
pH 6.5 (start buffer) and dialysed against start buffer overnight at 4’C. The IgM enriched sample 
was applied to a Source 15Q column (Pharmacia), which had been equilibrated in start buffer.
The column was washed through with two column volumes of start buffer to remove unbound 
proteins. A linear gradient of elution buffer (0.02 M K2HPO4/O.O2  M KH2PO4, 0.5 M NaCI, pH6.5) 
was applied to the column to elute the IgM antibody and collected in 5 ml fractions. IgM 
containing fractions were identified by dot blot (section 2.1.8) using a HRPO-conjugated anti­
murine IgM antibody and pooled. Purity of the pooled fractions was determined using SDS- 
PAGE and Western blot; concentration of the purified antibody was assessed using the Micro 
BCA assay (section 2.1.5).
2.1.14.3. Purification of IgG Isotype mAbs using a Prosep A column
Prosep®-A ‘High Capacity’ (Bioprocessing, Consett, UK) comprises Staphylococcal Protein A 
coupled to a porous glass bead matrix. Protein-A binds to subclasses of immunoglobulin (Ig) G 
from various animal species and with a particularly high capacity to those of murine, bovine, 
guinea pig, human and rabbit origin. A pre-column of Sepharose-4B (GE Healthcare) was used
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to remove any protein that bound non-specifically to the sepharose. The pre-column and Prosep- 
A column were prepared by being washed out of their storage solutions separately with 200 ml 
PBS each. All solutions were passed over these columns under gravity. The washing and 
elution conditions for IgGi isotype antibodies were altered to reduce contamination with bovine Ig. 
It was not possible to do this for other IgG isotype antibodies.
For all IgG isotype antibodies, the antibody-containing supernatant was passed sequentially over 
the pre-column and Prosep A column and the flow through collected. The column was washed 
with up to 500 ml PBS, until no more protein was detected using Coomassie protein assay 
reagent. Bound antibody was then eluted with 0.1 M glycine - HCI, pH 2.5 in 5 ml fractions into 
tubes containing 500 pi 1M Tris pH 7.0 to neutralise the sample. The protein content of the 
fractions was monitored either using the Coomassie protein assay reagent or by measuring the 
A280nm. Protein-containing fractions were pooled, dialysed against PBS overnight at 4‘C and 
concentrated by ultrafiltration. The prosep A column was washed with PBS. To maximise yield, 
the flow through was again passed over the column and any bound antibody eluted, pooled, 
dialysed and concentrated as described above. The protein concentration of purified antibody 
was determined either by measuring the A280 (section 2.1.6) or using the Micro BCA assay 
(section 2.1.5). The extinction coefficient of IgG antibodies is 1.4. The purity of the antibody was 
assessed by SDS-PAGE. The column was cleaned with 10% w/v HCI, pH 1.5 and stored in 0.1% 
v/vNaNa/PBS.
IgGi isotype antibody-containing supernatant was premixed in equal ratios with wash buffer (3 M 
NaCI, 1.5 M glycine, pH 8.9), passed over both columns in sequence and the run-through 
collected. The Prosep A column was washed with up to. 500 ml of wash buffer until no more 
protein was detected in the eluate, using the Coomassie protein assay (section 2.1.4). Bound 
antibody was eluted with elution buffer (0.1 M citrate buffer (0.1 M sodium citrate; 0.1 M citric 
acid), pH 5.2) in 5 ml fractions over 24 fractions. The A280 of the fractions were measured to 
determine their protein content, as citrate interferes with the Coomassie protein assay reagent so 
this could not be used. The protein-containing fractions were pooled, dialysed, concentrated, 
quantified and sample purity assessed as described earlier in this section. The column was 
washed with wash buffer and to maximise the yield of mAb, the run through was re-applied to the 
column. Any bound antibody was eluted, pooled, dialysed, concentrated, quantified and purity 
assessed as described above. The column was cleaned with 10% w/v HCI, pH 1.5 and stored in 
0.1% NaNa/PBS.
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2.2. Animals
All animals used were adults and obtained from breeding colonies in the Biomedical Services 
Unit, at the University of Wales College of Medicine (UWCM), Cardiff. To generate monoclonal 
antibodies, PVG C6 deficient rats 485 and C6 deficient Peru-Coppock mice, bred onto a C3H 
background were used. To generate polyclonal antibodies, C6 deficient rabbits 486 were used. 
These deficiencies had arisen spontaneously. Balb/c mice were used as a source of 
macrophages.
2.2.1. Serum Preparation
Collected blood was allowed to coagulate in a glass collection tube at room temperature for 30 
minutes, or at 4’C for blood collected from rabbits. The clotted blood was then centrifuged at 
2000 rpm for 10 minutes. The serum fraction was removed, aliquoted and stored at -70°C.
2.2.2. Preparation of mouse peritoneal macrophages
Balb/c mice were sacrificed using a Schedule 1 method and washed with 70% ethanol. Ten ml 
ice-cold RPMI medium was injected into the peritoneal cavity using a 21 gauge needle. The 
mouse abdomen was gently massaged and the medium containing resident macrophages then 
slowly withdrawn. The macrophages were pelleted by centrifugation at 2000 rpm, for 10 minutes. 
Finally, the cells were resuspended in the appropriate culture medium for addition to hybridoma 
cultures. Typically, the peritoneal washout of one mouse would yield enough macrophages for 50 
ml medium.
2.2.3. Polyclonal antibody production
A C6 deficient rabbit486 was immunised subcutaneously (s.c) with normal rabbit serum diluted in 
PBS, emulsified with Complete Freund’s adjuvant (CFA)(1.5 ml mannide monooleate, 8.5 ml 
paraffin oil, 5 mg Mycobacterium butyricum per 10 ml ampule, Difco). Two and four weeks after 
the first immunisation, boosts of C6 sufficient rabbit serum diluted in PBS and emulsified with 
Incomplete Freund’s adjuvant (IFA)(1.5 ml mannide monooleate, 8.5 ml paraffin oil per 10 ml 
ampule, Difco) were administered, s.c. A test bleed was taken, serum prepared and tested for 
anti-C6 antibody titre by ELISA. When a high titre was achieved, the rabbit was exsanguinated 
under terminal anaesthesia. The collected blood was allowed to clot and the serum was 
separated from the clot by centrifugation at 2500 rpm at 4°C. The antiserum was aliquoted and 
stored at -70’C.
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2.3. Tissue Culture
AH tissue culture reagents, except where stated, were from Gibco, Invitrogen Corporation 
(Paisley, UK). Tissue culture was performed under sterile conditions using sterile tissue culture 
plates and flasks (Nunc). Cells were maintained in a 5% CO2 in a humidified chamber at 37’C. 
Medium was pre-warmed to 37°C prior to administering to cells, except where stated.
2.3.1. Tissue culture cells and media
Mouse myeloma cell 
lines:
Ag14-SP2/0
NSO
Basic medium RPM11640 Medium, supplemented with 50 U/ml penicillin/ 50 ng/ml 
streptomycin, 1 pg/ml amphotericin B, 2 mM L-glutamine and 1 mM 
sodium pyruvate.
F-5 medium Basic medium supplemented with 5% v/v foetal calf serum (FCS).
F-10 medium Basic medium supplemented with 10% v/v FCS.
F-15 Medium Basic medium supplemented with 15% v/v FCS.
HAT medium F-15 medium supplemented with 0.1 mM hypoxanthine, 0.4 iM 
aminopterin and 16 tiM thymidine.
HT medium F-15 medium supplemented with 0.1 mM hypoxanthine and 16 
thymidine.
PEG-1500 50% w/v Polyethylene glycol 1500 in 75 mM HEPES, pH 8.0, Roche.
Freezing medium 10% v/v DMSO (Sigma) in FCS.
2.3.2. Freezing cells
Stocks of antibody secreting cells and myeloma cell lines were stored frozen in liquid nitrogen. 
Hybridoma and myeloma cells are weakly adherent to tissue culture flasks and therefore did not 
require trypsinisation before subcloning. Cells were detached from the surface on which they 
were growing by agitation. The suspended cells were pelleted by centrifugation at 1200 rpm for 5 
minutes. The pellet from one 80 cm2 flask was resuspended in 1 ml freezing medium and placed 
in cryovials (Greiner) [in aliquots of 1 x 106 cells in 1 ml in cryovials]. The cells were then slowly 
frozen in a Cryo 1° Freezing Container (Nalgene), which is designed to decrease in temperature 
by 1°C per minute when placed in a -70°C freezer. After approximately 24 hours, the frozen cells 
were transferred to liquid nitrogen for long-term storage.
2.3.3. Thawing cells
Frozen cells were stored in aliquots in liquid nitrogen and thawed rapidly by transferring to a 37°C 
water bath. The cells were immediately resuspended in F-15 medium and centrifuged at 1200 
rpm for 5 minutes. The pelleted cells were resuspended in 20 ml F-15 medium and plated out in
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T25 flasks. Freshly harvested mouse peritoneal macrophages were added to the culture medium 
to act as feeder cells.
2.3.4. Maintenance of myeloma cell lines
The mouse myeloma cell line Ag14-SP2/0 was used for fusion with mouse spleen cells and the 
mouse myeloma cell line NSO was used for fusion with rat spleen cells. These cell lines were 
obtained from The European Collection of Cell Cultures (ECACC). Both myeloma cell lines were 
maintained in F-10 medium in a volume of 20 ml in 80 cm2 flasks. To expand cultures, the cells 
were split 1:1. The flasks were agitated to dislodge cells, 20 ml fresh medium added to the flask 
and 20 ml of this suspension removed and placed in a new flask.
2.3.5. Monoclonal Antibody Production
Monoclonal antibodies (mAbs) were generated according to modifications of the method of Kohler 
and Milstein 484>487.
2.3.6. Immunisations
The table below summarises the details of the animals used for mAb production, the immunising 
antigen and the fusion partner:
Animal species Immunised with Myeloma fusion partner
C6 deficient mouse Purified human C6 Ag14-SP2/0
C6 deficient mouse Normal mouse serum Ag14-SP2/0
PVG/C6 deficient rat Normal rat serum NSO
The immunisation protocol was as follows: the first immunisation was administered s.c.; 
comprising 30 -  50 pg of the protein of interest in PBS, emulsified with CFA. Two and four weeks 
after the first immunisation, the animals were boosted (s.c.) with an equal volume of 30 -  50 pg 
antigen in PBS and emulsified with an equal volume of I FA. Several days following the last 
boost, the animals were tail-bled, serum prepared (section 2.2.1) and tested for anti-human C6 
antibodies by ELISA (section 2.3.8). The animal with the highest anti-C6 titre was boosted by 
intraperitoneal injection (i.p.) with approximately 20 pg antigen, diluted in PBS, 48 hours prior to 
sacrifice.
2.3.7. Generation of hybridomas
Once the animal with highest antibody titre against human C6 had been identified, the next step 
was to immortalise and select those B cells secreting anti-C6 antibodies. All wash steps were 
achieved by centrifugation at 1000 rpm for 5 minutes. The animal was exsanguinated under 
terminal anaesthesia and serum prepared (section 2.2.1). Its spleen was removed and
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repeatedly perfused with cold (4°C) RPM11640 medium using a 5 ml syringe and a 19 gauge 
needle to release spleen cells. The released cells were washed in cold RPM11640 medium three 
times.
Myeloma cells (SP2/0 or NSO) growing in log phase were harvested and washed once in F-10 
medium. Spleen cells were mixed with the myeloma cells at a ratio of 2:1, washed once in RPMI 
1640 medium and pelleted. The supernatant was completely removed, leaving a dry pellet, which 
was loosened by gentle agitation. Fusion was induced by the gradual addition of 1 ml PEG-1500 
dropwise to the cells over 1 minute with gentle agitation. The fused cells were left to rest for 30 
seconds and then 50 ml RPM11640 pre-warmed to 37‘C was slowly added. The cells were 
washed by centrifugation and resuspended in 100 ml (150 ml for rat fusion) HAT medium, to 
select for hybrid cells. The aminopterin in the HAT medium inhibits the de novo purine and 
pyrimidine synthesis pathway, so that cells have to synthesize nucleotides via the salvage 
pathway, which requires the addition of hypoxanthine and thymidine 488. Myeloma cells are 
immortal but are unable to utilise the salvage pathway due to a mutation in the enzyme 
hypoxanthine-guanine phosphoribosyl transferase (HPRT). Therefore, unfused myeloma cells 
will die in HAT medium. The unfused spleen cells will also die after a few days in culture, even 
though they are able to use the salvage pathway, because they are not immortal489. Hybridomas 
are immortal, due to the myeloma cell, and can utilise the salvage pathway, because of the 
splenocyte, and therefore will grow in HAT medium. Approximately 0.5 ml of cell suspension was 
added to each well of eight (twelve for rat fusion) 24-well plates that had previously been seeded 
with 0.5 ml (per well) of HAT medium containing mouse peritoneal macrophages to act as feeder 
cells. Approximately 10-14 days post-fusion visible clones were present in the majority of wells 
and were ready for screening for the presence of anti-C6 antibodies by ELISA (section 2.3.8). 
Positive wells were cloned by limiting dilution into HT medium in order to obtain a monoclonal 
antibody secreting cell line. Hypoxanthine and thymidine were provided in culture medium to 
ensure survival of the hybridomas during the transition from using the salvage pathway to the de 
novo purine and pyrimidine synthesis pathway. For cloning at limiting dilution, anti-C6 secreting 
cells were counted and adjusted so that sequential rows of wells in 96 well plates were seeded 
with 100,30,10,3,1, and 0.3"cells per well. One hundred microlitres of HT medium containing 
mouse peritoneal macrophages were also added to each well, as feeder cells. When visible 
clones were present in wells seeded with 1 and 0.3 cells per well, these were screened by ELISA 
and cloned out again as described above, but in F-15 medium only. Typically, a total of three 
rounds of screening and subcloning at this dilution were required to ensure monoclonality, 
although sometimes further rounds were required.
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Once the cell lines were monoclonal, they were expanded, some were frozen down as stocks and 
the rest were expanded further into 175 cm2 tissue culture flasks and maintained in 30 ml F-5 
medium. Once a week, the medium was collected and replaced with fresh medium. The 
collected medium was centrifuged at 1000 rpm' to remove cell debris. Sodium azide (0.01%
(v/v)) was added as a preservative and the supernatant stored at 4°C until the antibody was 
purified.
2.4. Haemolysis Assays
Classical pathway mediated haemolytic assays were used to identify functional C6-containing 
fractions whilst purifying C6490, to determine the functional activity of purified C6 across species 
and to characterise the functional blocking activity of antibodies and phage-peptides generated 
against purified C6.
2.4.1. General materials
Complement Fixation Diluent (CFD): 1 tablet was dissolved in 100 ml of deionised water to a final 
concentration of 0.9 mM sodium barbital, 2.8 mM barbituric acid, 145 mM NaCI, 0.8 mM MgCb, 
0.3 mM CaCb, pH 7.2 + 0.2 (Oxoid, Basingstoke, UK).
Alsever’s solution: 144 mM Na3C6H5C>7.2H20,27 mM glucose, 72 mM NaCI, pH 6.1.
Sheep blood in Alsever’s solution, TCS Biosciences Ltd., Claydon, Buckinghamshire, UK.
Rabbit blood in Alsever’s solution, BMS, UWCM.
2.4.2. Antibody-sensitisation of sheep and rabbit erythrocytes
To prepare a 2% stock solution of antibody-sensitised sheep erythrocytes (sheep EA) or rabbit 
erythrocytes (rabbit EA), 1 ml of sheep blood or 1 ml of rabbit blood was diluted in 20 ml CFD and 
centrifuged at 2000 rpm for 5 minutes. Four hundred of the packed erythrocytes (E) were 
removed and washed three times in CFD as described above, before being resuspended in 10 ml 
CFD and warmed at 37°C for 5 minutes. To sensitise the sheep E, 10 ml of pre-warmed CFD 
containing Amboceptor (rabbit anti-sheep E)(Dade-Behring, Marburg, Germany) diluted 1/250 
was added to the warm sheep E and mixed gently at room temperature for 30 minutes. The 
rabbit E were sensitised in the same way, except that they were incubated with mouse anti-rabbit 
E (BMS, UWCM) at a dilution of 1/200. The antibody-sensitised erythrocytes were washed three 
times in CFD and resuspended in a final volume of 20 ml CFD. Sheep EA and rabbit EA were 
stored at 4°C for up to 1 week.
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2.4.3 Titration of test serum
Doubling dilutions of the test serum were made into 50 pi CFD (final volume) in a round-bottomed 
microwell plate, to which a further 50 pi each of CFD and EA were then added. The maximum 
lysis control wells contained 100 pi dhfeO and 50 pi EA and the background lysis control wells 
contained 100 pi CFD and 50 pi EA. The plate was incubated at 37'C for 30 minutes before 
being centrifuged at 2500 rpm for 5 minutes to pellet the cells. Supernatant from each well (100 
pi) was transferred to a flat-bottom microwell plate and the release of haemoglobin into the 
supernatant was measured at A4i5nm.
To calculate the percentage of lysis, the following equation was used:
A4i5nm (sample) -  A4i5nm (background lysis control)
% lysis = 100 X -------------------------------------------------------------------------------
A4i 5nm (maximum lysis control) -  Ausnm (background lysis control)
A measurement of the serum complement haemolytic activity (CH50) was obtained by plotting the 
calculated % lysis against serum dilution and the dilution of serum at which 50-70% haemolysis 
occurred was determined.
2.4.4. Reconstitution of C6 deficient serum with functional C6
Reconstitution experiments with C6 were performed - either to identify functionally active C6 
containing fractions during C6 purification or to determine the minimal concentration of C6 
required for C-mediated haemolysis to occur.
To identify functionally active C6 containing fractions, rat C6 deficient (C6D) serum was titrated in 
a similar way to that described in section 2.4.3. Two sets of doubling dilutions of rat C6D were 
made in 50 pi CFD (final volume) in a round bottom microwell plate. To one set 10 pi functionally 
active C6 in CFD was added; to the other set 10 pi CFD was added and to both sets 50 pi sheep 
EA were added. For the maximum lysis control 60 pi dH20 was added to 50 pi sheep EA and for 
the background lysis control 60 pi CFD was added to 50 pi sheep EA. The plate was incubated 
at 37'C for 30 minutes before being centrifuged at 2500 rpm for 5 minutes to pellet the cells. 
Supernatant from each well (90 pi) was transferred to a flat-bottom microwell plate and the 
release of haemoglobin into the supernatant was measured at A4i 5nm. The percentage of lysis 
was calculated as detailed in section 2.4.3 and a CH50 value was obtained by plotting the 
calculated % lysis against serum dilution. A dilution of rat C6D serum at which 50-70%
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haemolysis occurred when C6 was present, but at which dilution no lysis occurred when C6 was 
absent was chosen for the subsequent reconstitution assays.
To identify C6 containing fractions, 10 pi test sample (either neat or diluted 1:10 in CFD) was 
mixed with 50 jJ C6D rat serum diluted in CFD at a pre-determined dilution and 50 \x\ of sheep 
EA in a found bottom microtitre plate. Maximum and background lysis controls, as well as a 
positive control containing 10 pi functionally active C6 were also included. The plate was 
incubated at 37‘C for 30 minutes and centrifuged at 2500 rpm for 5 minutes. Supernatant from 
each well (90 pi) was transferred to a flat-bottom microwell plate and the release of haemoglobin 
into the supernatant was measured at Ausnm. The percentage of lysis was calculated as detailed 
in section 2.4.3.
To determine the minimal concentration of C6 required for C-mediated haemolysis to occur 
doubling dilutions of C6D serum were made in 50 pi CFD (final volume) in a round bottom 
microtitre plate. Ten microlitres human C6 (0-200 pg/ml) in CFD was added to each dilution of 
C6D serum along with 50 pi EA and incubated for 30 minutes at 37°C. Maximum and 
background lysis controls were also included. The plates were centrifuged at 2500 rpm, the 
supernatants collected (90 pi) to a flat bottom microtitre plate and A4i5nm measured. The 
percentage of lysis was calculated and the CH50 obtained as described in section 2.4.3.
2.4.5. Haemolytic assay to test the activity of potential inhibitory agents
A titration was carried out to determine the dilution of serum that induced 80% haemolysis, as 
detailed in section 2.4.3. Serial dilutions of the test sample were made into CFD (50 pi total 
volume) in a 96-well round bottom plate. To this, serum (50 pi) at a predetermined dilution in 
CFD was added and the plate pre-incubated at 37°C for 30 minutes. Fifty microlitres EA were 
then added to each well and the plate incubated for a further 30 minutes at 37‘C. Maximum and 
background lysis controls, as well as relevant controls for the test sample were included. For 
antibodies being tested this was an antibody that did not recognise C6 and was not a known 
blocker of C-mediated haemolysis. Wild-type phage was the control when phage-peptides were 
tested. The plate was centrifuged at 2500 rpm for 5 minutes, the supernatant from each well (100 
pi) transferred to a flat-bottom microwell plate and the release of haemoglobin into the 
supernatant measured at A4 i5nm. The percentage of lysis was calculated as detailed in section
2.4.3. For a rapid screen enabling a higher throughput of phage-peptides on one plate, 
subsequent phage-peptides were screened at one dilution only to determine whether they had 
inhibitory activity.
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2.5. Surface Plasmon Resonance (SPR) using the BIAcore 3000
The BIAcore491 instrument provides the means to study protein-to-protein interactions in real time 
with small amounts of unlabelled material by measuring surface plasmon resonance (SPR). It 
comprises three major components: the sensor chip, a microfluidics system492 and SPR detector. 
SPR is an electron charge density wave effect that arises at the surface of a metallic film (sensor 
chip) when light is reflected at the film under specific conditions. The resonance is a result of 
energy and momentum being transformed from incident photons into surface plasmons and is 
sensitive to the refractive index of the medium on the opposite face of the film from the reflected 
light. If a molecule binds to the chip surface, then there is a change in the refractive index of the 
medium and this is recorded on the sensorgram. All sensor chips comprise a glass slide coated 
with gold to which a matrix is attached. The ligand of interest is immobilised onto this matrix and 
the microfluidics system delivers the molecule of interest (analyte) to it in a controlled manner. 
Quantitative information about the specificity, kinetics, affinity and concentration of the analyte for 
the ligand can then be gathered.
The BIAcore 3000 was used in ail experiments and all buffers used were filtered (0.2 |am) and 
degassed before use on the BIAcore 3000. As the coupling chemistry was the same for both 
types of sensor chip used, the immobilisation of ligand onto the sensor chip surface is detailed 
below. Methods specific to the experiments are described in the relevant chapter.
2.5.1. Immobilisation of Ligand onto the Sensor Chip Surface
A number of sensor chips with matrices of different compositions attached to the surface are 
available. These different matrices enable the favourable immobilisation of a wide range of 
ligands of interest onto the surface. In this study, the CM-5 sensor chip (BIAcore AB, Uppsala, 
Sweden) and the Pioneer Chip F1 (BIAcore AB, Uppsala, Sweden) were used. 
Carboxymethylated dextran is covalently attached to the surface of both chips, but the dextran 
molecules on the Pioneer Chip F1 are shorter than those on the CM-5 chip. However, the ligand 
is covalently coupled (immobilised) onto both types of sensor chip via amine groups and so the 
immobilisation methods are identical. For immobilisation, the ligand interacts with the chip 
surface via electrostatic interactions -  this usually occurs maximally below the pi of the ligand and 
therefore, the optimal pH for achieving maximal attachment of ligand to the surface of the chip 
was determined. Ligand diluted in 10 mM sodium acetate buffer, pH range 3.5 -  5.0, was 
injected over the sensor chip surface. Having selected the pH at which to carry out the 
immobilisation, the ligand was immobilised onto the flow cell surface (figure 2.1). To ‘activate’ the 
sensor chip surface, a mixture of NHS (0.05 M N-hydroxysuccinimide in H20)(BIAcore AB,
Figure 2.1 Chemistry of amine coupling of ligand to the CM-5 or Pioneer F1 sensor chip surface
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To immobilise a ligand onto the surface of a CM-5 or Pioneer F1 chip by amine coupling, the surface of the 
sensor chip is first activated by passing a mixture of freshly mixed 0.2M 1-ethyl-3-(3-dimethylaminopropyl)- 
carbodiimide (EDC) (final concentration) and 0.05 M N-hydroxsuccinimide (NHS) (final concentration) over it, 
This alters the surface chemistry, so that when the ligand with free amine groups is flowed over the sensor 
chip surface, the ligand forms a covalent bond with the surface via the amine group. When the target RU 
has been reached, 1 M ethanolamine-HCI pH 8.5 is passed over the surface, blocking any free reactive 
groups, so that no other proteins can bind to the surface.
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Uppsala, Sweden) and EDC (0.2 M N-ethyl-N’-(dimethylaminopropyl)-carbodiimide in 
H20)(BIAcore AB, Uppsala, Sweden) was injected over it. The ligand was injected over the 
sensor chip and allowed to covalently bind to the surface. To block any free reactive groups 
remaining, ethanolamine (1M ethanolamine hydrochloride, adjusted to pH 8.5 with 
NaOH)(BIAcore AB, Uppsala, Sweden) was passed over the sensor chip surface. Noncovalently 
bound material was removed by flowing 10 mM sodium hydroxide over the flow cell. On the CM- 
5 chips, an additional flow cell was treated in a similar way, but omitting the immobilisation of 
ligand, so that it could be used as a reference blank flow cell. For the Pioneer F1 chip, an 
irrelevant peptide was immobilised onto the sensor chip and used as a reference.
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Chapter 3: Purification and functional characterisation of human C6 and 
reconstitution of C activity in C6 deficient human and rodent sera with human 
C6
3.1. Introduction
The C protein C6 is a central target of this study. Therefore, before work could start on 
generating agents that block C6 activity, pure C6 was required. Although pure human C6 is 
available commercially (Quidel.San Diego, California, USA), it is expensive and sold in small 
amounts (250 pg costs approximately £150.00). As C6 is present in human plasma at up to 100 
mg/L and out-of-date plasma was freely available from the Welsh Blood Transfusion Service, it 
was cost-effective to develop our own in-house methods of C6 purification. Traditionally, multi- 
step classical methods including ion exchange chromatography have been used for purifying C6 
and other C proteins from human plasma 49°. Ion exchange chromatography is ideal for purifying 
from complex mixtures of proteins as it separates proteins according to charge. Various classical 
methods have been published for purifying C proteins 490,493-495 ancj these have now been further 
modified and optimised for use in-house. Such methods, however, are time consuming, 
inefficient and importantly often the functional activity of the protein is either significantly reduced 
or lost -  this is particularly the case with C6496. Therefore, better purification methods were 
required. Affinity chromatography separates proteins on the basis of a specific and reversible 
interaction between a protein (or group of proteins) and a particular ligand, coupled to a 
chromatographic matrix. It is the only purification technique that enables the purification of a 
biomolecule on the basis of its biological function or individual chemical structure 497. For this to 
be successful, the coupled ligand must retain its specific binding affinity for the target molecules 
and after washing away unbound material, the binding between the ligand and target molecule 
must be reversible to allow the target molecules to be removed in an active form. The target 
protein can be eluted from the affinity medium either specifically using a competitive ligand, or 
non-specifically, by changing the pH, ionic strength or polarity, depending on the nature of the 
target-ligand interaction. Varipus biological interactions can be exploited in this way, including 
those between glutathione and glutathione-S-transferase (GST), lectins and glycoproteins as well 
as antibodies and antigens. Due to the specificity of these interactions, the target protein can be 
collected in a purified, concentrated and biologically active form from a complex mixture of 
proteins in one step. Purification that would otherwise be time-consuming, difficult or even 
impossible using other techniques can often be easily achieved with affinity chromatography.
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This has been done successfully for other C proteins, using specific anti-C antibodies coupled to 
a matrix. Small quantities of human C6 have previously been purified by affinity chromatography 
498 using the anti-human C6 mAb WU 6.4458. However, attempts to purify greater amounts of C6 
have been hampered by the fact that large quantities of antibody are required for column 
preparation. As the hybridoma cell line secreting WU 6.4 is not available to provide sufficient 
quantities of mAb, an in house anti-C6 secreting hybridoma would be of significant benefit, 
enabling affinity purification of C6 to be performed in house.
The requirements of a reliable C6 purification protocol were twofold: first, to be capable of 
purifying large quantities of C6 speedily and efficiently; secondly, the purified C6 should be 
biologically active. This would enable functional studies to be performed using classical 
haemolytic assays with C6 deficient human sera and reconstituting activity using purified C6. In 
addition, mouse, rat and rabbit C6 deficient sera were available in house, allowing the 
investigation of the functional homology of C6 across species, both in vitro and in vivo. For 
example, human C6 has been shown to reconstitute C6 activity in C6-deficient rats in previous 
studies 274-498. Also, pure, biologically active C6 was an essential tool for later investigations in 
this study, including generating anti-C6 antibodies, identifying phage-peptides that recognise C6, 
and further characterising these reagents in functional blocking assays.
The aims of the investigations described in this chapter were threefold: first, to develop and 
optimise an efficient method for the purification of human C6, free of contaminating serum 
proteins and free of other C proteins. Second, to determine the functional activity of the purified 
C6 by reconstituting human C6 deficient serum in C-mediated lytic assays. Finally, to test the 
capacity of purified C6 to restore C-haemolytic activity in rodent C6 deficient sera both in vitro and 
in vivo.
3.2. Specific Methods
3.2.1. The Purification of Human C6
As pure human C6 was required for this project, one of the first tasks was to purify it. Various 
purification methods were developed and used. These techniques are detailed in the following 
section, but are summarised schematically in figure 3.1.
3.2.1.1. Enrichment of C6 using PEG Precipitation
Human C6 was purified from fresh frozen plasma obtained from the Welsh Blood Transfusion 
Service (WBTS). Whether classical or affinity methods were used to purify C6, a precipitation
Figure 3.1 A summary of the methods used 
to purify C6 from human serum
7%-16% PEG cuts; 
bulk protein contaminants discarded
v
i
Human plasma
C6 enriched pellet after 
a 7% and 16% PEG cut
Affinity methods:Multi-step
chromatographic method:
mAb 23D1 coupled to 
Affi-gel™ hydrazide gel
mAb 7A2 coupled to Affi- 
gel™ Hz hydrazide gel
mAb 7A2 coupled to CNBr 
activated sepharose
DEAE column
MonoQ column
HA column
MonoS column Analysis of purification process by:
1. SDS-PAGE -  determination of purity
2. Western blot -  confirmation of presence of C6
3. Haemolytic assays -  demonstration of functional activity of C6
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step was performed to enrich the preparation with C6 and reduce the volume to be applied to 
columns. All steps were performed at 4°C in order to minimise the loss of functional activity of 
C6, as human C6 rapidly and spontaneously becomes non-functional at room temperature. The 
protease inhibitors PMSF and benzamidine were added at 1 mM final concentration to human 
plasma, mixed and centrifuged at 15,000 g for 10 minutes. To the supernatant, polyethylene 
glycol (PEG)-4000 was added from a 21% (w/v) stock solution in water to a final concentration of 
7% (w/v), stirred for 30 minutes, and centrifuged at 24,000 g for 20 minutes, 4°C. The resulting 
pellet containing high molecular weight contaminants was discarded. The 7% PEG-supernatant 
was adjusted to 16% (w/v) PEG-4000 by the addition of solid PEG-4000 (9g of PEG-4000 per 
100 ml supernatant), mixed and centrifuged as described above. The resulting pellet which 
contained the enriched C6 was then suspended in the relevant buffer for the purification method, 
whilst the supernatant was discarded.
3.2.1.2. Ion Exchange Chromatography
Ion exchange chromatography separates proteins with differences in charge. The separation is 
based on the reversible interaction between a charged protein and an oppositely charged 
chromatographic medium. Proteins bind to the chromatographic medium as they are loaded onto 
a column, then, by altering the conditions -  usually increasing the salt concentration or changing 
the pH, the bound substances are eluted differentially. In this way, target proteins are 
concentrated during binding and collected in a purified, concentrated form.
C6 was purified from human plasma by published classical methods 493495. As contaminating 
proteins were present after the first three chromatographic steps, an additional purification step 
was added - the Mono S column. All steps were performed at 4°C. The C6-enriched pellet from 
section 3.2.1.1. was dissolved in 25 mM NaBarbitone buffer, containing 5mM EDTA, 0.5 mM 
PMSF, 0.02% sodium azide, pH 7.2. The sample was then subjected to various ion exchange 
chromatographic steps, using several matrices (Table 3.1). All columns were equilibrated and all 
samples dialysed in the relevant start buffer prior to the application of sample to the column. 
Bound sample was eluted with a continuous linear gradient varying salt (NaCI) or phosphate 
concentration as appropriate. Fractions containing functional C6 were identified by haemolytic 
assay (section 2.4.4), pooled and dialysed in the relevant start buffer. If necessary, sample was 
concentrated using ultrafiltration (section 2.1.2) and filtered through a 0.2 ^m filter prior to being 
applied to a column.
After each chromatographic step, the C6-containing fractions were identified by haemolytic assay 
(section 2.4.4.) and pooled for the next chromatographic step. After the final step, fractions were
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subject to SDS-PAGE electrophoresis and western analysis to assess the purity of C6. The 
concentration of C6 was determined either using the BCA assay (section 2.1.4) or measuring the 
absorbance of each fraction at 280 nm (extinction coefficient =1.1) and stored in aliquots at - 
70°C until use. This helped retain the functional activity of C6 as it was lost when stored at -20°C.
Table 3.1. The sequential chromatographic steps C6 purification.
Chromatographic
matrix
Functional
group
Start buffer End buffer
DEAE-Sephacel 
(anion exchange)
Diethylaminoethyl 25mM NaBarbitone, 5 mM EDTA, 
0.5mM PMSF, 0.02% NaN3, pH 7.2
Start buffer + 1M 
NaCI, pH 7.2
Hydroxyapatite Calcium
phosphate
5 mM KPhosphate, pH 7.0 300 mM Kphosphate, 
pH 7.0
Mono Q (anion 
exchange)
Quaternary amine 20 mM KPhosphate, pH 7.0 Start buffer +1 M 
NaCI, pH 7.0
♦ MonoS (cation 
exchange)
Sulfonate 20 mM KPhosphate, pH 5.0 Start buffer + 0.5 M 
NaCI, pH 5.0
All matrices, apart from hydroxyapatite, were purchased from Amersham Pharmacia Biotech 
(Chalfont, Buckinghamshire, UK). Hydroxyapaptite is not an ion exchange matrix and was 
purchased from Bio-Rad (Hercules, California, USA).
♦Additional step added to classical methods to improve the purity of C6.
3.2.1.3. Affinity Chromatography
3.2.1.3.1. Preparation of an affinity column using Cyanogen Bromide (CNBr) activated 
sepharose
Cyanogen bromide (CNBr)-activated Sepharose 4B (Amersham Biosciences, USA) is a
preactivated gel for immobilisation of ligands containing primary amines.
Buffers Composition
Coupling buffer 0.1 M NaHC03 pH 8.3.0.5M NaCI.
Swelling buffer 1 mM HCI.
Blocking buffer 0.1 M Tris-HCI, pH 8.0.
Low pH wash buffer 0.1 M sodium acetate buffer pH 4.0,0.5 M NaCI.
High pH wash buffer 0.1 M Tris-HCI buffer, pH 8.0,0.5 M NaCI.
Ten milligrams of purified antibody was coupled to CNBr-activated Sepharose 4B using the 
buffers listed above as detailed in the manufacturer’s instructions (Catalogue number: 17-0430- 
01) (wwwl .amershambiosciences.com). Freeze-dried gel (1g per 3 mg of antibody) was washed 
and swelled on a sintered glass filter using approximately 200 ml swelling buffer per gram of 
freeze-dried powder. The gel was mixed with the antibody (1 mg/ml, which had been dialysed 
into coupling buffer) and mixed end over end for 1 hour at room temperature. After this, the gel
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was washed with a minimum of 5 gel volumes of coupling buffer and the coupling efficiency 
analysed by quantifying unbound antibody using the Coomassie protein assay. The remaining 
active groups on the sepharose gel were deactivated or blocked after coupling by incubating the 
gel for 2 hours in blocking buffer. As Tris-HCI was used, this added an excess of small primary 
amine. The gel was then washed, alternating between low and high pH wash buffers, at least 
three times in order to remove excess of uncoupled ligand. This ensured that no free ligand 
remained ionically bound to the immobilised ligand. Columns were stored in 0.1% sodium azide 
(NaN3)/PBS.
3.2.1.3.2. Preparation of an affinity column using Affi-Gel® Hz Hydrazide Gei
Although activated sepharose coupled antibodies efficiently, the coupled anti-C6 antibody was 
prone to leaching from the column, so that very quickly the coupled antibody was eluted from the 
column, making it useless. Affi-Gel® Hz Hydrazide Gel (Bio-Rad Laboratories, Hercules, 
California, USA) is an agarose support which reacts with the aldehydes of oxidized 
carbohydrates, forming stable, covalent hydrazone bonds. The Fc region of IgG isotype 
antibodies comprises approximately 3% carbohydrate and by oxidation, it can be coupled to the 
Affi-Gel Hz gel. As the Fc region of the antibody is coupled to the matrix, it is more likely that the 
antibody will be presented on the matrix in an orientation that will be optimal for affinity 
purification. Antibody was coupled to the Affi-Gel® Hz Hydrazide Gel, according to the 
manufacturers instruction manual (www.bio-rad.com, catalogue number 153-6060). All steps 
were performed at 4'C, except where specified.
Buffer Composition
Affi-gel coupling buffer Made up from Affi-gel 10X Coupling buffer (Cat No 153-6054, 
BioRad), adjusted to pH 5.5.
Sodium periodate stock 
solution
25mg sodium periodate dissolved in 1.2 ml dH20.
The purified mAb to be coupled was prepared for oxidation by dialysing it against two changes of 
Affi-gel coupling buffer overnight to achieve a 1,000-fold excess of buffer to antibody. To oxidise 
the mAb, one tenth the volume of sodium periodate stock solution was added to the mAb (e.g. 2 
ml stock solution to 20 ml antibody at 1 mg/ml) and the solution mixed gently in the dark for 1 
hour at room temperature. Glycerol was immediately added to the oxidised antibody at a final 
concentration of 20 mM and allowed to mix for 10 minutes. The antibody was dialysed against 
two changes of Affi-gel coupling buffer overnight to achieve a 1,000-fold (v/v) excess of buffer to 
antibody.
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The Affi-gel Hz gel was prepared as follows: to remove the isopropanol in which it was stored, the 
gel/isopropanol slurry was transferred to a container and the gel allowed to settle. The 
isopropanol supernatant was removed and Affi-gel coupling buffer added at twice the gel volume. 
This was mixed well and the gel allowed to settle. The supernatant was removed and the gel 
wash repeated. Finally, an equal volume of coupling buffer was added to the gel and mixed. The 
slurry was then added to a leak-proof reaction container and allowed to settle. The buffer above 
the settled gel was removed.
For optimal coupling to Affi-gel Hz gel it is recommended the IgG concentration should be 1-10 
mg/ml. The oxidised, desalted IgG was added to the washed affi-gel Hz hydrazide gel. The mAb 
was coupled to the gel by mixing overnight at room temperature. The gel/IgG slurry was poured 
into a column, the eluant collected and the volume measured. The gel was washed with one 
column volume of 20 mM K2HPO4/2 O mM KH2PO4, 0.5 M NaCI, pH 7.0. The column eluant was 
collected and saved for coupling efficiency determination. The column was washed with 20 mM 
K2HPO4/2 O mM KH2P04,0.5 M NaCI, 0.02% v/v sodium azide and stored at 4°C until used.
To calculate the coupling efficiency of the mAb to the column, the absorbance at 280 nm in the 
eluates was measured against an appropriate buffer blank. The following equations were then 
used:
AbS280nm /1.4 = (mg IgG/ml) x dilution x volume = total IgG 
[total coupled protein] =
[total protein before coupling]-[total uncoupled protein (eluant + 0.5 M NaCI wash)]
% protein coupled = 100 X ([total coupled protein] I [total protein before coupling])
The column was pre-conditioned by applying 2-4 bed volumes of 0.1% v/v diethylamine (DEA) in 
PBS, pH 11.5. The column was regenerated with at least 5 bed volumes of PBS before use.
3.2.1.3.3. Affinity purification of human C6
The C6 enriched PEG pellet (section 3.2.1.1.) was dissolved in PBS and centrifuged at 15000 g 
for 20 minutes to remove undissolved material before passing it over the affinity column. The C6 
affinity column was pre-equilibrated with 10 column volumes PBS and the C6 containing solution 
passed over it at approximately 0.5 ml per minute. The breakthrough was retained and the 
column washed with at least 20 column volumes PBS until no more protein was detected in the 
run through by Coomassie protein reagent. Bound C6 was eluted from the column with elution 
buffer (0.5% v/v DEA in PBS, pH 11.5) in 1 ml fractions until no more protein was detected using
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Coomassie reagent. Fractions were neutralised by the addition of 200 pi 1M Tris-HCI, pH 7.0. 
The column was rinsed with PBS to remove elution buffer from the column and the breakthrough 
re-applied to the column to maximise yield. Bound C6 was eluted as described above; the 
column was washed with PBS and stored in 0.01% NaN3 v/v in PBS at 4’C.
Protein containing fractions (1 ml) were assayed for C6 activity by haemolytic assay (section 
2.4.4), pooled, dialysed against PBS overnight and concentrated by ultrafiltration. The protein 
concentration of the concentrate was determined by measuring A280 or using the BCA assay, 
functional activity was determined using a haemolytic assay and purity was determined by SDS- 
PAGE and western blot. Finally, the purified C6 was aliquoted and stored at -70°C.
3.2.2. Reconstitution of C6 deficient serum with purified human C6
3.2.2.1. Reconstitution of different species sera in vitro with purified human C6
The following experiments were performed using sera from humans, mice, rats and rabbits that 
had previously been confirmed as genetically deficient in C6 and dysfunctional in haemolytic 
assays. The aim of the investigations described was to determine whether human C6 was 
capable of restoring C lytic function to the aforementioned deficient sera. Sheep EA were used 
for all sera tested, apart from mouse serum, for which rabbit EA were used. The concentration of 
C6 in normal human blood ranges between 20 - 80 pg/ml4" ,  therefore the concentration range of 
C6 used to reconstitute C6 deficient (C6D) serum was 1 -  200 pg/ml.
For the reconstitution assay, 10 pi C6 (1 - 200 pg/ml final concentration) was added to 50 pi C6D 
human serum (diluted 1 in 5 -1  in 640 in CFD, except for experiments involving mouse sera, in 
which case dilutions were in CFD supplemented with 0.1% (w/v) gelatine and 2.5% (wN) 
dextrose) and incubated together with 50 pi 2% sheep EA for 30 minutes at 37°C (described in 
section 2.4.). After centrifugation at 1500 g, the supernatants were collected and absorbance at 
415nm measured. The percentage of lysis was calculated and the CH50 value calculated 
according to the instructions in section 3.2.2.3.
3.2.2.2. Reconstitution of C6 deficient mice in vivo with human C6
To investigate whether the haemolytic activity of C6 deficient mice could be restored over 12 
hours with human C6, purified human C6 (300 pg per mouse) was administered (i.p. injection) to 
C6 deficient mice. Thirty minutes and 2 hours post-injection, the mice were tail-bled and serum 
prepared (section 2.2.1). Twelve hours post-injection, the mice were exsanguinated under 
terminal anaesthesia and serum prepared. To determine whether the administration of human
61
C6 had reconstituted haemolytic activity, haemolytic assays were performed (section 2.4.) using 
rabbit EA and the CH50 at each timepoint calculated as below.
3.2.2.3. Calculation of Complement Haemolytic activity required to achieve 50% 
haemolysis of activated sheep erythrocytes (CH50) via the C classical pathway
CH50 describes the amount of complement haemolytic activity in serum required to produce 50% 
haemolysis of antibody sensitised erythrocytes under specific conditions. The CH50 is inversely 
proportional to the amount of serum required to produce 50% haemolysis of activated 
erythrocytes, referred to as the X50. The X50 and CH50 values for the C6 reconstitution assays 
performed in this chapter were calculated by a method adapted from the standard operating 
procedure (SOP) for serum complement haemolytic activity (CH50) used in the Cellular 
Immunology Laboratory, Section of Immunology, Department of Medical Biochemistry and 
Immunology at the University Hospital of Wales.
After the haemolytic assays had been performed, the X value, the volume (pi serum/well) per well 
was calculated and the logio for each point determined. The Y value, the percentage of cells 
lysed was calculated and then the value of logio(Y/1-Y) determined. To determine X50, the 
volume of serum required to produce haemolysis of 50% of activated erythrocytes, logioX was 
plotted against logio(Y/1-Y).
At 50% haemolysis, Y = 0.5, hence (Y/1-Y) = 1, 
therefore logio(Y/1-Y) = logiol = 0.
A trendline was fitted to the data and the equation of the line determined. This equation was then 
used to calculate the value of: 
logioX at logio(Y/1-Y) = 0,
which is the logio of the X50. The antilog ( 10X50) was calculated, giving the X50 for that serum 
sample.
CH50 Units/ml = 1/Xsox 2000.
The normal range for classical pathway CH50 values in human serum are 1000 -  2000 when 
performed with 1% EA; in these experiments, 2% EA were used. This may result in an altered 
normal range for the CH50 values.
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3.3. Results
3.3.1. Purification of human C6 using ion exchange chromatography
Human plasma, obtained from the WBTS (1L starting volume) was subject to PEG precipitation, 
followed by a series of column purification steps (described in section 3.2.1.). At each point in 
this process, material was reserved and analysed by SDS-PAGE and in parallel by western blot 
under non-reducing conditions in order to assess the degree of purification achieved (Figure 3.2). 
Owing to the complex nature of the sample, the C6 PEG enriched pellet is seen as a broad smear 
of proteins with no discemable band corresponding to C6 either on the coomassie blue stained 
gel or the western blot. Following elution from the DEAE column, the pooled fractions are better 
resolved on both gels, demonstrating the removal of major contaminating proteins and 
enrichment of C6 as a band of 100 kDa. The mono Q column removed the majority of the 
remaining contaminants, leaving two major bands, one consistent with C6, the other with a 
molecular weight of approximately 70 kDa. The identification of the protein peak containing 
functionally active C6 (as determined by haemolytic assay) corresponds to 2 peaks of 
absorbance at 280 nm on the chromatogram (Figure 3.3). In order to remove the remaining 
contaminants the pooled fractions were passed over the mono S column. Fractions of the protein 
peak containing functionally active C6 (as determined by haemolytic assay) correspond to a 
single peak on the chromatogram (Figure 3.4) and the coomassie stained gel and western blot 
(Figure 3.2) shows that most of the contaminating proteins were removed and the major band 
corresponds to C6. However, an additional band of 70 kDa remained in all but one of the 
fractions and was also detected by western blot, confirming it is a fragment of C6. The mAb WU
6.4, the detecting antibody used for figure 3.2b recognises a truncated form of C6 as well as full 
length C6. Truncated C6 is made by individuals with a subtotal deficiency in C6 and has a 
molecular weight of 79 - 80 kDa499'500. It is unlikely that plasma collected from normal individuals 
contained a truncated form of C6, but more likely that the C6 degraded either during storage in 
the expired plasma or as it was being purified. Gel filtration was not used to separate these 
different molecular weight proteins, as they were such similar molecular weights they would have 
co-eluted from a column together. Although C6 was successfully purified, the yield was 0.56 mg 
per 1 L volume of starting material. Assuming there is 80 mg/L C6 in plasma, the yield of purified 
C6 using this method is less than 1%. The functional quality of the purified C6 was also poor and 
the process time consuming. Therefore, better methods of C6 purification needed to be 
developed.
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Figure 3.2 Purification of human C6 using ion exchange chromatography 
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Collected fractions containing functional C6 activity at each purification step were pooled and passed 
over the next chromatographic column. Pooled material was retained at each step and equal volumes of 
sample analysed under non-reducing conditions by (A) SDS PAGE, stained with Coomassie blue 
reagent to assess the degree of purification reached at each step. The same material was also subject 
to (B) Western blotting. After SDS PAGE and transfer to nitrocellulose, protein was probed with the anti­
human C6 antibody WU6.4 (1 i^g/ml) and anti-mouse Ig-HRPO (1/1000) as a secondary antibody.
Bands were detected with ECL and visualised by autoradiography. Protein molecular weight markers 
(M) were also run.
Figure 3.3 Typical chromatogram of partially purified C6 being passed over a
MonoQ column
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C6-containing fractions eluted from an HA column were pooled, dialysed against MonoQ start buffer 
and applied to a MonoQ column pre-equilibrated with MonoQ start buffer. To elute proteins from the 
column, a linear salt gradient was applied and a chromatogram recorded (A). To identify the C6- 
containing fractions, 10 pi of each fraction was incubated with rat C6 deficient serum and 2% sheep EA 
for 30 minutes and centrifuged. The supernatants were collected and the A415 nm measured. As can 
be seen from Figure 3.3B, C6 was eluted between fractions 19-31. Fractions 22-27 were pooled and 
dialysed against Mono S start buffer.
Figure 3.4 Typical chromatogram of partially purified C6 being passed over a
MonoS column
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Eluted fractions
C6-containing fractions eluted from the MonoQ column were pooled, dialysed against MonoS start buffer 
and applied to a MonoS column pre-equilibrated with MonoS start buffer. To elute proteins from the 
column, a linear salt gradient was applied and a chromatogram recorded (A). To identify the C6- 
containing fractions, 10 pi of each fraction was incubated with rat C6 deficient serum and 2% sheep EA 
for 30 minutes and centrifuged. The supernatants were collected and the A415 nm measured. As can 
be seen from Figure 3.4B, C6 was eluted between fractions 27-30. These fractions correspond to the 
largest fraction peak in Figure 3.4A.
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3.3.2. Purification of human C6 using affinity chromatography
Although C6 had been successfully purified using classical chromatographic methods, the 
process was inefficient, with a yield of less than 1% and time consuming, taking approximately 
one week. I generated a panel of mAbs that recognised human C6 and so I tried an alternate 
method for C6 purification, based on affinity chromatography.
3.3.2.1. Anti-C6 monoclonal antibody 7A2 coupled to cyanogen bromide sepharose 
column
The anti-C6 mAb 7A2 (developed in section 4.3.4.) was selected to be coupled to a 
chromatographic matrix for affinity purification as BIACore studies indicated that 7A2 had a high 
affinity for C6 (section 4.3.6.). Proteins are frequently purified using affinity chromatography in 
house and antibodies are routinely coupled to cyanogen bromide (CN-Br) activated sepharose, 
as was 7A2 (section 3.2.1.). Purified mAb (10 mg) was coupled to preswollen CN-Br sepharose 
gel by mixing together for 1 hour. Unbound antibody was removed by washing and the coupling 
efficiency was 97%. Any remaining active groups on the sepharose were blocked and to ensure 
any ionically bound ligand was removed, the gel washed a further three times alternately with low 
and high pH wash buffers.
From a starting volume of 200 ml, plasma was PEG-precipitated and subjected to affinity 
chromatography (as described in section 3.2.1.). Throughout this process, material was retained 
at each step for analysis to assess functional activity by reconstitution of C6 deficient serum in a 
haemolytic assay and purity by SDS-PAGE and western blot in parallel under non-reducing 
conditions, shown in Figures 3.5a, b and c respectively. For the reconstitution assay, 1 pi of test 
sample was added to 50 pi C6 deficient serum diluted 1 in 200 in CFD and incubated together 
with 50 pi 2% sheep EA for 30 minutes at 37*C. The starting material caused 96% haemolysis, 
but this was reduced to 32.5% after the first PEG cut, suggesting some C6 had been lost; after 
the second PEG cut the C6 enriched pellet caused 45% haemolysis. The apparent increase in 
haemolytic activity between the first and second PEG cut was due to the pellet from the second 
PEG cut being resuspended in a smaller volume than the supernatant of the first PEG cut. Of the 
eluted fractions, only fractions 2 - 4 had haemolytic activity, causing 6.3%, 5.4% and 3.8% 
haemolysis respectively and demonstrating the presence of C6. Owing to the complex nature of 
the sample, the plasma, C6 PEG enriched supernatant and C6 PEG enriched pellet are seen as 
broad smears of proteins with no discernable band corresponding to C6 either on the coomassie 
stained gel or the western blot. The major band in eluted fractions 1 -  6 had a molecular weight
Figure 3.5 Purification of human C6 using affinity chromatography: 
7A2 coupled to cyanogen bromide (CNBr) activated sepharose 
A. C6 reconstituting activity of fractions collected from column
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C6 was precipitated by a 7% (v/v) and 16% (v/v) PEG cut, resuspended in PBS and applied to the 7A2 coupled 
CNBr-activated sepharose column. The breakthrough was reserved and the column washed with PBS. C6 was 
eluted from the column with 0.5% DEA in PBS and protein containing fractions collected. These were subject to a 
haemolytic assay using C6D rat serum.
B. Coomassie staining
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C. Western Blot
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Equal volumes of samples collected at each purification step of affinity purification using the anti-C6 
antibody, 7A2, coupled to cyanogen bromide sepharose were run under non-reducing conditions on a 7.5% 
SDS PAGE gel and either B. stained with coomassie blue reagent or C. blotted onto nitrocellulose. Protein 
was probed with the rabbit anti-rabbit C6 polyclonal antibody R1075 (1:1000) and goat anti-rabbit Ig-HRPO 
(1:1000) as a secondary antibody. Bands were detected with ECL and visualised by autoradiography. M - 
protein molecular weight markers.
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of approximately 220 kDa. A faint band of 100 kDa corresponding to C6 was visible in fraction 2 
and the haemolytic assay data confirmed that this was functionally active. In a subsequent 
experiment, the fractions were subject to SDS-PAGE electrophoresis under reducing conditions 
and stained with coomassie blue (Figure 3.6). The 220 kDa high molecular weight band was not 
present and instead a band between 60 -  70 kDa was present in each of the wells where the high 
molecular weight band had been seen before. This suggested that the high molecular weight 
band was probably antibody eluted from the column. The yield was 10 pg from 200 ml starting 
material, however, much of this was eluted antibody.
3.3.2.2. Purification of C6 with 7A2 coupled to the Affi-gel® Hz hydrazide matrix
The continued problems with the elution of 7A2 from the CN-Br sepharose led to the search for 
alternative matrices to couple 7A2. Affi-gel® Hz hydrazide gel forms covalent hydrazone bonds 
with oxidized carbohydrates, which are present in the Fc region of IgG isotype mAbs. This is 
advantageous as the mAb is presented in an optimal orientation for affinity purification and the 
hydrazone bond formed during coupling is very stable.
To prepare 7A2 for coupling to the Affi-gel®, 3.5 mg antibody was dialysed into coupling buffer 
and then oxidised using sodium periodate solution for 1 hour at room temperature. The reaction 
was stopped by the addition of glycerol and the antibody-containing mixture dialysed against 
coupling buffer. The Affi-gel® was washed into coupling buffer, oxidised 7A2 added and the 
coupling reaction allowed to take place with gentle mixing overnight at room temperature. The 
eluant from the antibody-gel mixture was reserved for determining the coupling efficiency, which 
was 67.7%. The column was washed with 20 mM Kphosphate buffer, 0.5M NaCI, 0.02% (v/v) 
NaN3, which removed some of the antibody, reducing the coupling efficiency to 45.2%. The 
column was stored in this buffer at 4'C until required.
From a starting volume of 250 ml, plasma was PEG-precipitated and subjected to affinity 
chromatography (described in section 3.2.1.). Throughout this process, material was retained at 
each step for analysis to assess functional activity by reconstitution of C6 deficient serum in a 
haemolytic assay and purity by SDS-PAGE and western blot in parallel under non-reducing 
conditions, shown in Figures 3.7a, b and c respectively. For the reconstitution assay, 1 pi of test 
sample was added to 50 pi C6 deficient serum diluted 1 in 200 in CFD and incubated together 
with 50 pi 2% sheep EA for 30 minutes at 37°C. Fractions 2 -15 had abundant haemolytic 
activity, peaking at 41.4% haemolysis in fraction 6. Owing to the complex nature of the sample, 
the C6 PEG enriched supernatant, C6 PEG enriched pellet and breakthrough from the column
Figure 3.6 Analysis of reduced samples from Figure 3.5 by SDS-PAGE
Eluted fractions 
1 2 3 4 5 6 7 8  9 M
•220 kDa
■130 kDa
■90 kDa 
■70 kDa
Reduced
antibody-
fragment
I  60 kDa
 50 kDa
Twenty microlitres of each fraction eluted from the affinity column comprising the anti-C6 antibody 7A2, 
coupled to cyanogen bromide sepharose were run under reducing conditions on a 7.5% SDS PAGE gel 
and stained with coomassie blue reagent. M - protein molecular weight markers.
Figure 3.7 Purification of human C6 using affinity chromatography:
7A2 coupled to Affi-gel® Hz hydrazide gel
A. C6 reconstituting activity of fractions collected from column
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C6 was precipitated by a 7% (v/v) and 16% (v/v) PEG cut, resuspended in PBS and applied to the 7A2 coupled affi- 
gel® column. The breakthrough was reserved and the column washed with PBS. C6 was eluted from the column 
with 0.5% DEA in PBS and protein containing fractions collected. These were subject to a haemolytic assay using 
C6D rat serum.
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Samples collected at each purification step: resuspended C6 enriched pellet following 16% PEG cut, C6 enriched 
supernatant after removal of particular debris by centrifugation, breakthrough from column, fractions 2 -7  
collected from column, (M) protein molecular weight markers, fractions 8 -1 5  collected from column, purified 
pooled C6, (M) protein molecular weight markers and run under non-reducing conditions on 7.5% SDS PAGE gel 
and either B. stained with coomassie blue reagent or C. blotted onto nitrocellulose. Protein was probed with 
mouse anti-human C6 mAb 23D1 (1 jig/ml) (developed in section 4.3.4.) and goat anti-mouse Ig-HRPO (1:2000) 
as a secondary antibody. Bands were detected with ECL and visualised by autoradiography.
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are seen as broad smears of proteins with no discemable band corresponding to C6 either on the 
coomassie stained gel or the western blot. Although C6 was not the major band, it was clearly 
visible in fractions 3-8 on the coomassie gel and detectable by western blot in fractions 2 -12 , 
with an approximate molecular weight of 100 kDa, correlating with the functional data obtained. 
The C6 -containing fractions were pooled, dialysed and concentrated and visible by coomassie 
staining and western blot. Additional bands were observed in several of the fractions on the 
coomassie gel and all the fractions by western blot. The molecular weights of these bands were 
consistent with antibody being eluted from the column. A total of 4.35 mg C6 was purified from 
250 ml plasma, which represents a yield of 22% C6, based upon there being 80 mg/L C6 in 
plasma, which was the highest yield of C6 from the protocols to date, although the preparation 
was contaminated with additional protein, most likely antibody.
3.3.2.3. Purification of C6 with 23D1 coupled to the Affi-gel® Hz hydrazide matrix
Although the coupling of 7A2 to affi-gel® had yielded the greatest amount of purified C6 from the 
protocols attempted to date, such preparations were contaminated with antibody, suggesting it 
was leaching from the affinity column. To overcome this problem, a different anti-C6 mAb clone, 
23D1, was coupled to the affi-gel® Hz hydrazide gel (section 3.2.1.).
To prepare 23D1 for coupling to the affi-gel®, 11.4 mg of antibody was oxidised as described and 
allowed to couple overnight at room temperature. The eluant from the antibody-gel mixture was 
reserved for determining the coupling efficiency, which was 60.3%. After washing, antibody had 
been washed from the column, reducing the coupling efficiency to 34.3%. The column was 
stored in 20 mM Kphosphate buffer, 0.5M NaCI, 0.02% (v/v) NaN3 at4'C until required.
From a starting volume of 200 ml, plasma was PEG-precipitated and subjected to affinity 
chromatography (described in section 3.2.1.). Throughout this process, material was retained at 
each step for analysis to assess functional activity by reconstitution of C6 deficient serum in a 
haemolytic assay and purity by SDS-PAGE and western blot in parallel under non-reducing 
conditions, shown in Figures 3.8a,b and c respectively. For the reconstitution assay, 10 pi of test 
sample was added to 50 pi C6 deficient serum diluted 1 in 200 in CFD and incubated together 
with 50 pi 2% sheep EA for 30 minutes at 37’C. Fractions 2 - 21 had abundant haemolytic 
activity, peaking at 29.8% haemolysis in fraction 4. Owing to the complex nature of the sample, 
the C6 PEG enriched pellet and breakthrough from the column are seen as broad smears of 
proteins with no discemable band corresponding to C6 on the coomassie stained gel. C6 was 
the major band in fractions 2 -1 8  on the coomassie stained gel and fractions 2 -  20 by western
Figure 3.8 Purification of human C6 using affinity chromatography:
23D1 coupled to Affi-gel® Hz hydrazide gel
A. C6 reconstituting activity of fractions collected from column
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C6 was precipitated by a 7% (v/v) and 16% (v/v) PEG cut, resuspended in PBS and applied to the 23D1 
coupled affi-gel® column. The breakthrough was reserved and the column washed with PBS. C6 was eluted 
from the column with 0.5% DEA in PBS and protein containing fractions collected. These were subject to a 
haemolytic assay using C6D rat serum.
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Samples collected at each purification step B. resuspended C6 enriched pellet following 16% PEG cut, 
breakthough collected from column, fractions 2 -11  collected from column, (M) protein molecular weight 
markers, fractions 12-20 collected from column, (M) protein molecular weight markers and run under non­
reducing conditions on 7.5% SDS PAGE gel and stained with coomassie blue reagent. C. Samples were blotted 
onto nitrocellulose after being subject to SDS-PAGE, fractions 2 -1 2  collected from column, (M) protein 
molecular weight markers, fractions 13-21 collected from the column, (M) protein molecular weight markers. 
Protein was probed with mouse anti-human C6 mAb 27B1 (1 jj.g/ml) and goat anti-mouse Ig-HRPO (1:2000) as 
a secondary antibody. Bands were detected with ECL and visualised by autoradiography.
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blot, with a molecular weight of 100 kDa, correlating with the functional data obtained. A total of 
3.95 mg C6 was purified from 200 ml plasma, representing a yield of 25% C6 based upon there 
being 80 mg/L of C6 in plasma. This was the largest amount of C6 yielded from the purification 
protocols to date and the affinity column is stable through multiple cycles of use and is now 
routinely used to purify C6 in house.
3.3.3. Reconstitution of haemolytic activity using human C6
Having successfully purified functional human C6 enabled me to tackle some important biological 
questions relating to C6 function, such as the possible functional homology across different 
species. To compare the relative functional efficacy of human C6 at reconstituting C6 deficient 
sera, the amount of C haemolytic activity in serum required to induce 50% haemolysis of 
activated erythrocytes, referred to as CHso, was calculated (section 3.2.3.). For all the in vitro 
reconstitution assays, 10 pi C6 (1 -  200 pg/ml final concentration) was added to 50 pi C6 
deficient serum (human, rabbit or rat) diluted 1 in 5 -1  in 640 in CFD and incubated together with 
50 pi 2% sheep activated sheep erythrocytes for 30 minutes at 37’C (described in section 2.4.4.). 
After centrifugation, the supernatants were collected and absorbance at 415 nm measured. The 
percentage of lysis was calculated and plotted graphically. Human C6 was also used to 
reconstitute the haemolytic activity of C6 deficient mouse serum under the same conditions 
described (2.4.4.), except that instead of sheep EA, 2% rabbit EA were used and all dilutions 
were in CFD supplemented with 0.1% (w/v) gelatine, 2.5% (w/v) dextrose.
3.3.3.1. Human serum in vitro
The human C6D serum was a gift from Dr Ann Orren. The graph of haemolysis is shown in 
Figure 3.9. C6-deficient serum had no detectable haemolytic activity, in comparison to normal 
human serum, which caused 100% lysis. At all concentrations of C6 added; 1,10,50,100 and 
200 pg/ml, haemolytic activity was restored to 100% lysis even at the lowest dilution of serum. As 
the serum was further diluted, the haemolytic activity was reduced in a dilution dependent manner 
in a similar way to normal human serum.
The CH50 values were determined and are shown in Table 3.2. The values for the reconstituted 
sera are equivalent to the CH50 value for normal serum, affirming that the purified human C6 can 
restore full C haemolytic activity to C6D human serum and that C6 is not a limiting component for 
C lysis. This is in agreement with other studies 501-502.
/
Figure 3.9 The reconstitution of human C6 deficient serum with purified human C6
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The ability of purified human C6 to reconstitute C-mediated lytic activity to genetically C6 deficient 
human serum was investigated in a haemolytic assay. In a round-bottomed 96-well plate, C6 
deficient serum (50 pi), diluted over the range 1 in 5 -1  in 640 was reconstituted with 10 pi purified 
human C6 to give final concentrations of: 1 pg/ml, 10 pg/ml, 50 pg/ml, 100 pg/ml or 200 pg/ml C6. 2% 
sheep EA (50 pi) was added to each well and the plate incubated at 37°C for 30 minutes. After 
centrifugation, the supernatants were collected and transferred to a flat-bottomed plate and the 
absorbance measured at 415 nm. For comparison, unreconstituted C6 deficient serum and normal 
human serum were also included in the assay. For each dose of C6 used to reconstitute the C6 
deficient serum, the percentage of haemolysis was calculated and plotted on the graph above. Each 
data point represents the mean of value +/- standard deviation of the mean of a single experiment 
performed in triplicate.
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Table 3.2 Calculation of X50 and CH50 values of C6 deficient human serum reconstituted
with purified human C6.
Sample X50 (pi serum) CH50
Normal human serum 0.44 4540
C6 deficient serum (C6DS) - -
C6DS +1 pg/ml human C6 0.41 4880
C6DS + 10 pg/ml human C6 0.36 5560
C6DS + 50 pg/ml human C6 0.36 5560
C6DS + 100 pg/ml human C6 0.37 5400
C6DS + 200 pg/ml human C6 0.53 3780
To calculate the CH50 of the reconstituted and normal sera, the degree of lysis (Y 
sample was calculated:
for each
A4i5nm (sample) -  A4i5nm (background lysis control)
Y = ---------------------------- ------------------------------------------------------
A4i5nm (maximum lysis control) -  Atisnm (background lysis control)
The logio of the volume of serum (pi /well) was plotted against logio (Y/1 -  Y) and the equation of 
the line determined. At 50% haemolysis, the Y-axis, logio (Y/1-Y) = 0. The equation of the line 
was then used to calculate the value of logioX at logio(Y/1-Y) = 0, which is the logio of the X50. 
The antilog (10X50) was calculated, giving the X50 for that serum sample. The CH50 was 
calculated according to the equation:
CH5o = L  x2000 
X50
68
3.3.3.2. Rabbit serum in vitro
To determine whether purified human C6 could reconstitute haemolytic activity to C6 deficient 
rabbit serum, human C6 was incubated with C6 deficient rabbit serum. The percentage of lysis 
was calculated and plotted graphically, shown in Figure 3.10.
Unreconstituted C6-deficient serum had no detectable haemolytic activity, in comparison to 
normal rabbit serum, which caused 50% lysis. At concentrations between 50 -  200 pg/ml C6 
added haemolytic activity was restored to an either equal or greater level than that for normal 
serum. When the serum was reconstituted with 1 or 10 pg/ml C6, haemolysis occurred at a lower 
level than that for normal serum.
The CH50 values were calculated and these values are shown in Table 3.3. The CH50 values for 
the reconstituted sera are equivalent to the CH50 value for normal rabbit serum, affirming that the 
purified human C6 can restore full C haemolytic activity to C6D rabbit serum and that C6 is not a 
limiting component for C lysis.
3.3.3.3. Rat serum in vitro
Purified human C6 was incubated with C6 deficient rat serum to determine whether it could 
reconstitute C-mediated haemolytic activity of C6 deficient rat serum. A graph of the percentage 
of haemolysis is shown in Figure 3.11. C6-deficient rat serum had no detectable haemolytic 
activity, in comparison to normal rat serum, which caused 100% lysis. At all concentrations of C6 
added, 1 -  200 pg/ml, the haemolytic activity of the serum was restored to a level equivalent to 
normal serum.
The CH50 values were calculated and these values are shown in Table 3.4. The CH50 value for 
the unreconstituted C6D rat serum is close to zero, whilst the CH50 values for the reconstituted 
serum are either equivalent to or greater than the CH50 values for normal rat serum, confirming 
that the purified human C6 can restore full C haemolytic activity to C6D rat serum and that C6 is 
not a limiting component for C lysis.
3.3.3.4. Mouse serum in vitro
The ability of purified human C6 to reconstitute C-mediated haemolytic activity of C6 deficient 
mouse serum was also addressed. The percentage of lysis was calculated and plotted on a 
graph (Figure 3.12).
Figure 3.10 The reconstitution of rabbit C6 deficient serum with purified human C6
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The ability of purified human C6 to reconstitute C-mediated lytic activity to genetically C6 deficient 
rabbit serum was investigated in a haemolytic assay. In a round-bottomed 96-well plate, C6 deficient 
serum (50 jj.I), diluted over the range 1 in 5 — 1 in 640 was reconstituted with 10 pi purified human C6 
to give final concentrations of: 1 pg/ml, 10 pg/ml, 50 pg/ml, 100 pg/ml or 200 pg/ml C6. 2% sheep EA 
(50 pi) was added to each well and the plate incubated at 37°C for 30 minutes. After centrifugation, 
the supernatants were collected and transferred to a flat-bottomed plate and the absorbance measured 
at 415 nm. For comparison, unreconstituted C6 deficient serum and normal rabbit serum were also 
included in the assay. For each dose of C6 used to reconstitute the C6 deficient serum, the 
percentage of haemolysis was calculated and plotted on the graph above. Each data point represents 
the mean of value +/- standard deviation of the mean of a single experiment performed in triplicate.
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Table 3.3 Calculation of X50 and CH50 values of C6 deficient rabbit serum reconstituted with
purified human C6.
Sample X50 (pi serum) CH50
Normal rabbit serum 10.38 194
C6 deficient serum (C6DS) - -
C6DS +1 pg/ml human C6 * *
C6DS +10 pg/ml human C6 11.41 176
C6DS + 50 pg/ml human C6 9.72 200
C6DS +100 pg/ml human C6 8.82 220
C6DS + 200 pg/ml human C6 7.06 280
To calculate the CH50 of the reconstituted and normal sera, the degree of lysis (Y) for each 
sample was calculated:
A4i5nm (sample) -  A4i5nm (background lysis control)
Y = ----------------------------------------------------------------------------------
A4 i5nm (maximum lysis control) - /Wisnm (background lysis control)
The logio of the volume of serum (pi /well) was plotted against logio (Y/1 -  Y) and the equation of 
the line determined. At 50% haemolysis, the Y-axis, logio (Y/1 -Y) = 0. The equation of the line 
was then used to calculate the value of logioX at logio(Y/1-Y) = 0, which is the logio of the X50. 
The antilog (10X50) was calculated, giving the X50 for that serum sample. The CH50 was 
calculated according to the equation:
CHso = l  x2000 
X50
* It was not possible to calculate the CH50 for reconstitution with 1 pg/ml human C6 as the raw 
data gave negative results when attempting to calculate log values.
Figure 3.11 The reconstitution of rat C6 deficient serum with purified human C6
100
200 ug/ml C6 
* — 100 ug/ml C6 
50 ug/ml C6 
10 ug/ml C6 
— 1 ug/ml C6 
■#— C6DS
c/>C/)>
o
E(D
CO
-CZ
oo
-20 Volume of serum (pi)
The ability of purified human C6 to reconstitute C-mediated lytic activity to genetically C6 deficient rat 
serum was investigated in a haemolytic assay. In a round-bottomed 96-well plate, C6 deficient serum 
(50 pi), diluted over the range 1 in 5 -1  in 640 was reconstituted with 10 pi purified human C6 to give 
final concentrations of: 1 pg/ml, 10 pg/ml, 50 pg/ml, 100 pg/ml or 200 pg/ml C6. 2% sheep EA (50 pi) 
was added to each well and the plate incubated at 37°C for 30 minutes. After centrifugation, the 
supernatants were collected and transferred to a flat-bottomed plate and the absorbance measured at 
415 nm. For comparison, unreconstituted C6 deficient serum and normal rat serum were also included in 
the assay. For each dose of C6 used to reconstitute the C6 deficient serum, the percentage of 
haemolysis was calculated and plotted on the graph above. Each data point represents the mean of 
value +/- standard deviation of the mean of a single experiment performed in duplicate.
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Table 3.4 Calculation of X50 and CH50 values of C6 deficient rat serum reconstituted with
purified human C6.
Sample X50 (pi serum) CH50
Normal rat serum 0.686 2920
C6 deficient serum (C6DS) 84.1 20
C6DS +1 pg/ml human C6 0.567 3520
C6DS +10 pg/ml human C6 0.621 3220
C6DS + 50 pg/ml human C6 0.457 4380
C6DS +100 pg/ml human C6 0.58 3440
C6DS + 200 pg/ml human C6 0.77 2600
To calculate the CH50 of the reconstituted and normal sera, the degree of lysis (Y) for each 
sample was calculated:
A4i 5nm (sample) -  A4 i5nm (background lysis control)
A4i5nm (maximum lysis control) -  A4 i5nm (background lysis control)
The logio of the volume of serum (pi /well) was plotted against logio (Y/1 -  Y) and the equation of 
the line determined. At 50% haemolysis, the Y-axis, logio (Y/1 -Y) = 0. The equation of the line 
was then used to calculate the value of logioX at logio(Y/1-Y) = 0, which is the logio of the X50. 
The antilog (10X50) was calculated, giving the X50 for that serum sample. The CH50 was 
calculated according to the equation:
C H 5o = 1  x 2000 
X50
Figure 3.12 The reconstitution of mouse C6 deficient serum with purified human C6
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The ability of purified human C6 to reconstitute C-mediated lytic activity to genetically C6 deficient 
mouse serum was investigated in a haemolytic assay. In a round-bottomed 96-well plate, C6 deficient 
serum (50 ^l), diluted over the range 1 in 5 -1  in 640 was reconstituted with 10 ^l purified human C6 to 
give final concentrations of: 1 pg/ml, 10 pg/ml, 50 pg/ml, 100 pg/ml or 200 pg/ml C6. 2% sheep EA (50 
\i\) was added to each well and the plate incubated at 37°C for 30 minutes. After centrifugation, the 
supernatants were collected and transferred to a flat-bottomed plate and the absorbance measured at 
415 nm. For comparison, unreconstituted C6 deficient serum and normal mouse serum were also 
included in the assay. For each dose of C6 used to reconstitute the C6 deficient serum, the percentage 
of haemolysis was calculated and plotted on the graph above. Each data point represents the mean of 
value +/- standard deviation of the mean of a single experiment performed in triplicate.
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C6-deficient serum caused a maximum of 3.5% haemolysis and when reconstituted with 1 |jg/ml 
C6 a similar level of lysis was caused - 4.4%. Normal mouse serum caused an average of 67% 
lysis and an equivalent amount of lysis occurred when the C6 deficient serum was reconstituted 
with 200 pg/ml purified human C6 - 68%. At concentrations between 10-100 pg/ml C6 added, 
haemolytic activity was restored to lower activity than normal mouse serum.
The calculated CH50 values are shown in Table 3.5. The CH50 values for sera reconstituted with 
100 or 200 Mg/ml C6 are equivalent to the CH50 value for normal serum, whilst C6 deficient serum 
reconstituted with 1 - 50 pg/ml C6 have lower CH50 values than normal mouse serum. This 
demonstrates that the purified human C6 can restore C haemolytic activity to C6D mouse serum.
3.3.3.5. Mouse serum in vivo
Having determined that purified human C6 reconstituted C activity of C6 deficient mouse serum in 
vitro, purified human C6 was administered to C6 deficient mice in vivo to investigate whether their 
dysfunctional C activity could be restored. Each mouse was reconstituted with 150 pg C6 per 
mouse. Haemolytic assays were carried out to find out whether the administered C6 had 
reconstituted C lytic activity of the serum, 50 pi serum (diluted 1 in 10 -1  in 1280 in CFD) 
collected at each timepoint was incubated with 50 pi 2% rabbit EA for 30 minutes at 37°C (section
2.4.). The percentage of lysis was plotted graphically (Figure 3.13).
As expected, C6-deficient mouse serum had no detectable haemolytic activity. Thirty minutes 
after the C6 had been administered to the mice the haemolytic activity of the serum had 
increased to 42.8% at the lowest dilution of serum. Two hours after the administration of C6, the 
haemolytic activity of the serum collected from the mice had increased to 62% at the lowest 
serum dilution. Twelve hours after the administration of C6, the haemolytic activity of the serum 
collected from the mice had increased further still to 100% at the lowest dilution of serum.
The CHso values for the reconstituted sera at the collection timepoints were calculated and are 
shown in Table 3.6. The CH50 values for the reconstituted sera increase over the time course. 
This is in comparison to C6 deficient rats reconstituted with human C6, in which the reconstituted 
haemolytic activity was still detectable 24 hours after reconstitution, although it was decreasing 
498. It was anticipated that serum would have contained greatest haemolytic activity 30 minutes 
post administration of C6. One explanation for this may be that C6 was slowly absorbed from the 
peritoneum following the i.p. injection and that if the C6 had been injected intravenously, the 
expected results may have been obtained. Nevertheless, these data do demonstrate that the C 
lytic activity of C6 deficient mice can be reconstituted by the administration of human C6 and that
Figure 3.13 The reconstitution in vivo of C6 deficient mice with purified human C6
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The ability of purified human C6 to reconstitute genetically C6 deficient mouse serum in vivo was 
investigated. Three hundred micrograms of purified human C6 was administered by i.p. injection to 
each mouse. Thirty minutes, two hours and twelve hours post C6 administration, blood was 
collected from each mouse and serum prepared. To determine whether the purified human C6 had 
reconstituted C activity in the C6 deficient mice, the collected serum was assessed in a haemolytic 
assay. In a round-bottomed 96-well plate, serum collected at each timepoint (50 jjJ), diluted over 
the range 1 in 10 -1  in 1280 was incubated with 2% rabbit EA (50 p.l) at 37°C for 30 minutes. After 
centrifugation, the supernatants were collected and transferred to a flat-bottomed plate and the 
absorbance measured at 415 nm. For comparison, serum collected from a C6 deficient mouse 
which had not received human C6 was also included in the assay. For each timepoint after the 
administration of purified human C6 to the C6 deficient mice, the percentage of haemolysis was 
calculated and plotted on the graph above. Each data point represents the mean of value +/- 
standard error of the mean of a single experiment performed in triplicate.
Time 0 
Time 0.5 
Time 2 
Time 12
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Table 3.5 Calculation of X50 and CH50 values of C6 deficient mouse serum reconstituted
with purified human C6.
Sample X50 (pi serum) CHso
Normal mouse serum 7.75 258.0
C6 deficient serum (C6DS) - -
C6DS +1 pg/ml human C6 226.9 8.8
C6DS +10 pg/ml human C6 18.19 109.9
C6DS + 50 pg/ml human C6 11.86 168.6
C6DS +100 pg/ml human C6 7.89 253.4
C6DS + 200 pg/ml human C6 5.76 347.2
To calculate the CH50 of the reconstituted and normal sera, the degree of lysis (Y) for each 
sample was calculated:
A4 i5nm (sample) -  A4i 5nm (background lysis control)
A4i 5nm (maximum lysis control) -  A4 i5nm (background lysis control)
The logio of the volume of serum (pi /well) was plotted against log™ (Y/1 -  Y) and the equation of
the line determined. At 50% haemolysis, the Y-axis, logio (Y/1-Y) = 0. The equation of the line
was then used to calculate the value of logioX at logio(Y/1-Y) = 0, which is the logio of the X50.
The antilog (lO*50) was calculated, giving the X50 for that serum sample. The CH50 was
calculated according to the equation:
C H 5o =  1 x 2000 
X50
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Table 3.6 Calculation of X50 of serum collected from C6 deficient mice after reconstitution
with purified human C6.
Sample X50 (pi serum) CH50
0 hours - -
0.5 hours 5.78 340
2 hours 4.28 460
12 hours 2.2 900
To calculate the CH50 of the reconstituted and normal sera, the degree of lysis (Y) for each 
sample was calculated:
A4 i5nm (sample) -  A4i5nm (background lysis control)
A4i5nm (maximum lysis control) -  A4 i 5nm (background lysis control)
The logio of the volume of serum (pi /well) was plotted against logio (Y/1 -  Y) and the equation of
the line determined. At 50% haemolysis, the Y-axis, logio (Y/1 -Y) = 0. The equation of the line
was then used to calculate the value of logioX at logio(Y/1-Y) = 0, which is the logio of the X50.
The antilog (lO*50) was calculated, giving the X50 for that serum sample. The CH50 was
calculated according to the equation:
CH5o = 1 x2000 
X50
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the C6 retains its functional activity in the circulation for at least twelve hours after the 
administration of the C6.
3.4. Discussion
This chapter describes and compares methods for C6 purification and culminates in the 
development of a fast, reliable purification protocol for human C6 that is now routinely used within 
the department. The purified human C6 was free of contaminating proteins, including other C 
proteins and was shown to be functionally active in restoring C-induced lysis in C6D human 
serum. In addition, the cross-species activity of the purified human C6 was also investigated. In 
vitro haemolytic assays demonstrated that human C6 was effective in restoring C activity in C6 
deficient rat, rabbit and mouse sera. This effect was also tested in vivo when C activity in C6 
deficient mice was fully restored for at least 12 hours post administration of human C6 (300 pg) 
by i.p. injection.
Classical methods for C6 purification involved several chromatographic steps typically taking 7-10 
days for completion. The isolated C6 had a molecular weight of 100 kDa and an additional 
protein band at approximately 70 kDa, both detectable on Coomassie stained polyacrylamide 
gels and by western blot. Typically the yield of C6 was 0.56 mg from a starting serum of 1 L. The 
expected yield (based on a normal serum range of 80 pg/ml (equivalent to 80 mg/L of C6) from 
1L of serum, if 100% C6 was purified would be 80 mg. This discrepancy highlights that the 
process was very inefficient, with more than 99% of C6 available in plasma being lost during 
purification. In addition to the poor yield, there was also some evidence of C6 degradation, as 
highlighted by western blot analysis (Figure 3.2) in which the mAb WU 6.4 stained two bands, 
one at 100 kDa and a smaller band at 70 kDa. This smaller C6 fragment was co-purified with full 
length C6, suggesting that these molecules shared the same ionic properties even though they 
had different molecular weights. It is unclear whether C6 was already degraded in the expired 
plasma or whether it degraded during the purification procedure, even though preventative 
measures, such as including protease inhibitors and carrying out the process at 4°C were taken. 
However, the process took several days and pure, concentrated proteins are always more stable 
than proteins at low concentration in complex mixtures; the protein concentration of the 
preparation decreased during the procedure. In other studies, samples containing C6 in serum, 
which is a complex, concentrated protein mixture, have been left at room temperature apparently 
without deleterious effects 499>503.
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Due to the poor yield and degradation of C6 using classical purification methods, affinity 
chromatographic methods were attempted. The mAb 7A2 was first coupled to CN-Br activated 
sepharose, leading to the isolation of C6 as detected by SDS-PAGE with Coomassie staining and 
western blot with a band of 100 kDa. However, the major protein eluted from the column had a 
molecular weight of 220 kDa and upon reduction several bands were observed with molecular 
weights consistent with antibody, suggesting that it was leaching from the column. The mAb 7A2 
was then coupled to Affi-gel™ leading to the isolation of functional C6, with a molecular weight of 
100 kDa, detectable by SDS-PAGE with Coomassie staining and western blot. From a starting 
volume of 250 ml, 4.35 mg of C6 was purified, representing a yield of 22% - a significant 
improvement on all previous attempts at purifying C6. However, contaminating protein was 
present, again consistent with antibody leaching from the column. This suggested that the 
antibody leaching was occurring not due to the properties of the column matrix but due to the 
properties of the antibody itself. Finally, the mAb 23D1 (developed in section 4.3.4.) was coupled 
to Affi-gel™ and a single band of 100 kDa, detectable by SDS-PAGE and western blot was 
purified, with no contamination. From a starting volume of 200 ml, 3.95 mg of C6 was purified, 
representing a yield of 25%. This was the highest yielding protocol for C6 purification and the 
mAb was stable on the column. This method has now become the routine method for C6 
purification in house.
The concentration of C6 in the serum of healthy individuals varies widely, ranging between 20 -  
80 pg/ml4" .  Patients with C6 levels between 0.3 -  3.0 pg/ml are classified as having a subtotal 
C6 deficiency (C6SD) 499 and those in which C6 is undetectable or the levels are below 0.3 pg/ml 
are considered to be totally C6 deficient (C6Q0) 499'503. C6Q0 individuals are susceptible to 
Neisserial infections, but patients with C6SD are not503, even though levels of C6 in their serum 
are very low. The concentrations of C6 used to reconstitute C6Q0 serum in this study ranged 
from 1 -  200 pg/ml, a range that covered the abnormally low levels of C6 detected in C6SD 
patients, normal C6 levels and abnormally high levels of C6. The added C6 reconstituted 
haemolytic activity of the C6Q0 serum to similar levels of normal human serum at all 
concentrations tested. Taken together with the literature that C6SD individuals are not 
susceptible to Neisserial infections and the C6 they produce is functionally active 499 these 
findings suggests that even very low levels of C6 are sufficient to afford protection against such 
diseases. These data suggest that in the human terminal pathway C6 concentration cannot be 
limiting, considering that the range of C6 concentrations used in these assays resulted in similar 
levels of haemolysis. However, these results are not directly comparable to published analyses 
of C6SD patients 503 as the haemolytic assays were carried out in a different way. It was also
76
found that all of the C6SD patients tested made a truncated form of C6 only, with a molecular 
weight of 85 kDa and it is possible that this form of C6 does not have the same activities as 
normal C6, although it has been shown that it is bactericidally active 500.
The reconstitution assays demonstrate that human C6 can be used to reconstitute not only 
human C6 deficient serum, but also C6 deficient serum from mice, rats and rabbits. It has 
previously been shown that the rat C6 sequence is 82% homologous to the human C6 sequence 
485 whilst the mouse C6 amino acid sequence is 75% homologous to the human C6 sequence504 
and the data presented here showed there is functional equivalence of C6 between the species 
tested, even though the molecular weights of mouse and rat C6 differ from that of human C6 
485.505-507 |n addition to their sequence similarity, mouse and human C6 share a similar modular 
structure. All C6 sufficient mice produce C6A which has a molecular weight of 91 kDa and lacks 
the factor I modules (FIMs) of human C6 504 Some mouse strains produce additional forms of 
C6, designated C6B and C6C with molecular weights of 107 kDa and 91-107 kDa 504-507. Rat 
C6 has a molecular weight of approximately 90 kDa 485. Following the discovery of a strain of C6 
deficient rats (PVG/C6-) 508, the strain was characterised 485. Full length human C6 cDNA was 
used as a probe to clone rat C6 from a C6 sufficient strain rat liver cDNA library for comparative 
purposes. Confirmation of the identity of the putative rat C6 cDNA sequence was based upon 
homology with the human C6 cDNA sequence, demonstrating the sequence similarity between 
C6 of the two species. Currently, nothing has been published regarding the sequence of rabbit 
C6. Genetically C6-deficient rabbits were identified over 40 years ago 486; this deficiency arises 
as a result of a single gene defect that is not known to be associated with other genetic 
abnormalities 509. C6 deficient rabbits have been used in various disease models, such as 
investigating the influence of C5b-9 on reperfusion injury 51°. C6 deficient rabbit serum has also 
been reconstituted with human C6 501, demonstrating that there is functional homology between 
rabbit and human C6.
Purified human C6 has previously been used successfully in vivo in two studies to reconstitute 
PVG/C6- rats in models of disease 274-498. In the study by Mead et a l498, a model of human 
demyelinating multiple sclerosis was induced in C6 sufficient and deficient rats. C6-deficient rats 
displayed no demyelination and had a reduced clinical score in comparison to the C6 sufficient 
rats. Reconstitution of the C6-deficient rats with human C6 at a dose of 8 mg/kg restored serum 
haemolytic activity to 70 -100% of that in C6 sufficient rats for at least 24 hours and induction of 
disease resulted in pathology indistinguishable from that of the C6 sufficient rats. In the C6 
reconstitution in vivo experiment in mice in the current study, haemolytic activity took time to be 
restored after C6 had been administered and was only fully restored at the last time point taken,
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12 hours after C6 had been administered. On first inspection, the time taken for haemolytic 
activity to be restored seems to be a long time -  however, the C6 had been administered by i.p. 
injection meaning that it would have to enter the bloodstream before it could be detected and this 
might take some time. In the study by Mead et a l498, the human C6 was administered i.v. and 
reconstituted haemolytic activity measured 24 hours later. There is no data available on how 
quickly the C6 activity was functionally reconstituted.
In addition to demonstrating that human C6 can be used to restore the haemolytic activity of 
mouse, rat and rabbit serum, this investigation confirmed previous reports that C6 is not a rate- 
limiting component of the terminal pathway in humans 502. Furthermore, these data suggest that 
C6 is not a rate-limiting component of the terminal pathway in rats, rabbits or mice.
In summary, a fast and efficient affinity protocol for purifying human C6 has been developed, 
using an antibody generated during the course of this study. The C6 purified in this way is 
functionally active and is capable of reconstituting C6 deficient human, rat, rabbit and mouse 
serum in vitro. Moreover, the purified human C6 also reconstituted C6 deficient mice in vivo to 
generate functionally active serum complement from these mice as determined in haemolytic 
assays. The purified C6 will be useful in generating further antibodies and peptide fragments that 
recognise C6 and in the characterisation of these reagents.
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Chapter 4: The Generation and Characterisation of anti-C6 antibodies.
4.1. Introduction
Inappropriate and chronic C activation is implicated in the initiation or progression of various 
autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis, glomerulonephritis or as a 
consequence of ischemia-reperfusion injury251. The pro-inflammatory by-products of C activation 
C3a and C5a, recruit and activate neutrophils, whilst the MAC can initiate signalling cascades 
within cells possibly leading to apoptosis or kill them directly 110,112,113 By using C component 
deficient animals in models of C-mediated disease, the contribution of those components to the 
development of the disease can be elucidated.
Multiple sclerosis and the corresponding animal models, experimental allergic encephalomyelitis 
(EAE) and Ab-mediated demyelinating EAE (ADEAE) have traditionally been considered to be T 
cell-mediated diseases511. However, the activities of the MAC, formed as a result of C activation, 
have recently been highlighted in the development of pathology in these diseases in studies using 
C6 deficient PVG (PVG/C6- ) rats. In the first seminal study, EAE was induced in normal PVG 
rats and PVG/C6~rats by immunisation with myelin basic protein (MBP). ADEAE was also 
induced, with an additional injection of anti -  myelin oligodendrocyte glycoprotein (MOG) mAb 498. 
Demyelination, mononuclear cell infiltration and axonal injury was observed in the normal rats, 
but neither demyelination nor axonal injury was observed in the PVG/C6”  rats even though the 
levels of mononuclear cell infiltration were equivalent to those seen in the normal rats. 
Reconstitution of the C6 deficiency with human C6 lead to pathology and clinical disease 
indistinguishable from that in the normal rats, demonstrating the involvement of the MAC in the 
progression of this disease. In the second study, the induction of EAE led to the development of 
symptoms in 70% of the PVG/C6-  rats and 95% of the normal rats immunized512, although these 
were significantly milder in the C6-deficient rats. Similar levels of C3 deposition were seen in the 
spinal cords of the normal and C6-deficient rats, whilst C9 deposition was detected only in the 
spinal cords of normal rats, consistent with the inability of the C6-deficient rats to form MAC. The 
anti-MBP response was similar in both strains, but the numbers of white blood cells, neutrophils 
and basophils in the peripheral blood increased more in the normal rats. RT-PCR showed no 
differences in cytokine profiles of CD4+ T cells between C6 deficient and normal rats, although 
the infiltrate of CD4+ T cells was significantly lower in the C6-deficient rats. Taken together with 
results from other studies 5i3-5i6, these experiments strongly suggest that the MAC plays a critical 
role in the progression of this disease and that inhibiting C6 activity might be clinically beneficial.
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Despite evidence demonstrating the clear involvement of MAC in contributing to the development 
of various pathologies, there are currently very few examples in the literature of inhibitory 
antibodies being raised against any of the terminal complement components with the intention of 
developing them for therapeutic use. An inhibitory anti-human C8 mAb, clone 133.3, was tested 
in ex vivo models of hyperacute rejection (HAR)517 and CPB518. In both studies, the mAb 
inhibited sC5b-9 formation. In the HAR model, this inhibition protected rat hearts from organ 
damage when perfused with human serum. In the CPB model, platelet activation was observed 
in control experiments, but this was inhibited in samples to which the anti-C8 mAb had been 
added. Although these results are encouraging, this mAb has not been developed further.
The anti-C6 mAb, clone WU 6.4 was generated with a view to making an inhibitor of sC5b-9 
formation 458. Extensive characterisation in vitro demonstrated it inhibited C-mediated haemolysis 
and TCC generation, but not sufficiently well to be developed as an anti-C6 drug.
Polyclonal anti-C6 inhibitory Fab fragments were used to elucidate the role of the MAC in acute 
passive transfer experimental autoimmune myasthenia gravis (EAMG)519. These were co­
administered with the EAMG inducing agent, an anti-acetylcholine receptor (AChR) mAb. Serum 
C6 was reduced to 8% in rats receiving the highest dose of anti-C6 Fab (0.12 mg/ml) and 
symptoms and signs associated with acute EAMG, such as muscle weakness, electrophysiologic 
abnormalities and loss of AChR were inhibited. Clinical symptoms were also inhibited in rats 
receiving a lower dose of anti-C6 Fab (0.08 mg/ml), although muscle AChR were still lost. 
Macrophage accumulation at muscle motor end-plates was inhibited by both doses of anti-C6 
Fab. This study not only demonstrates the role played by MAC in this model, but highlights the 
therapeutic potential of developing anti-terminal complement component antibodies, in particular 
against C6.
Several anti-human C5 mAbs have been described, including clone N19-8458, which blocked C5a 
generation and inhibited MAC formation although its scFv antibody counterpart lacked the ability 
to inhibit C5a generation 459,468 The anti-C5 mAb clone 5G1.1 has been made into two 
products 469; an scFv antibody, marketed as Pexelizumab™ and the humanised mAb, now called 
Eculizumab™. All of these anti-C5 mAbs are discussed in greater detail in section 1.9.8.
Blocking mAbs raised against rat C5 and murine C5 have also been described 52°. An anti­
murine C5 mAb provided protection against C5b-9 mediated damage in collagen-induced arthritis 
521. Anti-rat C5 mAb, clone 18A inhibited C5b-9 mediated haemolysis and significantly reduced 
cell apoptosis, necrosis and infiltration by polymorphonuclear leukocytes in a model of myocardial 
ischemia-reperfusion (l/R) injury 52°. Anti-C5 mAbs not only block C5b-9 formation, but also
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inhibit C5a generation. To specifically inhibit MAC formation only, mAbs need to be raised 
against one of the terminal complement complex components: C6, C7, C8 or C9.
As so few anti-C6 antibodies have been described, the main aim of this chapter was to generate 
polyclonal and monoclonal antibodies against human, rabbit, rat and mouse C6. The ultimate 
aim of this study is to generate agents that inhibit C6 activity. Therefore, these antibodies were 
assayed for C6 blocking activity in classical pathway mediated haemolytic assays using human 
serum. Inhibitory antibodies with an IgG isotype were further characterised, to determine whether 
any of the mAbs recognised and functionally inhibited C6 from other species. Finally, the binding 
affinities of selected mAbs for human C6 were measured and epitope mapping studies carried 
out.
4.2. Specific methods and protocols
4.2.1. Determination of Binding Affinities and Epitope Mapping of anti-C6 mAbs using 
Surface Plasmon Resonance Technology
Surface plasmon resonance (SPR) technology using the BIAcore 3000 was used to measure the 
binding affinities of the anti-C6 mAb clones 7A2 and 23D1 for C6. The same technology was also 
used to determine the epitope each mAb recognised.
4.2.1.1. Determining the binding affinity of mAbs for C6
The affinity of the anti-C6 mAbs for human C6 was assessed on the BIAcore 3000. C6 was 
immobilised onto the flow cell of a CM5 sensor chip as described (section 2.5.1.). A reference 
flow cell on the same chip was prepared by activating the surface and blocking it. This ensured 
that control flow cell would have the same surface charge as the experimental flow cell.
For the binding affinity experiments, mAb (100 pi) was injected over the flow cell on which C6 was 
immobilised at a variety of concentrations (10.4 nM -1  pM) over 5 minutes at a flow rate of 20 
pl/minute. The dissociation of mAb from C6 as HBS-EP buffer (10 mM HEPES, pH 7.4,150 mM 
NaCI, 3 mM EDTA, 0.005% (v/v) Surfactant-P20) was flowed over the sensor chip surface was 
monitored over 15 minutes and the data recorded on a sensorgram. The mAb was passed over 
the reference flow cell at the same time. Any mAb remaining bound to the flow cell surfaces at 
the end of this time was removed by flowing over 0.2% (v/v) diethylamine in PBS. To calculate 
the net RU change when a mAb bound and dissociated from C6, the reference flow cell 
sensorgram was subtracted from the C6 immobilised flow cell sensorgram. A program in the
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BIAcore 3000 controlling software was used to fit various models to the data; this was then 
interpreted to determine the affinity of the mAb for C6.
For each set of affinity binding experiments, a control experiment to assess whether any mass 
transfer effects were occurring was carried out. The aim of these experiments is to determine 
whether the observed on-rates when analyte is flowed over the ligand are diffusion limited. If they 
are diffusion limited, then as the flow rate is altered, the on-rate will change and mass transfer 
effects are occurring. If the mass transfer effects are minimal, then when superimposed upon 
each other, the gradients of the observed on-rates gradients for each sensorgram as the mAb is 
passed over should be identical. Briefly, mAb (3.125 jug/ml) was passed over the C6 immobilised 
and reference flow cell surfaces at flow rates of 5,15 and 75 jal per minute and the sensorgrams 
compared. All solutions used on the BIAcore 3000 were filtered and degassed before use.
4.2.1.2. Epitope mapping experiments
To investigate the antigenic sites on C6 recognised by the anti-C6 mAbs, the BIAcore 3000 was 
used. Rabbit anti-mouse immunoglobulins (RAM Ig) were immobilised onto the flow cell surface 
of a CM - 5 sensor chip (section 2.5.1.). To ensure the reference flow cell surface had the same 
charge as the experimental flow cell surface, the reference flow cell was subject to the same 
immobilisation procedure, omitting the immobilisation of anything onto the surface.
A two-site assay was used to map the epitopes on C6 recognised by the anti-C6 mAbs. The first 
anti-C6 mAb (100 fxg/ml) was passed over the flow cell on which the RAM Ig had been 
immobilised and allowed to bind. C6 (100 fig/ml) was then injected over the flow cell and allowed 
to bind to the anti-C6 mAb already bound. To avoid binding of the second mAb to unoccupied 
RAM Ig sites, purified mouse Ig (100 i^g/ml) was injected over the antibody-C6 complex to block 
these sites. The second anti-C6 mAb (100 fig/ml) was then injected over the flow cell. At the 
end of the experiment, the bound components were removed by injecting 10 mM glycine, pH 1.7 
(20 yl) over the surface. All the data were recorded on a sensorgram. At the same time, the 
same components were passed over the reference blank flow cell and recorded on a 
sensorgram. For analysis, the reference sensorgram was subtracted from the experimental 
sensorgram. To ensure that the binding of the second antibody was specific for human C6, the 
experiment was repeated, but with the omission of passing over the C6.
The flow rate during each experiment was 20 jil per minute; each component was passed over 
the flow cell for 5 minutes. All experiments were carried out in HBS-EP buffer (0.01 M HEPES pH
7.4,0.15 M NaCI, 3 mM EDTA, 0.005% (v/v) Surfactant-P20) and all components were in HBS- 
EP buffer.
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4.3. Results
4.3.1. Rabbit anti-rabbit C6 polyclonal antibody
Western blotting (section 2.1.11.) was used to determine the specificity of the rabbit anti-rabbit C6 
polyclonal antibody (section 2.2.3) for other species C6 (Figure 4.1). This antibody recognised 
two bands in the normal human serum sample, the upper at the expected molecular weight of C6. 
The lower may have been a degradation product of C6. The antibody did not recognise any 
components of C6 deficient human serum. This antibody did not appear to recognise mouse C6 
as no staining was detected in the normal mouse serum or the C6 deficient serum. It did 
recognise a band just below 98 kDa in the normal rat serum sample, which is consistent with the 
molecular weight of rat C6. A band of a similar molecular weight was observed in the C6 
deficient rat serum sample, suggesting that the band was not specific for C6. Single bands of a 
similar molecular weight as the human C6 were observed for guinea pig, goat and sheep serum. 
No staining was observed for the chicken serum sample. As this antiserum recognised C6 in the 
human serum sample but did not recognise mouse C6, it was not characterised further.
4.3.2. Rat anti-rat C6 monoclonal antibodies
Two C6 deficient rats were immunised with normal rat serum containing rat C6, as described in 
section 2.3.6. and tested for anti-C6 antibodies by ELISA using human C6 (Figure 4.2). Rat 2 
had the highest titre and was exsanguinated under terminal anaesthesia, its spleen removed and 
used to generate hybridomas (section 2.3.7.). Two anti-C6 mAbs were isolated, clones 2D1 and 
7D1. Both mAbs inhibited C-mediated haemolysis of erythrocytes when human serum was used 
as the source of C in a dose-dependent manner (Figure 4.3), suggesting that these antibodies 
were functionally blocking for human C6. Antibody 2D1 inhibited C-mediated haemolysis by up to 
90.5%; 7D1 by up to 62.6%. Neither mAb recognised human C6 by western blot (data not 
shown). Clone 2D1 had an IgM isotype, whilst the 7D1 was weakly positive for all isotypes 
tested, suggesting that it was not actually monoclonal. Clone 2D1 was not further characterised 
due to its isotype and 7D1 was not investigated further because it was not monoclonal.
4.3.3. Mouse anti-mouse C6 antibodies
Three C6 deficient mice were immunised with C6 sufficient mouse serum (section 2.3.6.) and 
tested for anti- C6 antibodies by ELISA using human C6 (Figure 4.4). B cells were isolated from
Figure 4.1 Western blot to determine whether the polyclonal rabbit anti-rabbit C6
antibody recognises other species C6
250 kDa 
148 kDa
98 kDa
64 kDa
-50 kDa
M£
o3
CO
Q 5 S
Serum (2 jal) was diluted in dH20  (2 jal) and non-reducing buffer (2 jal), run on a 7.5% 
SDS-PAGE gel and transferred to nitrocellulose by electroblotting for 1 hour. Protein was 
probed with the rabbit anti-rabbit C6 antibody (1:5000) and goat anti-rabbit Ig-HRPO 
(1:25000) as a secondary antibody. Bands were detected with ECL and visualised by 
autoradiography. M -  protein molecular weight markers.
Figure 4.2 Screening ELISA to determine the rat with the highest rat anti-rat C6
antibody titre
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The two immunised rats were tail bled, the collected blood allowed to clot and serum 
prepared. To determine which rat had the highest titre of anti-rat C6 antibodies, a 
screening ELISA was used. All incubations were for 1 hour at 37°C and all wash 
steps comprised three washes. A 96-well ELISA plate was coated with 10 j^g/ml 
human C6 (50 fil/well). After washing, the plate was blocked in blocking buffer. The 
plate was washed again and the rat anti-rat C6 anti-serum was added to the plate at 
several dilutions in blocking buffer. The anti-serum was removed, the plate washed 
and HRP-conjugated anti-rat immunoglobulins diluted 1/1000 in blocking buffer. After 
washing, the plate was developed with OPD substrate. Development was stopped 
with 10% (v/v) H2S 04 and the plate was read at 490 nm. Above, the volume of anti­
serum has been plotted on a logarithmic scale against A490. As rat 2 had a slightly 
higher titre against C6, it was chosen to be sacrificed and its spleen used in a fusion.
Figure 4.3 Haemolytic assays to investigate whether the rat anti-rat C6 
antibodies, 2D1 and 7D1 are able to inhibit C-mediated lysis.
A. 100
o
E
CD
CO
X
B.
80 HELC1
60
20
0
10 20 30
Volume of supernatant (^ 1)
40 50
120 7D1
HELC1100
80
60
40CO
20
10 20 30
Volume of supernatant ( i^l)
40 50
Supernatant was collected from hybridoma cell lines and dilutions made over a range in CFD. Fifty 
microlitres were added to 50 i^l diluted human serum and 50 jil 2% sheep EA in a 96 round-bottomed 
well. This mixture was incubated at 37°C for 30 minutes. The plates were then centrifuged at 2500 
rpm for 5 minutes and the supernatants transferred to a flat-bottomed microtitre plate and the 
absorbance measured at 415 nm. The percentage of haemolysis was calculated for each sample and 
plotted against the volume of supernatant. The graph show the mean for each sample point ± the 
standard error of the mean. For 2D1, n=2; 7D1, n=6. As a non-inhibitory antibody secreting cell line 
control, supernatant collected from the hybridoma cell line secreting the anti-human CD59 mAb, clone 
HEL-C1 was included in each assay.
Figure 4.4 Screening C6 deficient mice immunised with normal mouse serum to 
establish titre levels for anti human C6 antibodies
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Three C6 deficient mice were subject to an immunisation protocol. To determine 
which mouse had the highest anti-C6 titre, an ELISA was carried out. Each mouse 
was tail bled and serum prepared. An ELISA plate was coated with purified human 
C6 (1 ng/ml) for 1 hour at 37°C. The plate was washed three times with 0.1% 
Tween/PBS and blocked for 1 hour at 37°C with blocking buffer (1% BSA/0.1% 
Tween/PBS). Anti-serum from each mouse was diluted in blocking buffer and added 
to the plate for 1 hour, 37°C. The plate was washed and HRP-conjugated mouse 
immunoglobulins diluted 1 in 1000 in blocking buffer for 1 hour, 37°C. After washing, 
the plate was developed with OPD substrate and the colour reaction stopped by the 
addition of 10% H2S 04. The plate was read at 490 nm and the dilution of serum 
plotted against A490. From this, mouse 2 had the highest anti-C6 titre and was 
selected to use for a fusion in the first instance. Ultimately, all three mice were used 
in fusions.
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the spleen of the mouse with the highest titre of anti-C6 antibodies and fused with the mouse 
myeloma cell line SP2/0 (section 2.3.7.). Mouse anti-C6 secreting cells were selected for by 
screening against human C6, ensuring the antibodies would be cross-reactive with both mouse 
C6 and human C6. Ultimately, all three mice were used for the fusions. From these three 
fusions, eight mAbs were identified, designated 1B1,1C1,2B5,4A5,5A5,5C4,7D1 and 8A4. 
Supernatants collected from these cell lines were used to characterise the properties of each 
mAb clone and this data is summarised in Table 4.1. Two of the mAbs, clones 5C4 and 8A4 
recognised human C6 by western blot (Figure 4.5). Haemolytic assays were conducted to 
determine whether any of the mAb clones could inhibit C-mediated lysis (Figure 4.6). As a non- 
inhibitory antibody secreting cell line control, supernatant collected from the hybridoma cell line 
secreting the anti-human CD59 mAb, clone HEL-C1 was included in each assay. Monoclonal 
antibody clones 2B5,5C4,7D1 and 8A4 inhibited C-mediated haemolysis of human serum dose- 
dependently in comparison to the control, suggesting that these antibodies were functionally 
cross-reactive with human C6. Antibody 2B5 inhibited C-mediated haemolysis by up to 92.6%; 
5C4 by up to 80.5%, 7D1 by up to 78.5% and 8A4 by up to 91.5%. The isotype (2.1.13.) of all of 
these antibodies was IgMK. Due to their isotype and inability to recognise C6 by western blot, the 
majority of these antibodies were not characterised further, although 8A4, which inhibited C- 
mediated lysis and recognised human C6 by western blot, was purified by classical methods, as 
described in section 2.1.14.2. and tested for its ability to recognise other species C6 by western 
blot (section 4.3.3.1.).
Table 4.1 Summary of the characterisation of the mouse anti-mouse C6 mAbs.
Clone Recognition of 
human C6 by ELISA
Recognition of 
human C6 by 
Western blot
Capable of inhibiting C- 
mediated haemolysis when 
human serum used
Isotype
1B1 Yes No Weakly inhibitory IgMK
1C1 Yes No Weakly inhibitory IgMK
2B5 Yes No Yes IgMK
4A5 Yes No No IgMK
5A5 Yes No Weakly inhibitory IgMK
5C4 Yes Yes Yes IgMK
7D1 Yes No Yes IgMK
8A4 Yes Yes Yes IgMK
Figure 4.5 Detection of human C6 by mouse anti-mouse C6 antibodies,
A. 5C4 and B. 8A4
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Serum (15 jj.I) was diluted in dH20  (85 jal) and non-reducing loading buffer (50 \ i \ )  
and applied to a 4% stacking gel with a single well and electrophoresed through on a 
7.5% SDS-PAGE running gel and transferred to nitrocellulose by electroblotting for 1 
hour. The nitrocellulose was then cut into strips running the length of the gel before 
supernatant containing the test antibody, 5C4 and 8A4 diluted 1:1 with 0.1% 
tween/PBS or control antibody WU 6.4 (1 jag/ml) diluted in 0.1% tween/PBS was 
incubated with each strip (2 ml). After washing, bound antibody was probed with 
goat anti-mouse Ig-HRPO (1:2000) (Bio-rad) as a secondary antibody. Bands were 
detected with ECL and visualised by autoradiography.
Figure 4.5 Detection of human C6 by mouse anti-mouse C6 antibodies,
A. 5C4 and B. 8A4
A. 5C4 B. 8A4
5C4 WU6.4
130 kDa
90 kDa
70 kDa
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70 kDa
Serum (15 jJ) was diluted in dH20  (85 jj,I) and non-reducing loading buffer (50 jal) 
and applied to a 4% stacking gel with a single well and electrophoresed through on a 
7.5% SDS-PAGE running gel and transferred to nitrocellulose by electroblotting for 1 
hour. The nitrocellulose was then cut into strips running the length of the gel before 
supernatant containing the test antibody, 5C4 and 8A4 diluted 1:1 with 0.1% 
tween/PBS or control antibody WU 6.4 (1 jig/ml) diluted in 0.1% tween/PBS was 
incubated with each strip (2 ml). After washing, bound antibody was probed with 
goat anti-mouse Ig-HRPO (1:2000) (Bio-rad) as a secondary antibody. Bands were 
detected with ECL and visualised by autoradiography.
Figure 4.6 Haemolytic assays to investigate whether the monoclonal mouse 
anti-mouse C6 antibodies inhibit C-mediated lysis.
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Supernatant was collected from hybridoma cell lines and dilutions made over a range in CFD. Fifty 
microlitres were added to 50 j^ l diluted human serum and 50 1^ 2% sheep EA in a 96 round-bottomed well. 
This mixture was incubated at 37°C for 30 minutes. The plates were then centrifuged at 2500 rpm for 5 
minutes and the supernatants transferred to a flat-bottomed microtitre plate and the absorbance measured at 
415 nm. The percentage of haemolysis was calculated for each sample and plotted against the volume of 
supernatant. For 1B1, n=14; 1C1, n=12; 2B5, n=18; 4A5, n=10; 5A5, n=10; 5C4, n=3,7D1, n=12; 8A4, n=6. 
Error bars are the standard error of the mean.
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4.3.3.1. The purification of the mouse anti-mouse C6 mAh, clone 8A4
The chromatogram of the purification of mAb 8A4 is shown in Figure 4.7. IgM containing 
fractions were identified by dot blot (section 2.1.8) using an HRPO-conjugated anti-murine IgM 
antibody (Figure 4.8), pooled and concentrated using ultrafiltration. Purity of the pooled fractions 
was determined using SDS-PAGE (Figure 4.9a) and western blot (Figure 4.9b); concentration of 
the purified antibody was assessed using the Micro BCA assay (section 2.1.5), demonstrating 
that from a starting volume of 1L conditioned tissue culture supernatant, a total of 16.4 mg 
antibody 8A4 was purified. To confirm that the purified antibody 8A4 recognised human C6, 
purified human C6 was subject to SDS-PAGE, transblotted and 8A4 used as a primary antibody 
(Figure 4.10). This shows that mAb 8A4 detects purified human C6 as a single band with an 
approximate molecular weight of 98 kDa under non-reducing conditions. 8A4 was then tested for 
cross-reactivity with other species C6 using C6 sufficient and deficient sera (Figure 4.11). Mouse 
serum was not included as the secondary antibody would have recognised it in a non-specific 
manner. These data show that antibody 8A4 did not recognise C6 in the sera from the species 
tested, other than human, although a high molecular weight band was detected in the normal and 
C6 deficient rat serum sample, which is probably unrelated to C6. mAb 8A4 consistently 
specifically stained purified human C6 and C6 in human serum.
4.3.4. Mouse anti-human C6 mAbs
Three fusions were performed with B cells isolated from C6 deficient mice that had been 
immunised with purified human C6. In the first fusion, seven of the eight antibody-secreting 
clones identified had an IgM isotype; clones 2D2,3D6,4A1,4C6,4D1,5D1 and 8C5; one, clone 
7A2 had an IgGi isotype. The antibodies with an IgM isotype were not characterised further as 
IgM isotype antibodies are not suitable for use therapeutically. Thereafter, to ensure only 
antibody-secreting clones with an IgG isotype were selected, the secondary antibody used in the 
C6 screening ELISA was changed from an anti-mouse IgG antibody that recognised both heavy 
and light chains and hence could recognise antibodies with an IgM isotype through the light 
chains, to one that recognised the Fc region of antibodies with an IgG isotype only. In the 
subsequent fusions, thirteen clones with an IgG isotype were identified: 12A1,13A2,17B1,18A1, 
22B1,23D1,24C2,25C5,26C2,26B4 and 27B1.
Supernatants collected from these cell lines were investigated for their ability to inhibit C- 
mediated lysis in a haemolytic assay (Figure 4.12). Initially, supernatant collected from the 
hybridoma cell line secreting HELC1, an antibody raised against human CD59 was used as an
Figure 4.7 Chromatogram of partially purified antibody, 8A4 being passed over
a SourceQ column
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Conditioned medium collected from cells secreting clone 8A4 was subject to precipitation using 45%
AmS04 saturation. After centrifugation, the supernatant was discarded and the pellet resuspended in 
a minimal volume of 20 mM K2HPO4/20 mM KH2P04, pH 6.5 (start buffer) and dialysed against this 
overnight. The IgM enriched sample was applied to a Source 15Q column pre-equilibrated in start 
buffer and an increasing linear gradient of end buffer (start buffer containing 0.5M NaCI) applied. The 
FPLC was programmed to collect the eluate in 5ml fractions.
Figure 4.8 Dot blot of fractions from eluted column to find the IgM containing peak
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Two microlitres of each fraction (A3 -  D12; thereafter every fifth fraction) was dotted onto nitrocellulose 
membrane and allowed to dry at room temperature, before being blocked with 5% (w/v) milk/0.1 % (v/v) 
Tween/PBS for 30 minutes at room temperature. After washing, the blot was incubated with HRPO-anti- 
mouse IgM (n-chain specific) antibody diluted 1:5000 in 0.1% (v/v) Tween/PBS and incubated at room 
temperature for 1 hour. After five washes with 0.1 % (v/v) Tween/PBS, the blot was developed with the 
addition of ECL.
Figure 4.9 The purification of the mouse anti-mouse C6 mAb, 8A4
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The mouse anti-mouse C6 antibody with an IgM isotype, 8A4 was purified using 
classical methods. To assess purity, the purified sample (1) and (M) protein 
molecular weight markers were subject to SDS-PAGE on a 7.5% non-reducing gel 
and A. stained with Coomassie or B. blotted onto nitrocellulose, and probed with 
goat anti-mouse IgM (1:2000). Bands were detected with ECL and visualised by 
autoradiography.
Figure 4.10 The detection of human C6 with the mouse anti-mouse C6 mAb, 8A4
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Purified human C6 (1) and (M) protein molecular weight markers were subject to 
7.5% SDS-PAGE, electroblotted onto nitrocellulose and probed with the mouse 
anti-mouse C6 mAb, 8A4 (2pg/ml) and goat anti-mouse IgM (1:1000) as a 
secondary antibody. Bands were detected with ECL and visualised by 
autoradiography.
Figure 4.11 Western blot to determine the cross-reactivity of the mouse
anti-mouse C6 mAb 8A4 for C6 from other species serum
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Different species of animal sera, as well as human sera were run under non-reducing conditions on 
7.5% SDS PAGE gel and transferred onto nitrocellulose by electoblotting. After blocking the blot with 
5% (w/v) milk/0.1 % Tween/PBS, protein was probed with mouse anti-mosue C6 mAb 8A4 (4 pg/ml) 
and goat anti-mouse IgM-HRPO (1:1000) as a secondary antibody. Bands were detected with ECL 
and visualised by autoradiography.
Figure 4.12 Haemolysis assay to determine whether the monoclonal mouse
anti-human C6 antibodies inhibit C-mediated lysis
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Supernatant was collected from hybridoma cell lines and dilutions made over a range in CFD. Fifty 
microlitres were added to 50 pi diluted human serum and 50 pi 2% sheep EA in a 96 round-bottomed 
well. This mixture was incubated at 37°C for 30 minutes. The plates were then centrifuged at 2500 
rpm for 5 minutes and the supernatants transferred to a flat-bottomed microtitre plate and the 
absorbance measured at 415 nm. The percentage of haemolysis was calculated for each sample, 
averaged and plotted against the volume of supernatant. For 7A2, n=4; 12A1, n=6; 13A2, n=12; 17B1, 
n=6; 18A1, n=4; 22B1, n=4; 23D1, n=16; 24C2, n=12; 25C2, n=2; 26C2, n=6; 26B4, n=10; 27B1, n=20. 
Error bars are the standard error of the mean.
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antibody secreting cell line control. However, the mouse anti-human C6 antibody, clone 7A2 had 
such a similar non-inhibitory activity that it was subsequently used as the control antibody 
supernatant. Out of all the antibodies tested, 23D1 and 27B1 inhibited C-mediated haemolysis of 
human serum dose-dependentiy in comparison to the control. Antibody clones 24C2,25C5 and 
26B4 showed some inhibitory activity in comparison to the control when used neat in the 
haemolytic assay. Antibody 23D1 inhibited C-mediated haemolysis by up to 58.0% and 27B1 by 
up to 78.6%. Culture supernatant collected from the clones 7A2,23D1 and 27B1 were purified 
and investigated for their ability to inhibit C-mediated haemolysis (Figure 4.13). As an inhibitory 
control, the mAb WU6.4, donated by Professor R. Wurzner was included in the assays. Clone 
7A2 had no inhibitory activity, whilst mAb 23D1 inhibited C-mediated haemolysis by up to 99% at 
the highest concentration (187.5 pg/ml) used. This effect was dose-dependent. Clone 27B1 also 
inhibited C-mediated haemolysis dose-dependently up to almost 100% at the highest 
concentration used.
Supernatants collected from these cell lines were also investigated for their ability to recognise 
purified human C6 by western blot. Three of them, clones 7A2,23D1 and 27B1 recognised 
human C6 by western blot (Figure 4.14.). The data regarding the characterisation of all these 
mAbs are summarised in Table 4.2. Two of the three inhibitory antibodies, clones 23D1 and 
27B1, as well as clones 7A2 and 24C2, were further characterised (sections 4.3.5. and 4.3.6.).
4.3.5. Determining the cross-reactivity of the mAb clones 7A2,23D1 and 27B1 with other 
species C6
Western blotting was used to determine whether the mAb clones 7A2,23D1 and 27B1 had any 
cross-reactivity with C6 from other species. The clones 23D1 and 27B1 were tested in 
haemolytic assays using rat and guinea pig sera for any functional inhibitory activity against rat 
and guinea pig C6.
4.3.5.1. Western blotting to determine the cross-reactivity of the mAb clones 7A2,23D1 
and 27B1 with other species C6
The anti-C6 mAb clones 7A2,23D1 and 27B1 were assessed for their ability to recognise rat, 
mouse, rabbit, guinea pig, goat, chicken, sheep and bovine C6 by western blot. To confirm the 
specificity of the test antibody for C6, C6 deficient sera was included on the western blot 
alongside normal serum, if available, to provide a means of comparison. Samples of purified
Figure 4.13 Haemolytic assay demonstrating that the inhibitory properties of the
monoclonal antibodies 23D1 and 27B1 are retained when purified.
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Purified mAb was diluted over the range 0 -187.5 jig/ml in CFD. Fifty microlitres were added to 50 |il 
diluted human serum and 50 ^l 2% sheep EA in a 96 round-bottomed well. This mixture was incubated 
at 37°C for 30 minutes. The plates were centrifuged at 2500 rpm for 5 minutes and then the 
supernatants were transferred to a flat-bottomed microtitre plate. The absorbance was measured at 
415 nm. The percentage of haemolysis was calculated for each sample and plotted against the 
concentration of mAb. Error bars are the standard error of the mean; n=2 for each condition.
Figure 4.14 Western blot to determine whether the mouse anti-human C6 mAbs
7A2,23D1,24C2 and 27B1 recognise purified human C6 by Western blot
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Serum (15 jil) was diluted in dH20  (85 jal) and non-reducing loading buffer (50 jxl) 
and applied to a 4% stacking gel with a single well and electrophoresed through on a 
7.5% SDS-PAGE running gel and transferred to nitrocellulose by electroblotting for 1 
hour. The nitrocellulose was then cut into strips running the length of the gel before 
supernatant containing the test antibodies, 23D1, 24C2 and 27B1 diluted 1:1 with 
0.1% tween/PBS, or in the case of 7A2 diluted to 1 jag/ml in 0.1% tween/PBS. A 
control antibody WU 6.4 (1 jag/ml) diluted in 0.1% tween/PBS was also incubated 
with each strip (2 ml). To determine whether there was any non-specific binding of 
the secondary antibody to the serum, one strip was incubated in secondary antibody 
only. After washing, bound antibody was probed with goat anti-mouse Ig-HRPO 
(1:2000) (Bio-rad) as a secondary antibody. Bands were detected with ECL and 
visualised by autoradiography.
87
human C6, normal human serum and C6 deficient human serum were included on the western 
blots as a reference.
Clones 7A2 (figure 4.15), 27B1 (figure 4.16) and 23D1 (figure 4.18) all recognised purified human 
C6 and C6 in normal human serum, but did not recognise any component of C6 deficient human 
serum. Clone 7A2 (figure 4.15) stained a single band with a molecular weight of approximately 
64 kDa weakly in both the normal and C6 deficient rat and rabbit serum and also the guinea 
pigserum. This is not specific for C6, as C6 deficient rats do not make a truncated form of C6 
485,508j neither do C6 deficient rabbits486-509; also the molecular weight of rat C6 is approximately 
90 kDa48S. Single bands with a molecular weight in excess of 250 kDa were seen for human, C6 
deficient human, goat, chicken, sheep and bovine sera in the westerns probed with 7A2 (figure 
4.15) and 27B1 (figure 4.16). An identical blot was probed only with secondary antibody (figure 
4.17) and similar staining of high molecular weight bands was observed in these samples as well, 
suggesting that the observed staining of the high molecular weight bands was due to the 
secondary antibody recognising protein in a non-specific manner.
4.3.5.2. Haemolytic assays to determine whether mAbs 27B1 and 23D1 were functionally 
cross-reactive with other species sera
Purified anti-human C6 mAbs 23D1 and 27B1 were tested in haemolytic assays using rat and 
guinea pig sera for functional inhibitory activity against rat and guinea pig C6 (Figures 4.19A and 
B respectively). The non-inhibitory mAb, 7A2 was used as a reference non-inhibitory control, as 
was the mAb WU 6.4, which had previously been shown not to recognise rat or guinea pig C6 in 
serum by ELISA 522. Both the rat and guinea pig sera were diluted 1 in 100 as this dilution 
resulted in 80% haemolysis of sheep EA. In humans, the concentration of C6 in serum ranges 
between 20 -  80 pg/ml4" .  Based upon there being a similar concentration of rat or guinea pig 
C6 in the relevant sera, there would be approximately 10 -  40 ng of C6 per well in these 
experiments, whilst the concentration of antibody ranged between 1.85 ng (37 ng/ml) and 3.75 i^g 
(75 pg/ml) per well.
At the highest concentration added 75 jig/ml, there was 51% haemolysis in the presence of the 
non-inhibitory mAb, 7A2. This inhibition was not present when mAb 7A2 was diluted out further in 
comparison to no antibody being present (72% haemolysis). The mAbs 23D1, WU6.4 and 27B1 
all inhibited C-mediated haemolysis to some degree when present at high concentrations, 36.5%, 
26.5% and 45% respectively, and these effects were dose-dependent, but as with 7A2, these 
effects were rapidly diluted out. Given the excess the mAbs present were in relative to rat C6 in
Figure 4.15 Western blot to determine the cross-reactivity of the mouse
anti-human C6 mAb 7A2 with C6 from other species
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To determine if the mouse anti-human C6 mAb, 7A2 recognised other species C6, 
serum collected from the species listed above and purified human C6 were subject to 
SDS-PAGE, transblotted and 7A2 (1 pg/ml) was used as a primary antibody to detect 
C6. Secondary antibody was anti-mouse Ig-HRPO (1:10, 000 dilution) and bands 
were detected with ECL and visualised by autoradiography. Protein markers are 
depicted to the right of the figure.
Figure 4.16 Western blot to determine the cross-reactivity of the mouse
anti-human C6 mAb 27B1 with C6 from other species
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To characterise the ability of the mouse anti-human C6 mAb, 27B1 to recognise 
other species C6, serum collected from the species listed above as well as purified 
human C6, were subject to SDS-PAGE, transblotted and 27B1 (1 pg/ml) was used 
as a primary antibody to detect C6. Secondary antibody was anti-mouse Ig-HRPO 
(1:10,000 dilution) and bands were detected with ECL and visualised by 
autoradiography. Protein markers are shown on the right of the figure.
Figure 4.17 Western blot probed with secondary antibody only to determine 
the specificity of the primary antibodies 7A2 and 27B1
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To confirm the specificity of the mouse anti-human C6 mAbs 7A2 and 27B1 for 
various species C6, serum collected from the species listed above as well as purified 
human C6, were subject to SDS-PAGE, transblotted and probed only with the 
secondary antibody anti-mouse Ig-HRPO (1:10,000 dilution). Any bands were 
detected with ECL and visualised by autoradiography. Protein markers are shown on 
the right of the figure.
Figure 4.18 Western blot to determine the cross-reactivity of the mouse
anti-human C6 mAb 23D1 with C6 from other species
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To determine if the mouse anti-human C6 mAb, 23D1 recognised other species C6, 
serum collected from the species listed above and purified human C6 were subject 
to SDS-PAGE, transblotted and 23D1 (1 pg/ml) was used as a primary antibody to 
detect C6. Secondary antibody was anti-mouse Ig-HRPO (1:10, 000 dilution) and 
bands were detected with ECL and visualised by autoradiography.
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Figure 4.19 Haemolytic assay using rat serum to determine whether the 
antibodies 23D1 or 27B1 have inhibitory activity against either A. rat C6 or 
B. guinea pig C6.
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A dilution range of purified mAb was made (0 -  75 |ig/ml) in CFD. Fifty microlitres were added to 
either 50 |il diluted rat or guinea pig serum and 50 jil 2% sheep EA in a 96 round-bottomed well. This 
mixture was incubated at 37°C for 30 minutes. The plates were then centrifuged at 2500 rpm for 5 
minutes and the supernatants transferred to a flat-bottomed microtitre plate and the absorbance 
measured at 415 nm. The percentage of haemolysis was calculated for each sample and plotted 
against the concentration of mAb. Error bars are the standard error of the mean; n=2 for each 
condition.
order to be able to measure inhibition, these mAbs are at best weakly inhibitory of rat C6 activity. 
When guinea pig serum was used, no inhibition of guinea pig C6 activity was observed.
4.3.6. Measuring the affinity of the anti-human C6 mAbs 7A2 and 23D1 for human C6 using 
the BIAcore
BIAcore technology has previously been used to measure the affinities of antibodies for antigens 
523-526. using the software Biaevaluation 3.0, the affinity data obtained for each antibody was 
fitted to a bivalent analyte model, where it is assumed that the analyte (A) being passed over the 
immobilised molecule has two binding sites for the ligand (B), for example an antibody with an 
IgG isotype. The association and dissociation can be defined by the equations: 
ka1
A + B ^  AB, the first interaction occurring: 
kd1
ka2
AB + B ^  AB2, the second interaction 
kd2
The Rmax value is the response obtained when the ligand is saturated. Both the Chi2 value and 
the residual plot are statistical model fitting parameters; the smaller these values are, the better 
the fit of the model to the data. The Chi2 value represents the sum of squared residuals -  the fit 
is generally acceptable if this value is 2 or less. The residual plot describes the difference 
between the measured and calculated data; the residual plot of good fitting data will be between 
0.5 and 1 RU. The standard error should be no more than 2%. The data was also fitted to a 1:1 
Langmuir binding model, in order to determine the binding affinities of the mAbs for C6.
There was a change of 1383 RU when C6 (10 jog/ml in 10 mM sodium acetate buffer, pH 4.0) 
was immobilised onto the flow cell of a CM-5 sensor chip (Figure 4.20a). A reference flow cell 
with nothing immobilised on it was prepared at the same time (Figure 4.20b). The affinity data 
fitted to the bivalent analyte model for mAb clone 7A2 is detailed in Figure 4.21 and fitted to the 
1:1 Langmuir model in Figure 4.22. The sensorgram for the corresponding control experiment to 
determine if mass transfer effects had occurred during experiments is shown in Figure 4.23. The 
sensorgrams overlay each other perfectly, demonstrating that mass transfer effects were kept to 
a minimum in this experiment. The bivalent analyte model fits well to the data obtained for the
Figure 4.20 A. Immobilisation of purified human C6 on a CM-5 sensor chip and
B. preparation of a control surface
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A. After determining the rate at which purified human C6 (10 pg/ml in 10 mM sodium acetate buffer, 
pH 4.0) bound to the chip, the surface was activated by passing EDC/NHS over and then the C6 was 
injected over the chip and allowed to covalently couple to it When the target RU had been reached, 
ethanolamine was passed over the flow cell surface to block any free amine groups remaining. B. The 
control surface (nothing bound) was prepared by activating the surface and then blocking it as 
described.
Figure 4,21 Analysis of the binding affinity of the anti-C6 mAb clone 7A2 for
human C6 fitted to a bivalent analyte model
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Parameters Calculations
First association rate constant, ka1 3.11 x 104 ± 89.2 M -V
First dissociation rate constant, kd1 6.02 x 104 ± 6.61 x 10* s'1
Second association rate constant, ka2 1.99x10* ±1 .2 3 x1 04 RU-1s- 
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Second dissociation rate constant, kd2 0.0407 ±2 .47x1  O'3 S"1
First association equilibrium constant, KA 5.17 x 107 M'1
First dissociation equilibrium constant, KD 1.9x10^M
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The anti-C6 mAb 7A2 was injected over human C6 which had been immobilised onto 
a CM5 chip at a range of concentrations (10.4 nM — 1.0 jxM). At the end of each 
injection, the mAb was allowed to dissociate for 15 minutes. The data was recorded 
and fitted to a model of bivalent analyte binding to ligand. This is represented 
graphically above, where the coloured lines of each trace represent the experimental 
data obtained and the black lines represent the corresponding curve-fit. The 
interpreted data is summarised in the table above. The numbers following the ± 
represent the Standard Error.
Figure 4.22 Analysis of the binding affinity of the anti-C6 mAb clone 7A2 for
human C6 fitted to a Langmuir binding model
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Parameters Calculations
Association rate constant, ka 1.1 x 105 ± 120 M V
Dissociation rate constant, kd 1.41 x 104 ± 1.29 x 10-6 S'1
Association equilibrium constant, KA 7.83 x 108 M'1
Dissociation equilibrium constant, KD 1.28 x 10-9 M
D
■'m ax 339 ±0.222
Chi2 18.6
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Human C6 was immobilised onto a CM5 chip. To determine the affinity of the anti- 
C6 mAb 7A2 for C6, it was passed over the immobilised C6 at a range of 
concentrations (10.4 nM -1 .0  jj.M). At the end of each injection, the mAb was 
allowed to dissociate for 15 minutes. The data was recorded and fitted to a model of 
analyte binding to ligand in a 1:1 ratio (Langmuir). This is represented graphically 
above, where the coloured lines of each trace represent the experimental data 
obtained and the black lines represent the corresponding curve-fit. The interpreted 
data is summarised in the table above. The numbers following the ± represent the 
Standard Error.
Figure 4.23 Experiment to determine whether mass transfer effects occurred
during the binding affinity measurements of mAb 7A2 for human C6
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The mAb 7A2 (3.125 jag/ml in HBS-EP buffer) was passed over a flow cell on which 
human C6 had been immobilised at flow rates of 5 (turquoise line), 15 (navy line) and 
75 (red line) j i l  per minute. Sensorgrams of each experiment were recorded and 
have been superimposed on each other to determine whether any mass transfer 
effects are occurring. As the gradient of each trace are identical, this suggests that 
there were no mass transfer effects in this experiment.
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anti-C6 mAb 7A2 binding to human C6 (Figure 4.21). The data in the accompanying table shows 
that in general the standard errors for the calculated constants are less than 2%. The kd1 value is 
very small, suggesting that mAb 7A2 has a slow dissociation rate from human C6, which is seen 
on the graph. The Chi2 value and the residual plot value are both higher than desirable. By 
dividing the first dissociation rate (kdi) by the first association rate (kai), an affinity constant of 
mAb 7A2 for C6 could be calculated, which was 1.9 x 10*8 M. The calculated affinity constant of 
mAb 7A2 for C6 from the 1:1 curve-fit was 1.28 x 10-9 M.
The bivalent analyte fitted data for mAb clone 23D1 is shown in Figure 4.24. This shows the 
binding of mAb 23D1 to the immobilised C6 at a range of concentrations (coloured lines) and the 
bivalent analyte model curve fit to that data with the black lines. The mAb does not seem to be 
dissociating from the chip surface over time and is reflected in the very small value for the first 
dissociation constant, kd1, in the accompanying table. Apart from this, the standard errors are 
generally less than 1% of the calculated constants. The Chi2 value is below 2 and the residual 
variation is between 1 and 3, illustrating that the bivalent analyte model has fitted to the data well. 
The first dissociation rate (kdi) was divided by the first association rate (kai) to calculate an affinity 
constant of 9.57 x 10-11 M. To get an overall affinity of 23D1 for C6, the data was fitted to the 
Langmuir model (Figure 4.25) and the overall affinity constant was 6.18 x 10-13 M. The overlayed 
sensorgrams for the control mass transfer experiment are shown in Figure 4.26. There was a 
small change in RU in these experiments, because of the concentration (3.125 pg/ml) at which 
23D1 was passed over C6. The change in RU approach the minimal sensitivity level of the 
BIAcore 3000 and thus it is not possible to interpret this data.
4.3.7. Epitope mapping of the antibodies using SPR technology
The BIAcore was also used to determine the epitope specificities of the anti-human C6 mAbs 
7A2,23D1,24C2 and 27B1. Each mAb binds an epitope on the antigen; a pair of mAbs which 
bind to closely situated epitopes will interfere sterically with each other’s binding, whilst mAbs 
recognising distant epitopes will bind independently of each other. SPR technology has 
previously been used in epitope mapping studies 527'529.
Epitope mapping was carried out according to the manufacturers recommended protocols as 
detailed in section 4.2.3.2. 7245.7 RU of RAM Igs (BIAcore, cat no BR-1005-14) (30 jLig/ml in 10 
mM sodium acetate buffer, pH 5.0) were immobilised onto the surface of a CM-5 sensor chip 
(Figure 4.27a). A reference flow cell surface was prepared by subjecting it to the immobilisation 
procedure, without immobilising anything onto it (Figure 4.27b).
Figure 4.24 Analysis of the binding affinity of the anti-C6 mAb clone 23D1 for
human C6 fitted to a bivalent analyte model.
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Parameters Calculations
First association rate constant, ka1 2.8 x 104 ± 177 M 'V
First dissociation rate constant, kd1 2.68 x 10'6 ± 8.9 x 10'7 s '1
Second association rate constant, ka2 2.31 x 104 + 6.41 x 10-6 RU'1S‘1
Second dissociation rate constant, kd2 5.92 x 104 ± 4.48 x 10-6 S'1
First association equilibrium constant, KA 1.04 x 1010 M"1
First dissociation equilibrium constant, K0 9.57 x 1 0 11 M
Rmax 88.4 ±  0.554 RU
Chi2 1.68
Residual plot 1 -3
The mAb, 23D1 was passed over human C6 over a concentration range (5.21 x 
10'9 M -1 .6 7  x 10'7 M). At the end of each injection, the mAb was allowed to 
dissociate for 15 minutes. The data was recorded and the software, BIAevaluation 
3.0 used to align each trace and fit the data to a bivalent analyte model of binding. 
The coloured lines of each trace represent the experimental data obtained and the 
black lines represent the corresponding curve-fit.
Figure 4.25 Analysis of the binding affinity of the anti-C6 mAb clone 23D1 for
human C6 fitted to a 1:1 (Langmuir) binding model.
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Association rate constant, ka 7 .9 x1 0 4  ±1 9 7  M 'V
Dissociation rate constant, kd 4.88 x 10-8 ± 4.28 x 10'7 s_1
Association equilibrium constant, KA 1.62 x1012 M-1
Dissociation equilibrium constant, K0 6.18 x 10‘13 M
Rmax 63.7 ± 0.077 RU
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Several concentrations (5.21 x 10'9 M -1 .6 7  x 10’7 M) of the anti-C6 mAb 23D1 
were passed over a sensor chip surface on which human C6 had been immobilised 
and allowed to dissociate for 15 minutes. The data was recorded and the software 
BIAevaluation 3.0 used to align each trace and fit the data to a 1:1 Langmuir binding 
model. The coloured lines of each trace represent the experimental data obtained 
and the black lines represent the corresponding curve-fit.
Figure 4.26 Experiment to determine if mass transfer effects might have
affected the binding affinity measurements of mAb 23D1 for human C6
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The monoclonal antibody 23D1 (3.125 pg/ml) was injected over a sensor chip on 
which human C6 had previously been immobilised at flow rates of 5 (red line), 15 
(pink line) and 75 (green line) pi per minute. Sensorgrams were recorded of each 
experiment and above have been superimposed upon each other.
Figure 4.27 Immobilisation of A. rat anti-mouse immunoglobulins (RAM Igs)
onto a CM-5 sensor chip and B. preparation of a reference surface.
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A. The rate at which RAM Igs (30 pig/ml in 10 mM sodium acetate buffer, pH 5.0) was determined. 
The chip surface was activated by passing NHS/EDC over and then RAM Igs were injected and 
allowed to couple to it. The activated surface was blocked by passing ethanolamine over. B. The 
control surface was prepared by activating it and then blocking free amine groups as described.
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The first set of epitope mapping experiments was carried out with the mAb clone 23D1 being 
flowed over the RAM lg immobilised flow cell and also the reference surface, to act as a capture 
antibody for C6 and then either mAb clone 7A2,27B1,24C2 or WU 6.4 being passed over the 
captured C6. The anti-human C6 mAb clone WU 6.4 recognises the third thrombospondin repeat 
of C6 (modular structure shown in figure 1.2) 522 and was included in this experiment to gain more 
information about the epitopes recognised by the antibodies being characterised. A typical 
sensorgram of the epitope mapping experiment is shown in figure 4.28. The data from these 
experiments is summarised in table 4.3.
Although the specificity of the mAbs for C6 had been determined either by ELISA or Western blot, 
control experiments to confirm that the increases in RU observed when the mAbs were passed 
over the captured C6 were due to a specific interaction with C6 were carried out. Briefly, the 
same experiment was carried out for each of the antibodies, but with the omission of C6 being 
injected over the chip. This data is summarised in table 4.4.
Table 4.3. 23D1 versus 7A2,27B1,24C2 and WU 6.4
Capture mAb 
23D1 (RU)
Human C6 
(RU)
Blocking agent 
Mouse lg (RU)
Second mAb
7A2 (RU) 27B1(RU) 24C2 (RU) WU 6.4 (RU)
850.5 369.8 944.4 305.7 - - -
751.0 436.0 977.9 - 166.4 - -
667.9 364.8 1123.9 - - 129.0 -
528.8 337.9 1223.1 - - - 281.2
Table 4.4 23D1 versus 7A2,27B1,24C2 and WU 6.4 in the absence of human C6.
Capture mAb 
23D1 (RU)
Blocking agent 
Mouse lg (RU)
Second mAb
7A2 (RU) 27B1 (RU) 24C2(RU) WU 6.4 (RU)
289.6 756.6 194.8 - - -
305.8 764.9 - 403.7 - -
311.4 758.6 - - 117.6 -
309.2 749.4 - - - 73.2
Each of the mAb tested bound to C6 captured by immobilised 23D1 (Table 4.3). However, all of 
the mAbs also bound to the sensor chip in the absence of C6 (Table 4.4). As the mAbs had been 
shown to specifically recognise C6, the data suggest that the chip surface had not been 
completely blocked using mouse lg. This makes it impossible to accurately interpret the data 
shown in Table 4.3 or similar studies with the other mAbs captured on the chip. Due to time 
constraints, the epitope mapping experiments were not further optimised.
Figure 4.28 Typical sensorgram of an epitope mapping experiment
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Each reagent was injected over the flow cell to which the RAM Igs had been 
immobilised and the control cell at a concentration of 100 jug/ml, a flow rate of 20 
(xl/min for 5 minutes each. At the end of each experiment, the surfaces were 
regenerated with 10 mM glycine, pH 1.7. In this experiment mAb 23D1 was the 
capture antibody for C6 and mAb 7A2 was the secondary antibody.
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Less mAb 23D1 was captured on the chip surface for the control experiments (Table 4.4) than in 
the epitope mapping experiments (Table 4.3). This might indicate that the immobilised ligand 
was gradually denaturing, probably due to 10 mM glycine, pH 1.7 being passed over the surface 
at the end of each experiment to remove any remaining analyte. This is normal and defines the 
lifespan of the sensor chip and the decrease in RU observed when 23D1 was passed over the 
chip is likely a reflection of this phenomenon.
4.3.8. Analysis to determine whether any contamination was present in the samples 
passed over the BIAcore.
Data obtained from experiments involving the BIAcore, in particular the epitope mapping 
experiments indicated that the samples of mAb used might be of insufficient purity. The most 
probable source of contaminant would have been the medium in which the anti-C6 secreting 
hybridomas were cultured as this contained bovine lg. To investigate this, aliquots (10 jag) of 
mAbs and mouse immunoglobulins used in the epitope mapping experiments were subject to 
SDS-PAGE and in parallel, stained with coomassie blue (figure 4.29a) or subject to western blot 
and probed with either an anti-mouse immunoglobulin antibody (figure 4.29b), or an anti-bovine 
immunoglobulin antibody (figure 4.29c), each of which were non-cross species reactive. 
Coomassie staining showed that all of the samples -  purified mAbs 7A2,23D1,27B1,24C2, WU
6.4 and mouse IgG contained protein with a molecular weight consistent with that of IgG.
Western blotting of the mAbs and mouse IgG showed that they all contained mouse lg, as 
expected. However, by probing with the anti-bovine lg antibody, it could be seen that all of the 
purified mAbs, apart from WU6.4 were contaminated with bovine lg. As would be expected, the 
sample of mouse IgG did not contain any bovine lg, having been prepared from mouse serum. It 
is possible that the bovine lg retained in these preparations were competing with the anti-mouse 
lg immobilised on the sensor chip, limiting the amount of mouse lg able to bind to the anti-mouse
lg.
4.4 Discussion
This chapter describes the generation of a panel of polyclonal and monoclonal antibodies (mAbs) 
raised against rabbit, rat, mouse or human C6, that all recognise human C6. Many of the mAbs 
inhibited C-mediated haemolysis, presumably by interacting with C6. As the point of this work 
was to identify an inhibitory C6 mAb with a minimal C-activating isotype, two mAbs were selected
Figure 4.29 Coomassie staining and Western blotting to determine the purity of
reagents used in BIAcore experiments
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To determine whether the mAbs purified from tissue culture supernatant also 
contained bovine Ig, samples (10 j^g) of the mAbs were subject to SDS-PAGE and 
either A. stained with Coomassie, or transblotted to nitrocellulose, blocked and B. 
incubated with non-species cross reactive anti-mouse Igs or C. incubate with non­
species cross-reactive anti-bovine Igs. The blots were developed with ECL and 
visualised by autoradiography. 24C2 (1) and 24C2 (2) refer to different aliquots of 
stocks of this mAb.
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for more detailed characterisation, based upon their C6-inhibitory properties and isotype. For 
comparison, a non-inhibitory anti-C6 mAb with an identical isotype to the two inhibitory mAbs, 
clone 7A2, was also further characterised.
Of the antibodies raised against C6, the anti-rabbit C6 polyclonal antibody recognised two bands 
in human serum by western blot. The higher one had a molecular weight consistent with C6, the 
lower one was likely a degradation product of C6. In addition, this polyclonal antibody recognised 
guinea pig, goat and sheep C6 by western blot.
To date, no rat anti-rat C6 mAbs have been described. This is the first description of rat anti-rat 
C6 mAbs that are cross-reactive with human C6 by ELISA and also functionally, as they inhibited 
C-mediated haemolysis of sheep erythrocytes in the presence of normal human serum.
However, like the antibodies raised against mouse C6, the most inhibitory clone had an IgM 
isotype and for this reason, was not further characterised.
Eight mouse anti-mouse C6 mAbs were generated, which, like the rat anti-rat C6 mAbs have not 
been described before. All of them were cross-reactive with human C6 as measured by ELISA 
and six of these clones inhibited C-mediated haemolysis, presumably by functionally inhibiting C6 
activity. Clone 8A4 recognised human C6 by western blot, but not C6 in any of the other species 
sera tested. All of these mAbs had an IgM isotype: the first phase of the humoral immune 
response is characterised by an early rise of antigen-specific IgM due to clonal B-cell expansion 
530. In the second phase, interactions occur between B- and T-cells, leading to isotype switching 
and memory B-cell development531-532. As the C6 deficient mice were immunised with normal 
mouse serum, it is likely that the concentration of mouse C6 was not high enough to induce 
isotype switching. Antibodies with an IgM isotype are very large molecules and it is possible that 
the inhibition of C-mediated haemolysis observed in experiments may have been due to steric 
inhibition rather than a specific interaction between the mAb and the ‘active site’ of C6. IgM 
isotype mAbs are also more effective at inducing C activation than those of an IgG isotype 30>31.
As the ultimate aim of this project was to generate antibodies that inhibit MAC formation so that 
they might be tested as a treatment in animal models of C-mediated disease, any potential 
therapeutic benefit would be negated by their own C-activating properties. For this reason, these 
antibodies were not characterised further, although clone 8A4 was very good at recognising 
human C6 by western blot and will be a useful antibody for detecting C6.
Nineteen mouse anti-human C6 mAbs were identified, presenting a new and valuable resource to 
be used in research involving human C6. Seven of these had an IgM isotype and for reasons 
already discussed, were not further characterised. Of the twelve remaining, the three most 
interesting mAbs were selected for further characterisation: all of them - clones 7A2,23D1 and
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27B1, recognised C6 by western blot. Clone 7A2 did not inhibit C-mediated haemolysis, whilst 
clones 23D1 and 27B1 did.
Western blotting was performed to determine whether clones 7A2,23D1 and 27B1 recognised 
other animal species C6. Clones 27B1 and 23D1 detected human C6, but did not detect C6 in 
other sera tested. At high concentrations, mAbs 23D1 and 27B1 were weakly inhibitory against 
rat serum and had no activity against guinea pig serum in haemolytic assays. The functional data 
strongly suggest that mAb 7A2 recognises a different epitope from mAbs 23D1 and 27B1. The 
FI Ms domains of C6 enhance its activity, by forming the first reversible interactions with the 
C345C domain of C5 83-85, whilst the C control protein (CCP) modules are critical for its activity 
(discussed in section 1.1.2.)84, suggesting that C6 binds irreversibly to C5b through its CCP 
domains. C7 binds to the C345C domain of C5b through its FIMs domains with a higher affinity 
than C685, leading to the suggestion that during the initial stages of MAC formation, C6 interacts 
with C5b through its FIMs domains, which leads to interactions between other regions of C6, such 
as the CCP domains and regions of C5. The C7 FIMs domains then displace the C6 FIMs 
domains, forming C5b-7. Therefore, it is probable that mAbs 23D1 and 27B1 recognise either the 
FIMs domains or the CCP domains of C6. With hindsight, it would have been informative to 
perform reactive lysis assays to determine whether mAbs 23D1 and 27B1 inhibited C5b6 
formation or C7 binding to form a complex with C5b6.
SPR was used to measure the binding affinities of the anti-human C6 mAbs 7A2 and 23D1 for 
human C6. Data obtained from both experiments appeared to fit well to the bivalent analyte 
binding model. However, statistical analysis of the curve-fitting data showed that whilst this was 
true for mAb 23D1, the fit was not quite so accurate for mAb 7A2. The binding affinity of a mAb 
for antigen is usually in the order of 10*9 M 533. The anti-C6 mAb 7A2 had an affinity of 1.9 x 10-8 
M when the data was fitted to the bivalent analyte model and 1.28 x 10-9 M when fitted to the 1:1 
model of interaction. These binding affinities are in the lower range of the expected binding 
affinity of a mAb for antigen. The difference between the two affinities is most likely due to the 
way they were calculated. For example, the affinity from the bivalent analyte fitted data refers to 
the first interaction only, whereas in the 1:1 model, there is only one interaction characterised. 
Antibody 23D1 had a particularly high affinity for human C6, which was 9.57 x 10*11 M when fitted 
to the bivalent analyte model and 6.18 x 10-13 M when fitted to the 1:1 Langmuir model. These 
high affinities were mainly due to the slow dissociation rate of 23D1 from C6. On the 
sensorgram, it looked like the interaction between the mAb and the immobilised C6 was 
essentially irreversible. This is probably an indication that the observed slow rate was due to 
avidity rather than affinity. There are other instances in the literature where the affinities of mAbs
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from antigens have been determined using BIAcore technology and similar slow dissociation 
rates between antibody and antigen have been observed. For example, a mAb has been 
identified that binds to thrombin 534 and has a very slow dissociation rate that is almost 
irreversible 535.
Results from epitope mapping experiments initially looked very promising, but control 
experiments highlighted a lack of specificity of many of the mAb preparations and made it 
impossible to draw any meaningful conclusions as to the epitopes recognised by the mAbs. 
Western blotting showed that some of the samples were heavily contaminated with bovine Ig.
This was probably co-purified with the mouse Ig during the purification of the mouse Ig, as bovine 
Ig also has a high affinity for protein A. It is also possible that the rabbit anti-mouse (RAM) Ig 
immobilised on the chip surface may have been cross-species reactive with bovine Ig, so that the 
bovine Ig were captured by the immobilised RAM Ig. One way around this contamination 
problem would have been to culture the hybridomas in serum-free chemically defined culture 
medium, such as CD hybridoma medium (Invitrogen). In house, a number of measures have 
recently been instigated to deal with this problem. To minimise the presence of the bovine Ig in 
the culture medium, the hybridoma cell lines are now cultured in culture medium supplemented 
with low Ig-containing bovine serum instead of normal bovine serum. In addition, the hybridomas 
are cultured in high expression systems including Integra™ flasks (IBS Integra Biosciences, 
Switzerland) and the Technomouse™ system (IBS Integra Biosciences, Switzerland). Both of 
these systems are improvements upon standard tissue culture cultivation techniques in that 
nutrients and oxygen are delivered to the cells cultured within a compartment and simultaneously 
waste products and carbon dioxide are diffused out of the cell culture compartment, encouraging 
maximal cell growth and protein secretion, leading to the accumulation of milligrams of protein.
As well as altering the culture conditions, changes to the purification protocol of the mAbs from 
culture supernatant have been made. Both bovine Ig and mouse IgGi have a high affinity for 
prosep-G 536, meaning that bovine Ig can also be co-purified from the prosep-G. Mouse IgGnc 
binds to prosep-A at a capacity of approximately 13 mg/ml whilst bovine Ig binds to prosep-A at a 
capacity of 27 mg/ml537, but bovine Ig elutes from prosep-A at a different pH from mouse IgGi. 
These properties can be made use of by incorporating washes to specifically elute the bovine Ig 
before eluting the mAb of interest, allowing a greater degree of purity to be achieved.
In conclusion, a panel of nearly 30 different antibodies have been raised against rabbit, rat, 
mouse or human C6 and all recognise human C6. Anti-rat C6 and anti-mouse C6 mAbs have not 
been previously described and although the ones generated in this work were not further
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characterised, they will be useful tools in any research requiring anti-rat or anti-mouse C6 mAbs. 
Many of the antibodies had inhibitory activity in haemolytic assays and two with an IgG isotype 
were further characterised. These were found to be specific for human C6, meaning that their 
therapeutic potential cannot be investigated in animal models of disease in which C plays a role, 
although it will be possible to carry out further ex vivo studies using human serum (chapter 6).
/
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Chapter 5: The Identification of Peptides that bind C6 using Phage Display.
5.1 Introduction
The pharmaceutical industry is increasingly interested in developing peptides as drug candidates 
because they can be synthesised cheaply, and are stable, so that they can be stored for long 
periods at room temperature 538. The development of phage display technology has enabled 
peptides specifically recognising a protein to be rapidly identified. Phage display is a selection 
technique in which DNA encoding a peptide sequence or protein is fused to a gene encoding a 
coat protein of a bacteriophage (phage). This results in the expression or display of the peptide 
on the surface of the virion (Figure 5.1). Phage display provides a physical link between a vast 
library of random peptide sequences and the DNA encoding each sequence, allowing rapid 
identification of peptide ligands for a variety of target molecules, including antibodies, enzymes 
and cell-surface receptors, by an in vitro selection process called panning539-540. In its simplest 
form, panning is performed by incubating a library of phage-displayed peptides with immobilised 
target protein (on plates or beads), washing away the unbound phage, and eluting the 
specifically-bound phage. The eluted phage are then amplified and taken through additional 
panning and amplification cycles to significantly enrich the pool in favour of sequences that 
specifically bind the target protein. After 3 - 4 rounds of panning, individual clones are 
characterised by DNA sequencing. This process is depicted schematically in Figure 5.2.
Often, the panning procedure is more complex than that described above. For example, phage- 
peptides have been panned against immobilised, purified receptors541 as well as against intact 
cells s42-544 leading to the identification of functionally active peptides. Affinity tags can be 
attached upstream from the randomised region of the phage. This has enabled the substrates of 
enzymes to be determined, as it becomes possible to separate cleaved from uncleaved phage 
with the appropriate affinity matrix545. It is also possible to fuse longer DNA sequences to the 
phage genome, resulting in larger proteins being displayed by the phage, such as antibodies546, 
hormones547, protease inhibitors 355, enzymes 548 and DNA binding proteins549. The endless 
variations in the nature of the substrate the phage-peptides can be panned against, together with 
the fact that the DNA sequences of binding proteins can be rapidly obtained and thus used as 
source material to generate phage peptide libraries, makes phage display an extremely powerful 
tool that can be applied to many different fields in medical research 348-350.550-555 anc| the 
pharmaceutical industry 328,556-563,
Phage display has been used to identify C- inhibitory agents with therapeutic potential. For 
example, Compstatin, a peptide that blocks C3 convertase formation, was discovered by panning
Figure 5.1 A schematic diagram of the surface of a phage displaying peptides.
Phage
Major coat protein
Five copies minor coat 
protein, pill, each 
expressing a peptide.
The peptide sequence within the 
coat protein sequence
A-C-X-X-X-X-X-X-X-C-G-G-G-S
The surface of the bacteriophage (phage) comprises at least two types of protein, 
the major coat protein and the minor coat protein. Five copies of the minor coat 
protein, pill, are expressed per phage. In this example of phage display, DNA 
encoding random heptamer peptide sequences has been fused to the minor coat 
protein gene, gill. These are expressed along with the coat protein when it is 
made, resulting in the display of the peptide on the surface of the virion, as 
above.
Figure 5.2 A schematic diagram of the process of biopanning
A library of phage, 
each displaying a 
different peptide 
sequence, is exposed 
to a plate coated with 
the target
4Unbound phage is * 4 
washed away Y
Specifically-bound 
phage is eluted from 
target either with an 
excess of a known 
ligand for the target or 
by changing the pH
The eluted pool of 
phage is amplified and 
the process is repeated 
for a total of 3 - 4 
rounds After 3 - 4 rounds, individual 
clones are isolated, 
characterised and sequenced
Adapted from the Ph.D.-C7C™ Phage Display Peptide Library Kit instruction 
manual (New England Biolabs)
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a library against C3b361. Peptide 2J, which inhibits C1q activity was discovered by screening 
against C1q 359>360; both are described in further detail in section 1.9.5. Several anti-C5 scFV 
inhibitory antibodies have been developed in this way, including the licensed drug Pexelizimab™ 
471,564,565 (section 1.9.8.) and also TS-A12/22566. Although these particular scFv antibodies are 
designed to stop the C pathway, the therapeutic potential of most selected fragments is limited as 
they do not have binding sites for C1q 567-568, meaning that they lack the C-mediated effector 
function of naturally occurring antibodies. To overcome this problem, an anti-C1q antibody 
fragment, identified through phage display, was linked to hen-egg lysozyme (HEL)-specific 
antibody fragments, making a bispecific antibody (diabody) 569. In experiments, this diabody 
induced C-mediated cellular effector functions, for example, causing C-mediated lysis of HEL- 
coated erythrocytes.
The examples detailed in the preceeding paragraphs give strong justification for using phage 
display technology in the context of C6 analysis or inhibition. The aims of this chapter therefore, 
were to pan a phage library displaying random 7-mer cyclic peptide sequences to identify 
peptides binding purified human C6 and through successive rounds of panning, to enrich C6- 
binding peptides. These enriched phage-peptides were then to be isolated and tested for their 
ability to block C-mediated haemolysis through interaction with C6. Such interactions held 
promise, not only for generating C inhibitory peptides and thus therapeutically useful agents, but 
also for providing an insight into C6-interacting peptide sequences.
5.2 Specific methods and protocols
5.2.1. Selection of C6-binding cyclic peptides by bacteriophage display
The Ph.D.-C7C™ Phage Display Peptide Library Kit (New England Biolabs, Beverly, 
Massachusetts, USA) was used to identify peptides that bind purified human C6. This kit is 
based on a combinatorial library of random 7-mer peptides fused to a minor coat protein (pill) of 
M13 phage. A pair of cysteine residues flank each randomised sequence and under non­
reducing conditions, the cysteines spontaneously form a single disulphide bond, resulting in 
phage display of cyclic peptides. The disulfide-constrained heptapeptides are expressed at the 
N-terminus of pill, with the first cysteine preceded by an alanine residue, and the second cysteine 
followed by a short spacer (Gly-Gly-Gly-Ser) and then the wild-type pill sequence. Disulfide- 
constrained peptide libraries 570 have been shown to have greater binding affinities than linear 
peptide libraries 347,351,352,571 ancj ha v e  also been useful in the identification of structural epitopes 
572-573. The library consists of 1.2 x 109 electroporated sequences, amplified once to yield
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approximately 200 copies of each sequence in 10 pi of the supplied phage. Extensive 
sequencing of the naive library has revealed a wide diversity of sequences with no obvious 
positional biases 574.
Table 5.1 Kit components used:
Disulfide constrained heptapeptide 
phage display library
100 pi, 2 x 1013 pfu/ml. Supplied in TBS with 50% 
glycerol. Complexity = 1.2 x 109 transformants
-96 gill sequencing primer -  5’ -  H0CCC TCA TAG TTA GCG TAA CG -  3’, 100 
pmol, 1pmol/pl
E.coli ER2738 host strain F’lach A(lacZ)M15 proA+B- zzf::Tn10(TetR)/fhuA2 supE 
thi A(lac-proAB)A(hsdMS-mcrB)5(rk*mk McrBC). Host 
strain supplied as 50% glycerol culture; not competent.
5.2.1.1. Additional Buffers and Broths Required
All techniques described below were carried out with autoclaved tips, vials, flasks and solutions to 
prevent bacterial and DNAase contamination.
Table 5.2 The composition of buffers and broths used:
Lauria-Bertani (LB) broth: 1% tryptone w/v (Oxoid), 1% w/v NaCI, 0.5% w/v yeast extract (Oxoid) in 
dH20.
LB agar: As for LB, but with 1.5% w/v agar (Oxoid)
LB Tet plates: Tetracycline (20 pg/ml) was added to LB agar when the broth had cooled to 
50‘C.
Agarose Top: 1 % w/v bacto-tryptone, 0.5% w/v yeast extract, 0.5 g w/v NaCI, 0.1% w/v 
MgCl2.6H20,0.7 % w/v agar in dH20.
Glycerol stock solution 50% glycerol v/v in LB broth. Filter sterilised.
Coating buffer: 0.1 M NaHCOa, 0.1 M Na2C03, pH 9.6 in dH20.
Blocking buffer: 0.5% w/v BSA and 0.02% v/v NaN3 in coating buffer.
Washing buffer: 0.1 % v/v Tween-20 in PBS.
Stringent washing buffer: 0.5% v/v Tween-20 in PBS.
Elution buffer: 20 mM diethylamine, pH 11 in autoclaved dH20.
Neutralisation buffer: 1 M Tris-HCI buffer, pH 7.0 in dH20.
DH20: Deionised H2O.
Precipitation solution: 20% w/v/ PEG-8000,2.5 M NaCI in dH20.
Iodide buffer: 10 mM Tris-HCI, pH8.0,1mM EDTA, 4 M Nal in dH20
Sodium acetate buffer: Sodium acetate buffer: 3 M sodium acetate, adjusted pH 4.6 with acetic acid
5.2.1.2. Maintenance of the M13 Strain
M13 is a male-specific coliphage and therefore all cultures for M13 propagation were in colonies 
grown on media selective for presence of the F-factor. The F-factor of the host strain supplied,
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Escherichia coli(E.coli) ER2738 contains a mini-transposon that confers tetracycline (Tet) 
resistance. These were selected by growing on tetracycline -  containing media.
For general maintenance, ER2738 was streaked out from the glycerol stock onto an LB-Tet plate. 
The plate was inverted and incubated at 37°C overnight and stored wrapped with parafilm at 4‘C 
in the dark for a maximum of 1 month.
5.2.1.3. Culture of ER2738 for infection by phage
Ten millilitres of LB broth was inoculated with a single colony of ER2738 from the maintenance 
plate (section 2.6.2) and incubated with shaking at 37’C until mid-log phase (OD600 = 0.5, 
approximately 8 hours) growth was reached.
5.2.1.4. Phage Titering
Phage stocks were titered by diluting prior to infection, so that the multiplicity of infection (MOI) 
was much less than 1 (i.e. cells are in excess), ensuring that each plaque contained only one 
phage peptide sequence.
Three millilitres melted agarose top was dispensed into sterile culture tubes, one per expected 
phage dilution, and incubated at 45'C until use. LB agar plates were poured; one per expected 
dilution. Ten-fold serial dilutions of phage in LB broth were made. For amplified phage culture 
supernatants, dilution ranges were 108-109; for unamplified panning eluates; 101-104. A fresh 
pipette tip was used for each dilution. Two hundred microlitres of culture of ER2738 in mid-log 
phase (section 5.2.3) was dispensed into microfuge tubes, one for each phage dilution. Ten 
microlitres of each phage dilution was added to each tube, vortexed and incubated at room 
temperature for 1-5 minutes to allow the phage to infect the bacteria. Each dilution of infected 
cells were transferred to a culture tube containing the agarose top, vortexed, poured immediately 
onto the LB plate and spread evenly. The plates were allowed to cool, inverted and incubated 
overnight at 37°C. The plaques on each plate were counted on plates having approximately 100 
plaques. To calculate the phage titre in plaque forming units (pfu) per 10 pi, each number was 
multiplied by the dilution factor for that plate.
5.2.1.5. Panning Procedure
The selection for phage-peptides that bind human C6 was carried out according to the 
manufacturers’ methods. Briefly, ten wells of a 96-well microtitre plate were coated overnight at 
4°C with 100 pi per well of purified human C6 diluted to 100 pg/ml in coating buffer. The coating 
solution was removed and the wells blocked for 1 hour at 4°C with 200 pi blocking buffer per well. 
After removal of the blocking solution, the wells were washed five times with washing buffer (200
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pi per well). Phage (2 x 1011) were added to each well and incubated at room temperature for 1 
hour to permit binding. Following binding, the wells were washed with stringent washing buffer 
(200 pi per well) ten times to remove non-specifically binding phage. Specifically bound phage 
were eluted by incubation with elution buffer (100 pi per well) for 10 minutes and then transferred 
to fresh wells. Fifteen microlitres of neutralisation buffer was added to each well to neutralise the 
elution buffer. The eluate was titered as described in section 5.2.4. in order to determine how 
many phage-peptides had been eluted from this round of panning - referred to as output pfu.
One hundred microlitres of the pooled eluate was reserved and stored at4°C; the rest was 
amplified in the host strain by adding it to 10 ml E.coli ER2738 in early-log phase growth and 
incubated at 37°C with vigorous shaking for 4-6 hours. The culture was transferred to a 
centrifuge tube and centrifuged at 12000 g for 10 minutes at 4°C. The supernatant was 
transferred to a fresh tube and centrifuged again. The upper 80% of the supernatant was 
carefully removed and transferred to a fresh tube, to which 1/6 volume of precipitation solution 
was added. The phage were allowed to precipitate overnight at 4'C. The precipitated phage 
were centrifuged for 15 minutes, 12000 g, 4#C. The supernatant was decanted and the tubes re­
spun briefly. Any residual supernatant was removed with a pipette. The pellet was resuspended 
in 1 ml PBS and transferred to a microcentrifuge tube and centrifuged at 1000 g for 5 minutes at 
4’C to pellet residual cells. The supernatant was transferred to a fresh microcentrifuge tube and 
subject to a second precipitation with 1/6 volume of precipitation solution, on ice for 60 minutes. 
The tubes were centrifuged at 1000 g for 10 minutes at 4#C. The supernatant was discarded and 
the tubes briefly re-spun and any residual supernatant carefully removed. The pellet was 
resuspended in 200 pi PBS and microcentrifuged at 1000 g for 1 minute to pellet any remaining 
insoluble matter. The amplified eluate (supernatant) was transferred to a fresh tube and titered 
again (section 5.2.4.) to determine how many phage-peptides would be used in the next round of 
panning -  referred to as input pfu. This represented the end of the first round of panning. The 
second and third rounds of panning were conducted as described for the first round of panning, 
except that the amplified phage eluate from the first round was incubated with the C6 coated 
plate in the second round and the amplified phage eluate from the second round was incubated 
with the C6 coated plate in the third round of panning (Figure 5.2).
The percentage recovery of phage-peptides from each round of panning was calculated using the 
following equation:
Percent recovery of pfu = (output pfu I input pfu) x 100
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The degree of enrichment at each biopanning step was calculated by dividing the percentage 
recovery of phage peptides from a panning round by the percentage recovery of phage peptides 
from the first round of panning.
5.2.1.6. Isolation of phage-peptide DNA
Five hundred microlitres of phage-containing supernatant from the first centrifuge step in section
5.2.4 were transferred to a fresh eppendorf tube and precipitation buffer (200 pi) was added. The 
tube was inverted to mix the solutions, left to stand for 10 minutes at room temperature, then 
centrifuged at 1000 g, at room temperature, for 10 minutes. The supernatant was discarded; the 
tube was re-spun briefly and any remaining supernatant carefully removed with a pipette. The 
pellet was resuspended thoroughly in 100 pi iodide buffer to iyse the phage. The mixture was 
incubated for 10 minutes at room temperature and centrifuged at 1000 g, 10 minutes. The 
supernatant was discarded and the pellet resuspended in 100 pi sodium acetate buffer and 250 pi 
ethanol to precipitate the single stranded DNA and incubated for 10 minutes. The mixture was 
centrifuged at 1000 g for 10 minutes, the supernatant discarded and the pellet washed once by 
centrifugation at 1000 g, 10 minutes in 75% (v/v) ethanol. After removing the ethanol, the pellet 
was allowed to air dry and it was then suspended in 30 pi sterile H2O.
5.2.1.7. DNA sequencing of phage-peptides
PCR was used to amplify isolated phage-peptide DNA for automated dideoxy DNA sequencing. 
DNA extension was performed in one direction only and dye-labelled dideoxynucleotides were 
included in the reaction mixture. When a dideoxynucleotide was incorporated into the extending 
DNA, extension terminated. This resulted in cDNA of different lengths with a terminal dye- 
labelled dideoxynucleotide. Different dyes were used for each of the four dideoxynucleotides and 
when the PCR was applied to the automated sequencer the machine detected which 
dideoxynucleotide was present at the length of each length of cDNA. In this way, the sequence 
of the DNA was determined. The ABI Big Dye™ Terminator Cycle Sequencing Kit (Perkin Elmer) 
was used and the manufacturer’s recommended protocol was followed. PCR was performed on 
2.5 pi isolated phage-peptide DNA, in 15 pi final volume of 3.2 pmole primer, 1 pi of Big Dye 
premix, containing Ampli Taq® DNA polymerase, 5 pi Better Buffer. Thermal cycling was carried 
out in an OmniGene thermal cycler (Hybaid) with heated lid. As the PCR was being performed 
for sequencing, one primer only was required, to ensure the DNA extended in one direction only. 
This was supplied with the phage display peptide library kit and was specific for gill, the gene the 
DNA for the peptide sequence had been fused to.
Amplification was accomplished using the following conditions:
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Table 5.3 Cycling conditions for sequencing PCR:
Cycle number Cycle conditions
1 Cycle 96"C, 3 minutes
25 cycles
Denature - 96#C, 15 secs
Anneal - 50#C, 10 secs
Extend - 60°C, 4 minutes
The amplified DNA was precipitated by the addition of 2 pi sodium acetate buffer (section 5.2.5) 
and 95% (v/v) ethanol (50 pi) to the reaction tube. The mixture was mixed, incubated on ice for 
10 minutes, centrifuged at 1000 g for 30 minutes and the supernatant carefully removed. The 
pellet was washed in 250 pi 75% (v/v) ethanol and centrifuged at 1000 g for 10 minutes. 
Sequencing was carried out in house using an ABI model 373A automated DNA sequencer 
(Perkin Elmer).
5.2.1.8. Calculation of representation of a given peptide motif in library
According to the manufacturer’s instructions, the likelihood that the Ph.D.-C7C library contains a 
given peptide motif could be calculated using the data in Table 5.4 as follows. First, the observed 
frequencies of each residue in the motif (expressed as decimal values) in Table 5.4 were 
multiplied by each other in order to obtain the absolute probability p of obtaining that sequence. 
The expected number/, of independent clones within the library displaying a given motif was 
calculated by multiplying p by the complexity of the library, n (1.2 x 109).
The probability P{k) that the library contained exactly k clones displaying a particular motif was 
calculated using the Poisson distribution, P{k) = e-W/M.
If K=0 (i.e. the library does not contain the desired motif), then the equation is reduced to:
P(0) = e-* = e-"P.
Therefore, the probability P(k>0) that the library contains at least one independent clone 
displaying a given motif was calculated from the equation: P(k>0) = 1-P(0) = 1-e-nP.
5.2.2. Reconstitution of synthetic peptides
The sequences of the synthetic peptides made were: SACNNQPYKMCGGG and 
SACKTHTMHWCGGG (Severn Biotech Ltd., Kidderminster, UK) and were cyclised and purified 
to greater than 80% purity. The peptides were supplied as a lyophilised powder and due to their 
hydrophobic nature, reconstituted in DMSO (5% v/v in H2O) to dissolve the peptide. PBS was 
added, to make a final concentration of 100 pM of peptide. The dissolved peptides were 
aliquoted and stored at -70°C until use.
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pill leader sequence 
i
Start of mature peptide-plll fusion 
i
5’ -... TTA TTC GCA ATT CCT TTA GTG GTA CCT TTC TAT TCT CAC TCT GCTTGT 
3’ -... AAT AAG CGTTAA GGA AAT CAC CAT GGA AAG ATA AGA GTG AGA CGA ACA 
... Leu Phe Ala lie Pro Leu Val Val Pro Phe Tyr Ser His Ser Ala Cys
NNK NNK NNKNNK NNKNNK NNKTGC GGTGGAGGTTCG GCC GAA ACTGTTGAA 
NNM NNM NNM NNM NNM NNM NNM ACG CCA CCT CCA AGC CGG CTT TGA CAA CTT 
Xxx Xxx Xxx Xxx Xxx Xxx Xxx Cys Gly Gly Gly Ser Ala Glu Thr Val Glu 
1 Random peptide sequence 1
AGT TGT H A  GCA AAA TCC CAT ACA GAA AAT TCA TTT ACT AAC GTC TGG AAA GAC 
TCA ACA AAT CGT TTT AGG GTA TGT CTT TTA AGT AAA TGA TTG CAG ACC TTT CTG 
Ser Cys Leu Ala Lys Ser His Thr Glu Asn Ser Phe Thr Asn Val Trp Lys Asp
GAC AAA ACT TTA GAT CGT TAC GCT AAC TAT GAG GGC ... -3 ’
CTG TTT TGA AAT CTA GCA ATG CGA TTG ATA CTC CCG ... - 5’
Asp Lys Thr Leu Asp Arg Tyr Ala Asn Tyr Glu Gly ...
Figure 5.3. The N-terminal sequence of random disulfide-constrained heptapeptide-plll 
fusion, taken from the Ph.Q.- C7C™ phage display peptide library kit instruction manual.
The pill fusion leader sequence is removed upon secretion at the position indicated by the arrow. 
The alanine preceeding the first cysteine residue of the crosslink is the first amino acid residue at 
the N-terminus of the mature fusion protein. The hybridisation position of the -96 primer which is 
used for the sequencing PCR is indicated.
T
-96 sequencing primer
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Table 5.4 Amino acid distribution of the PH.D.-C7C™ library
Amino Acid Codons Expected frequency* Observed frequency
3 letter 
code -
1 letter 
code
Arg R CGK, AGG 9.4% 4.3% (25/581 )t
Leu L CTK, TTG 9.4% 9.6% (56/581)
Ser S TCK, AGT 9.4% 8.6% (50/581)
Ala A GCK 6.2% 6.5% (38/581)
Gly G GGK 6.2% 2.2% (13/581)
Pro P CCK 6.2% 10.7% (62/581)
Thr T ACK 6.2% 13.1% (76/581)
Gin Q CAG, TAG 6.2% 7.1% (41/581)
Val V GTK 6.2% 1.9% (11/581)
Asn N AAT 3.1% 6.4% (37/581)
Asp D GAT 3.1% 4.1% (24/581)
Cys C TGT 3.1% 0% (0/581 )t
Glu E GAG 3.1% 3.1% (18/581)
His H CAT 3.1% 6.9% (40/581)
lie I ATT 3.1% 2.1% (12/581)
Lys K AAG 3.1% 3.8% (22/581)
Met M ATG 3.1% 3.3% (19/581)
Phe F TTT 3.1% 2.1% (12/581)
Trp W TGG 3.1% 1.9% (11/581)
Tyr Y TAT 3.1% 2.4% (14/581)
‘ Expected frequency = # codons for that amino acid + 32 codons x 100%. Note use of reduced
genetic code NNK (32 codons) in library construction.
tArginines and single cysteines in the displayed peptide sequence interfere with secretion of pill 
and phage infectivity, respectively; consequently, clones with peptides containing Arg or Cys are 
selected against575.
*The stop codon TAG is suppressed by Gin in the strain used to propagate the library.
The library was supplied as having a complexity of 1.2 x109 transformants. The diversity of the 
library was not confirmed before use.
Reproduced from the Ph.D.-C7C™ phage display peptide library kit instruction manual.
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5.2.3. ELISA to determine whether synthetic peptides bind to C6
The peptides of two of the inhibitory phage peptides were synthesised and their ability to bind C6 
was tested by ELISA. Wells of a 96-well ELISA plate were coated with varying concentrations of 
peptide CNNQPYKMC (0 - 7.75 pM) or peptide CKTHTMHWC (0 -12.5 pM) in carbonate coating 
buffer (50 pi per well) for 2 hours at 37‘C. The plates were gently washed three times with 0.1% 
Tween/PBS (washing buffer) (200 pi per well) and then blocked for 1 hour, 37‘C with 1% 
BSA/0.1% Tween/PBS (blocking buffer) (100 pi per well). After washing once with washing 
buffer, human C6 (1 pg/ml) (50 pi per well) diluted in blocking buffer was added to each well and 
incubated for 1 hour at 37’C. After the plates were washed three times with washing buffer, the 
anti-human C6 antibody, WU 6.4 (1 pg/ml in blocking buffer) (50 pi per well) was added to each 
well and the plate incubated for 1 hour at 37'C. The plates were washed as described and 
incubated with anti-mouse Ig diluted 1 in 10,000 in blocking buffer (50 pi per well) for 1 hour at 
37‘C. The plates were washed three times with washing buffer and developed with the addition 
of OPD substrate (50 pi per well) and quenched with 10% H2SO4(50 pi per well). The 
absorbance was measured at 490 nm.
5.2.4. Analysis of specificity of the synthetic peptides for C6 using Surface Plasmon 
Resonance
Surface plasmon resonance (SPR) using the BIAcore 3000 was used to determine whether 
human C6 bound to the peptides of interest. The synthetic peptides were immobilised onto a 
Pioneer F1 sensor chip (BIAcore AB, Uppsala, Sweden), which has a short dextran matrix 
attached to its surface. Any changes in response units (RU) when the large C6 molecule was 
passed over the immobilised peptides would be more easily detected due to the short matrix than 
if the peptides had been immobilised onto the more often used CM-5 sensor chip surface that has 
a longer dextran matrix attached to it. The peptides were immobilised onto the sensor chip 
surface as described (section 2.5.1.) at pH 3.5 in 10 mM sodium acetate buffer.
5.2.4.1. Studies to determine whether C6 and C9 interact with peptides immobilised on a 
BIAcore F1 Pioneer Chip
A baseline value of RU was recorded, with HBS-EP (0.01 M HEPES pH 7.4,0.15M NaCI, 3 mM 
EDTA, 0.005% (v/v) Surfactant-P20) buffer flowing over the flow cells of the F1 pioneer chip. 
Purified human C6 or C9 in PBS were injected over the flow cells and at the end of the injection
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time, the change in RU was recorded. To remove analyte bound to the immobilised peptide,
0.2% (v/v) diethylamine in PBS was injected over the chip.
5.2.5. C6 ‘add-back’ haemolytic assays to investigate the functional activity of synthetic 
peptide
To investigate whether the synthetic peptides CNNQPYKMC and CKTHTMHWC had any C6 
functional inhibitory activity, a ‘C6-add back’ haemolytic assay was used. Briefly, genetically C6 
deficient rat serum was reconstituted with purified human C6. To test whether the peptides had 
any C6 inhibitory activity, varying concentrations of the peptides were pre-incubated with the C6, 
then the C6 deficient serum was added, followed by activated sheep erythrocytes (sheep EA). 
When peptide was not present, the sheep EA lysed. If the peptides had inhibitory properties, 
then lysis of the sheep EA would occur to a lesser extent or not at all.
To determine the dilution of C6 deficient rat serum and concentration of purified human C6 to 
use, a haemolytic assay was performed. C6 deficient rat serum was diluted in CFD over the 
range 1in 50 to 1 in 400 and 50 pi pre-incubated with varying concentrations of human C6 (0.039 
-  5 pg/ml) (50 pi) at 37#C for 30 minutes. To this mixture, 50 pi 2% sheep EA was added and the 
mixture incubated for 30 minutes at 37’C. After centrifugation, the supernatants were collected 
and absorbance measured at 415 nm. The percentage haemolysis was calculated (section 2.4). 
The dilution of C6 deficient rat serum and concentration of human C6 at which approximately 
80% of sheep EA were lysed was selected.
To determine whether the peptides could inhibit C6 activity, 50 pi peptide CNNQPYKMC (0 -  7.75 
pM) or peptide CKTHTMHWC (0 -12.5 pM) was pre-incubated with 50 pi human C6 (1.25 nM) 
for 1 hour at 37°C. Fifty microlitres C6 deficient rat serum, diluted 1 in 50 was added to the 
mixture and incubated for a further hour at 37‘C. 2% Sheep EA (50 pi) were then added and the 
mixture incubated for 30 minutes at 37°C. After centrifugation, the supernatants were transferred 
to a flat-bottomed microtitre plate and the absorbance measured at 415 nm. The percentage of 
lysis was calculated and a graph of peptide concentration versus percentage of lysis plotted.
5.3 Results
5.3.1. Identification and characterisation of phage-peptides that interact with human C6
5.3.1.1. Enrichment of the phage library during biopanning
C6 binding phage-peptides were selected for by panning 2 x 1011 plaque forming units (pfu) of 
phage-peptides on a C6 coated microtitre plate. Non-specifically binding phage were removed by
107
washing and specifically bound phage eluted by incubation with elution buffer. The eluate was 
titered in order to determine how many phage had been eluted, so that the percentage of 
recovery and enrichment factor of C6 binding phage-peptides could be calculated. Briefly, the 
phage were diluted and allowed to infect the bacterial strain of E.coli, ER2738. The infected 
bacteria were mixed with an agarose containing growth medium, spread evenly over an LB plate 
and grown overnight at 37’C. The plaques on each plate were counted and multiplied by the 
dilution factor of the phage to give the number of pfu or output at the end of the panning round. 
The phage in the eluate were then amplified and titered, to determine the number of pfu to be 
input into the next round of panning. This process was carried out for each round of panning. 
The percentage recovery of the phage peptides was calculated by dividing the number of pfu 
eluted by the number of pfu panned against C6 in a panning round and multiplying this figure by 
100. The degree of enrichment at each biopanning step was calculated by dividing the 
percentage recovery of phage peptides from a panning round by the percentage recovery of 
phage peptides from the first round of panning. These data are summarised in Table 5.5.
Table 5.5 The recovery of phage-peptides and the degree of enrichment reached during 
the rounds of biopanning
Biopanning Input (number of 
plaque forming 
units (pfu per 10 pi)
Output 
(pfu per 10 
Ml)
% Recovery of pfu 
(output pfu / input 
pfu) x100
Enrichment factor 
(present round % 
recovery/ round 1 
percent recovery)
Round 1 2x 1011 7.95 x103 0.00000397% 1
Round 2 1.4x106 1.65x102 0.0118% 2969
Round 3 2.3 x104 1.03 x104 44.78% 11,279,597
After the first round of biopanning, the input number of pfu into the two subsequent rounds 
decreased. This was unexpected and the manufacturers protocols recommended that 2 x 1011 
pfu were used in each round of biopanning to ensure that optimal enrichment of the target 
specific phage-peptides was occurring. It is possible that the infectivity of the phage were 
reduced, due to the sequences of the peptides they presented. No guidance was supplied by the 
manufacturer's for the output pfu that could be expected. As can be seen from Table 5.5, only
7950 virions were eluted from the first round of panning and this is reflected in the percentage of
/
virions recovered, 3.975 x10-6%. In the second round of biopanning, 165 virions were eluted and
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the percentage recovery rose from 3.975 x 10-6% in the first round to 0.0118% in the second 
round. In the final round of panning, 10,300 virions were recovered, representing a recovery of 
44.78%. The degree of enrichment was 1.128 x 107 from the first round to the final round. As the 
phage-peptide library originally contained 1.2 x 109 different sequences, this suggests that 
approximately 100 sequences may have been enriched from the original library, although many of 
these may be identical to each other.
5.3.1.2. The identification of inhibitory C6 binding phage-peptides
After three rounds of panning, ER2738 were infected with the enriched phage-peptide library and 
cultured on a plate. Individual clones were selected, amplified, isolated and either titered to 
investigate their potential inhibitory activity in haemolytic assays or DNA prepared for sequencing 
analysis (described in section 5.2).
Initially, to investigate whether the phage-peptides inhibited C-mediated lysis, equivalent numbers 
of phage were serially diluted and incubated with human serum in haemolytic assays (described 
in section 2.3.12.4). This data is shown in Figure 5.3, along with the corresponding sequence 
data. This shows that all of the phage-peptides tested inhibited C-mediated haemolysis in a 
dose-dependent manner and the negative control, wild-type phage had no inhibitory activity. Two 
consensus sequence peptides were identified; CKTHTMHWC and CNNQPYKMC. In further 
experiments, the haemolytic assay was used as a screen to test the inhibitory activity of phage- 
peptides at a single dose of equivalent numbers of phage in duplicate. This is summarised in 
Table 5.6; the percentage inhibition in the presence of 1 x 1011 phage particles is shown, together 
with corresponding sequence data. For completeness, the data in Figure 5.3 is also included. 
Information on the inhibitory activity of two of the clones sequenced was not obtained. Of the 
seventeen clones sequenced, nine different sequences were isolated. The sequence NNQPYKM 
was present in six independent clones, five of which had inhibitory activity between 75.3 -100%, 
whilst the clone KNQPPST which shared the consensus NQP, inhibited haemolysis by nearly 
80%. The two clones with the sequence KTHTMHW completely inhibited C-mediated lysis at the 
dose tested. Clones with the sequence FPIPLGS and the similar sequence clone FPIPLPS also 
fully inhibited C-mediated haemolysis. The clones TAKLENW and EPARSLQ almost completely 
inhibited haemolysis in the assay, whereas the phage displaying the sequence KTTSTSH 
inhibited haemolysis by 50%, the lowest degree of inhibition recorded. Inhibitory data for the 
phage-peptide with the sequence TAAGALS was not obtained. Peptides with consensus
Figure 5.3 Inhibition of C-mediated haemolysis by phage-peptides that bind C6
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To investigate whether the phage-peptides inhibited C-mediated lysis, equivalent 
numbers of phage were serially diluted and pre-incubated with human serum 
diluted 1 in 80 for 30 minutes at 37°C. 2% sheep EA was then added to the 
mixture and incubated for a further 30 minutes at 37°C. The samples were 
centrifuged and the absorbance of the supernatants read at 415 nm. The 
percentage of haemolysis was calculated and the values plotted as above. 
Phage-peptides displaying the same sequence are labelled with the same 
sequence and plotted in the same colour. M13, wild type phage negative control.
CKTHTMHWC
CNNQPYKMC
CKTHTMHWC
CEPARSLQC
CTAKLENWC
CFPIPLPSC
CNNQPYKMC
M13
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sequences are underlined in Table 5.6. These are NQP, contained in the sequences NNQPYKM 
and KNQPPST, and FPIPLXS, which represents the sequences FPIPLPS and FPIPLGS.
5.3.1.4 Calculation of representation of a given peptide motif in library
Once the peptide sequences had been determined, using data supplied by the manufacturers 
about the amino acid distribution in this particular library, it was possible to calculate the expected 
number (A) of independent clones within the library displaying a particular sequence and also the 
probability of at least one copy of that peptide occurring in the library (section 5.2.8.). For 
example, it was expected that at least one independent clone in the original library had the 
sequence NNQPYKM and that the probability that the library contained at least one copy of this 
peptide was 67.5%. These calculations are summarised in Table 5.7.
Table 5.7 Summary of the probability of the peptide motif sequences in the library.
Sequence Expected number of 
independent clones displaying 
motif in original library (A)
Percentage probability original 
library contains at least 1 clone 
with motif (PX100)
NNQPYKM 1.12 67.5%
KTTSTSH 52.31 100%
KTHTMHW 2.34 90.3%
EPARSLQ 6.52 99.9%
TAKLENW 1.41 75.5%
FPIPLPS 5.35 99.5%
TAAGALS 7.84 100%
KNQPPST 26.73 100%
FPIPLGS 1.1 66.7%
These data demonstrate that after three successive rounds of biopanning, the library was 
enriched for C6 binding phage-peptides. Furthermore, in the original library one clone only of 
three of the C6 binding phage-peptides was predicted to be present. This demonstrates that the 
process of panning is not only highly specific but is also highly sensitive, because a single peptide 
clone in the original library can be successfully selected and enriched for.
5.3.1.5. Searching NCBI Blast for sequence similarities with proteins
The NCBI BLAST website (address: htttp://www.ncbi.nlm.nih.gov/BLAST/) 576 was searched for 
short, nearly exact similar matches with proteins for each of the peptide sequences. On average, 
there were approximately 100 blast hits for each query sequence with varying degrees of match. 
Many were labelled unknown and hypothetical proteins, whose functions may in the future be
Table 5.6 A summary of phage-peptide inhibitory activity and matching 
sequence data
Peptide Percentage Inhibition 
(1 x 1011 phage peptides)
Sequence
1 100 CKTHTMHWC
2 92.6 CNNQPYKMC
3 100 CKTHTMHWC
4 98.2 CEPARSLQC
5 99.5 CTAKLENWC
6 100 CFPIPLPSC
7 100 CNNQPYKMC
8 80.2 CNNQPYKMC
9 75.3 CNNQPYKMC
10 49.8 CKTTSTSHC
11 Not tested CNNQPYKMC
12 Not tested CTAAGALSC
13 91.9 CNNQPYMC
14 96.2 CKTHTMHWC
15 79.8 CKNQPPSTC
16 100 CFPIPLGSC
17 98.1 CFPIPLGSC
Peptides 1 - 1 7  were tested for their ability to inhibit C-mediated lysis in a 
haemolysis assay. 1 x1011 phage peptide particles were pre-incubated with 
human serum diluted 1 in 80 for 30 minutes at 37°C before 2% sheep EA were 
added and the mixture incubated for a further 30 minutes at 37°C. The samples 
were centrifuged, the supernatants collected and their absorbance measured at 
415 nm. The percentage of inhibition was then calculated. The DNA of the 
phage-peptides was also collected and subject to sequencing by PCR with 
dideoxynucleotides. Underlined sequences show consensus sequences 
between different peptide sequences. Note: the first seven peptides are those 
shown in Figure 5.3
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defined and found to interact with C6. Some were not physiologically relevant, for example, six of 
the seven residues in the sequence FPIPLGS, FPIPL-S matched an unknown protein from a 
plant, Oryza sativa (japonica cultivar) and five residues in the sequence NNQPYKM, QPYKM, 
matched maturase K, an enzyme present in various species of Lily. However, two of the matched 
proteins were connected with the C system. Six of the seven residues in the sequence FPIPLPS, 
FPIPLP, shared sequence similarity with human, pig, sheep and rabbit pulmonary surfactant- 
associated protein B (SP-B). Six of the seven residues in the sequence TAAGALS, TAAGAL, 
had sequence similarity with human mannan-binding lectin serine protease 2 (MASP-2) and the 
19 kDa isoform of MASP-2, sMAp. The sequence mapped to the EGF-like domain of MASP-2 
and its smaller isoform, sMAp19.
The RGD motif in matrix proteins recognised by integrin aspi was identified by phage display 
s77-578. This suggests that short peptide sequences of three amino acids can be sufficient to allow 
important interactions between proteins to take place. It was investigated whether any three 
amino acid sequences within the 7-mer peptide sequences (identified as binding C6) had 
homology to the protein sequences of human C5, C6 or C7. Three amino acid sequences were 
compared with protein sequences of C5 (accession number P01031) 579*587, C6 (accession 
number P13671) 81.588-593 and C7 (accession number P10643)593-599 that had been downloaded 
from the NCBI Entrez Protein database (http://www.ncbi.nlm.nih.aov/entrez/viewer). The data is 
shown in Table 5.8 and the arrangement of the protein modules are described in section 1.1.2.
In all of the 7-mer sequences, apart from EPARSLQ, there was at least one three amino acid 
sequence that was homologous to C5, C6 or C7. All the motifs with homology to C5 were within 
regions of C5 that become C5b following cleavage of C5. NNQPYKM contained three motifs: two 
homologous to C5b and one homologous to C6. The sequence KTTSTSH also contained three 
motifs that matched sequences in C5b, C6 and C7. One of the motifs within TAKLENW was 
homologous with sequences in C5b, C6 and C7. The sequences FPIPLPS and FPIPLGS are 
very similar and they contained two identical motifs that were homologous with sequences in C5b 
and C6.
5.3.2. Characterisation of selected peptides
Two of the sequences showing good inhibition of haemolysis as phage peptides, CNNQPYKMC 
and CKTHTMHWC, were made as cyclic peptides (Severn Biotech, Kidderminster, UK and 
Eurogentec, Belgium). These were then tested in an ELISA for the ability to recognise C6, their 
inhibitory properties of C-mediated lysis and their ability to bind C6 on the BIACore.
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Table 5.8 Summary of areas of homology between 3 amino acid motifs in 7-mer peptides
and Complement components C5, C6 and C7.
7-mer peptide 
sequence
3 amino acid 
sequence
Residues 
homologous to in C5, 
C6 or C7
Protein modules residues are in
NNQPYKM PYK 351-353 In C5 6 chain
YKM 1326-1328 in C5 C5a’ chain
NNQ 825-827 in C6 1st FIMs domain
KTHTMHW KTH 1200-1202 in C5 C5a’ chain
KTTSTSH TST 1368-1370 in C5 C5a’ chain
211-213 in C7 Perforin-like domain
STS 876-878 and 903-905 in 
C6
2nd FIMs domain
TSH 236-238 in 01 Perforin-like domain
TAKLENW LEN 1176-1178 in C5 C5a’ chain
236-238 in C6 Perforin-like domain
356-358 in 01 Perforin-like domain
KLE 155-157 in C6 LDL-receptor class A domain
FPIPLPS IPL 963-965 in C5 C5a’ chain
PIP 186-188 in C6 Perforin-like domain
LPS 424-426 in C5 6 chain
283-285 in C7 Perforin-like domain
FPIPLGS IPL 963-965 in C5 C5a’ chain
PIP 186-188 in C6 Perforin-like domain
TAAGALS GAL 1321-1323 in C5 C5a’ chain
821-823 in 01 2nd FIMs domain
KNQPPST PPS 527-529 in 01 2nd TSP type-1 domain
EPARSLQ - - -
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5.3.2.1. Assessing the binding of C6 to the peptides
5.3.2.1.1. ELISA to determine whether the selected peptides bind human C6
An ELISA plate was coated with varying concentrations of peptide CNNQPYKMC (0 - 7.75 pM) or 
peptide CKTHTMHWC (0 -12.5 pM) for 2 hours, washed and blocked. After further washing, 
1pg/ml human C6 added to each well for 1 hour and the plate washed before the anti-human C6 
antibody, WU 6.4 (1 pg/ml) was added to each well for 1 hour. After washing, anti-mouse Ig 
diluted 1 in 10,000 was added to each well and incubated for a further hour. The plates were 
washed and developed with the addition of OPD substrate. The reaction was stopped with the 
addition of 10% HhSCMo each well and the absorbance measured at 490 nm. There was no 
evidence of binding above background with peptide NNQPYKM (Figure 5.4), suggesting that this 
peptide might not bind C6, or that when bound to plastic its binding activity was lost. However, 
the ELISA in which peptide KTHTMHW was coated on the plate developed in a dose-dependent 
manner (Figure 5.4). This suggested that KTHTMHW when coated on plastic did bind C6.
5.3.2.1.2. The use of SPR to determine whether the selected peptides bind human C6
To better determine whether the two peptides bound to C6 surface plasmon resonance (SPR) 
was used. To ascertain whether this was a specific interaction, the terminal C pathway 
component C9 was also passed over the immobilised peptides.
5.3.2.1.2.1. The immobilisation of peptides onto the surface of the F1 pioneer chip
Peptides CNNQPYKMC and CKTHTMHWC and a reference peptide, Po were immobilised on a 
Pioneer F1 sensor chip as described in section 2.5.1 .at pH 3.5 in 10 mM sodium acetate buffer. 
The target RU change for immobilising each peptide onto the sensor chip was 1000 based upon 
the manufacturers’ recommendations. The net change in RU after immobilisation of each peptide 
is shown in Table 5.9.
Table 5.9 Change in Response Units of each flow cell after immobilisation of peptide
Flow cell Peptide Net change in Response Units (RUs) 
after immobilisation
1 CNNQPYKMC 1825.8
2 CKTHTMHWC 1028.0
3 Po, irrelevant peptide 723.2
Figure 5.4 ELISA to determine whether human C6 binds to
peptides CNNQPYKMC and CKTHTMHWC
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A 96-well ELISA plate was coated with varying concentrations of peptide 
CNNQPYKMC (0 -  7.75 jiM ) or peptide CKTHTMHWC (0 -1 2 .5  jiM). All 
incubations were for 1 hour at 37°C and plates were washed a total of 3 times at 
each wash step. The plate was washed, blocked, washed and human C6 
(1 jug/ml) added to each well. After washing, the anti-human C6 antibody, WU
6.4 (1 jug/ml) was added to each well. The plate was washed and an anti-mouse 
immunoglobulin antibody was added to each well (diluted 1 in 10,000). After 
washing, the ELISA was developed by the addition of OPD substrate and the 
reaction stopped by the addition of 10% H2S 0 4. The absorbance of each well 
was measured at 490 nm.
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There was a change of 1825.8 RU when peptide CNNQPYKMC was immobilised onto flow cell 1 
of the F1 pioneer chip. When peptide CKTHTMHWC was immobilised onto flow cell 2 of the 
same chip there was a change of 1028 RU. Figure 5.5 shows the sensorgram of the 
immobilisation of peptide CKTHTMHWC. This is a typical representation of the immobilisation of 
the peptides onto the flow cells of the sensor chip. Towards the end of the immobilisation, as 
more peptide was injected over the flow cell, it failed to bind to the surface, demonstrating that it 
had become saturated with peptide. When peptide Po, an irrelevant peptide was bound onto the 
surface of flow cell 3, there was a change of 723.2 RU. Like the immobilisation of peptide 
CKTHTMHWC, the immobilisation of peptide Po had reached saturation and the target RU 
change of 1000 was not achieved.
5.3.2.1.2.2. The interaction of immobilised peptides with C6
Purified human C6 (0.1 pM and 1 pM) and C9 (1 pM) was passed over flow cells of the F1 
pioneer chip onto which CNNQPYKMC, CKTHTMHWC or an irrelevant peptide control, Po had 
been immobilised. The changes in the RU when these molecules were passed over are 
summarised in Table 5.10. The greater the increase in RU, the greater the amount of analyte 
binding to the immobilised peptide. The sensitivity of the BIACore 3000 is approximately 4 RU.
Table 5.10 Changes in RUs when C6 or C9 passed over immobilised peptides
Flow Cell 0.1 pM C6 (RU) (n = 
1)
1 pM C6 (RU) (n = 4) 1 pM C9 (RU) (n = 3)
CNNQPYKMC 12.7 27.1 5.5
CKTHTMHWC 6.6 19.8 5.0
Irrelevant peptide 4.3 6.9 3.8
The change in RU when 0.1 pM C6 was passed over a flow cell on which CNNQPYKMC had 
been immobilised was 12.7 and increased to 27.1 when 1 pM C6 was passed over. When 1 pM 
C9 was passed over the same flow cell, the average change in RU was 5.5. This showed that 
peptide CNNQPYKMC specifically recognised C6 but not C9 and that the observed changes in 
RU were dependent on the concentration of C6. The change in RU when 0.1 pM C6 was passed 
over the flow cell on which CKTHTMHWC had been immobilised was 6.6 and increased to 19.8 
when 1 pM C6 was passed over. In contrast, the average change in RU when 1 pM C9 was 
passed over the same flow cell was 5.0. This demonstrated that peptide CKTHTMHWC also 
recognised C6 but not C9 and that the observed changes in RU were dependent on the
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Figure 5.5 The immobilisation of peptide CKTHTMHWC onto the flow cell 
surface of an F1 pioneer chip
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An F1 pioneer chip was docked in the BIACore 3000 and HEPES buffered 
saline flowed over and a baseline response unit (RU) value recorded. To 
‘activate’ the flow cell surface, a mixture of EDC/NHS was injected over the flow 
cell. Peptide CKTHTMHWC was then passed over the flow cell and a 
measurement of RU was recorded before and after to determine whether it was 
binding to the surface. This was repeated a further four times, until no more 
peptide bound to the surface. Another sign the peptide was binding to the 
surface is that once it was starting to be injected over the flow cell, the RUs 
increased, as can be seen from the slope the first time the peptide is passed 
over. As the surface became saturated with peptide the gradient of the slope 
decreased with subsequent injections, until a flat plateau was reached. To block 
any remaining free reactive groups on the surface of the flow cell, ethanolamine 
was passed over. A reading was then taken to determine how many RUs of 
peptide had covalently bound to the flow cell surface.
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concentration of C6. When 0.1 pM C6 was passed over the flow cell on which Po peptide had 
been immobilised, the change in RU was 4.3 and increased to 6.9 when 1 pM C6 was passed 
over. When 1 pM C9 was passed over the same flow cell, the average change in the RU was
3.8, which is below the sensitivity of the BIACore 3000. This shows that the P0 peptide did not 
bind C6 or C9.
In summary, these data recorded on the BIACore suggest that both peptides specifically bind C6, 
but not C9. However, the changes in RU were low when C6 was passed over at both 
concentrations, which were in the micromolar range, suggesting that C6 has a low affinity for both 
peptides. Another reason for the small change in RU when C6 was passed over the flow cells 
might be due to the orientations and conformations of the peptides immobilised onto the chip 
surface. It would have been interesting to immobilise C6 onto a chip and pass the peptides over, 
but this was not done, mainly because the peptides are so small that if they had bound to 
immobilised C6, the change in RU might have been undetectable.
5.3.2.2. Assay to determine whether the selected peptides inhibit C-mediated haemolysis
The potential of the synthetic peptides CNNQPYKMC and CKTHTMHWC to functionally inhibit 
C6 activity was investigated in a ‘C6-add back’ haemoiytic assay. First, to determine the dilution 
of C6 deficient rat serum and concentration of purified human C6 to use, a haemoiytic assay was 
performed, diluting the concentrations of these two components (Figure 5.6). The dilution of C6 
deficient rat serum and concentration of human C6 at which approximately 80% of sheep EA 
were lysed was selected. Diluted peptide was pre-incubated with human C6 (1.25 nM -  up to 
10,000 fold less than the highest concentration of peptide used) for 1 hour at 37’C before 
genetically C6 deficient rat serum, diluted 1 in 50 was added and incubated for a further hour at 
37*C. Sheep EA were then added and the mixture incubated for 30 minutes at 37'C. After 
centrifugation, the supernatants were transferred to a flat-bottomed microtitre plate and the 
absorbance measured at 415 nm.
The concentration range of peptide CNNQPYKMC was 0 -  7.75 pM and for peptide 
CKTHTMHWC, 0-12.5  pM. The graph in Figure 5.7 shows that over these concentration 
ranges, neither peptide CNNQPYKMC nor peptide CKTHTMHWC was able to functionally inhibit 
C-mediated lysis.
Figure 5.6 Haemoiytic assay to determine the dilution of C6 deficient rat 
serum and the concentration of human C6 required to lyse 80% of 
activated sheep erythrocytes
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To determine the dilution of C6 deficient rat serum and concentration of purified 
human C6 to use in the ‘C6 add back’ haemoiytic assay, a haemoiytic assay was 
performed, diluting the concentrations of these two components. The dilution of 
C6 deficient rat serum and concentration of human C6 at which approximately 
80% of sheep EA were lysed was selected.
Figure 5.7 Assay to determine whether the synthetic peptides CNNQPYMC
and CKTHTMHWC can inhibit Complement-mediated haemolysis
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Diluted peptide was pre-incubated with human C6 (1.25 nM) for 1 hour at 37°C 
before genetically C6 deficient rat serum, diluted 1 in 50 was added and 
incubated for a further hour at 37°C. Sheep EA were then added and the 
mixture incubated for 30 minutes at 37°C. After centrifugation, the supernatants 
were transferred to a flat-bottomed microtitre plate and the absorbance 
measured at415nm .
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5.4 Discussion
This chapter described the selection of phage-peptides that bound human C6 through multiple 
rounds of biopanning and enrichment, the identification of selected phage-peptides that inhibited 
C-mediated haemolysis and the sequences of the respective peptides. The ability of two of these 
identified peptides to bind C6 and inhibit C-mediated haemolysis was also investigated.
In the second and third rounds of panning, the number of input pfu was below the optimum 
recommended, suggesting that phage infectivity may have been reduced in some way. The 
manufacturers instruction manual states that arginine and single cysteine residues displayed in 
the peptide sequence interfere with the secretion of pill and also phage infectivity, therefore, 
clones with peptides containing Arg or Cys are selected against 575. One of the selected phage- 
peptides from the final round of panning contained an arginine residue and if its infectivity was 
reduced as is likely, then this might explain the reduced pfu being put into the subsequent rounds 
of biopanning. Nevertheless, this does not seem to have adversely affected the selection or 
enrichment of the phage-peptides from the library because nine independent sequences were 
identified. Also, the panning was highly selective and specific as calculations showed it was likely 
there was only one copy each of three of the selected peptides in the original library.
Two approaches to searching for consensus sequences of the identified peptides in proteins were 
taken. Firstly, the NCBI BLAST website was used to search for sequence matches against the 
complete 7-mer peptides. The most notable result was the sequence TAAGAL matching the 
EGF-like domain of MASP-2 and sMAp 19. The MBL pathway is analogous to the start of the 
classical pathway of the C system but there has been no documented evidence of components of 
the MBL pathway interacting with the terminal pathway to date. Two of the peptides contained 
the consensus sequence FPIPLXS. However, BLAST searches failed to select the same protein 
matches when conducting searches for these sequences, making the other notable result, the 
sequence FPIPLP matching the leader sequence of the precursor pulmonary surfactant protein-B 
less significant. The second approach was to search the published sequences of C5, C6 and C7 
for shorter matching sequences within the isolated peptide sequences. When motifs three amino 
acids long were searched for, there were several hits. All motifs that had homology with C5 
mapped to the portion of the molecule that becomes C5b after C5 is cleaved by C5 convertase 
and had homology with residues in the a2-macroglobulin C-terminal region, apart from two motifs 
that had homology with the a2-macroglobulin N-terminal region of C5b. None of these matched 
the C345C domain that binds reversibly to the FI Ms domains of C6 and C7 (described in section
1.1.2. and figure 1.3)83'600. The FIMs domains in C7 are important for the ability of C7 to bind to
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C5b685. However, for C6, whilst the FIMs domains of C6 reversibly bind to C5b, it is the CCP 
domains in C6 that are essential for its activity M. One motif had homology for a sequence within 
the second FIMs domain in C7; given that the FIMS domains of C7 displace the FIMs domains of 
C6 from the C345C domain of C5, this could potentially represent a way of inhibiting C6 activity. 
In addition to the CCP domains of C6, it is thought that hydrophobic regions in both C6 and C5b 
are also involved in C5b6 formation, but the precise interactions remain to be elucidated83. It 
may be significant that two of the motifs that had homology with C5 were close to each other in 
the amino acid sequence: GAL at residues 1321-1323 and YKM at residues 1326-1328.
Although the FIMs domains within C7 are important for its activity, it is interesting that the other 
sequences with homology to C7 were of a hydrophobic nature; one of the motifs had similarity 
with the thrombospondin domain in C7 and four had homology with sequences in the perforin-like 
domain of C7. These results may be useful in investigating which areas of C5b, C6 and C7 
interact with each other during MAC formation.
Of those tested, all of the phage-peptides almost completely inhibited lysis in C-mediated 
haemoiytic assays apart from one, CKTTSTSHC, which inhibited haemolysis by less than 50%. 
This sequence did not contain any hydrophobic residues, whilst the other sequences with greater 
inhibitory activity contained amino acid residues that were predominantly uncharged or 
hydrophobic.
The peptide CKTHTMHWC bound C6 in an ELISA and both sequences specifically bound to C6 
on the BIACore. Although the phage-peptide versions of the synthetic peptides inhibited C- 
mediated cell lysis dose-dependently in haemoiytic assays, the peptides had no inhibitory activity. 
The phage-peptides may have inhibited C6 due to their size through steric effects and therefore 
this lack of inhibition for free peptide may be due the smaller size. It is recognised that some 
phage-peptides lose their binding ability or functional activity after being synthesised as peptides, 
as the phage coat can interfere with assays 601-602. Some of the peptides contained more than 
one three amino acid motif that had homology with C5, C6 or C7 and five copies of peptide were 
displayed on the surface of each phage. These were in relative proximity to each other and it 
may be this pentameric conformation was critical to the observed properties of the inhibitory 
peptides because each peptide might have bound to a different region of C6 or interfered with 
C5b binding to C6 and C7 binding to C5b6. It would be interesting either to couple single and 
multiple units of peptides to a larger protein or make a fusion protein containing the peptide and 
investigate whether the inhibitory activity of these peptides could be restored. This was not 
possible in this study, due to the constraints of time and limited amounts of the peptides available.
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Compstatin is a well-characterised peptide that binds C3 and was Identified through screening a 
random phage display library expressing 27-mer peptide sequences against C3 361. It was 
assumed that long peptides might adopt a secondary structure more conducive to binding than 
short peptides. However, in contrast to the library we used, these long peptides were not 
constrained by a pair of cysteine residues, although it was expected a certain proportion of 
peptides would contain pairs of cysteines capable of forming intramolecular disulfide bonds 603, 
thereby constraining the peptides in a potentially favourable conformation 604. The Ph.D.-C7C™ 
phage display library that we used was designed specifically to display peptides constrained in 
one conformation only, making the analysis of the characterisation of selected phage-peptides 
more reliable. However, in retrospect, in terms of having a greater chance of identifying a peptide 
with sequence similarity to a terminal C component or being able to select a peptide with 
functional blocking activity for C6, it may have been better to choose a phage-peptide library that 
displayed longer sequences of peptides.
In summary, the work conducted in this chapter has led to the identification of several phage- 
peptide clones that inhibit C-mediated haemoiytic activity. These clones were sequenced and 
35% of them had the identical sequence NNQPYKM; 18% of them had the sequence KTHTMHW. 
Based upon their frequency and inhibitory activity as phage-peptides, synthetic peptides with 
these sequences were made. Haemoiytic assays showed that these peptides no longer had 
inhibitory activity. However, studies on the BIAcore demonstrated that the peptides specifically 
bound to human C6, as opposed to another terminal complex component, C9. Although the 7- 
mer sequences did not share similarity with significant proteins when compared with databases, 
motifs three amino acids long did have homology with areas in C5b and C7 and represent an 
interesting area to explore in determining in particular the domains of C5b involved in binding to 
C6 during C5b6 and MAC formation.
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Chapter 6: Establishing an ex vivo model of cardiopulmonary bypass for the 
assessment of the capacity of anti-human C6 antibodies to inhibit formation 
of soluble C5b-9.
6.1. Introduction
Having generated antibodies that recognise and inhibit C6 in Chapter 4, the obvious next step was to 
test the most promising inhibitory antibodies of C6 activity in a model of pathology in which damage is 
mediated by the terminal complement complex. The anti-human C6 mAbs 23D1 and 27B1 were the 
best inhibitors but they did not recognise any other species C6 and so they could not be tested in 
animal models of disease. Therefore, an ex vivo model of extracorporeal circulation or 
cardiopulmonary bypass (CPB) was set up in order to test the therapeutic potential of these mAbs.
CPB is a necessary component of many types of cardiac surgery, but postoperative complications can 
occur, including respiratory failure, renal dysfunction, bleeding disorders, neurologic dysfunction and 
altered liver function. In turn, these can result in multiple organ failure (MOF) and eventually the death 
of the patient 262-266. These complications arise due to a complex systemic inflammatory response 
(Figure 6.1), initiated by several factors, including contact of blood components with the surface of the 
bypass circuit, thereby activating the C system and other proteolytic cascades, and endotoxemia 605. 
Raised levels of C3a and C5b-9 have been detected in patients both during and following CPB 267-269- 
273, but not in those who have undergone cardiac or other major surgery not requiring CPB 267-272. This 
is because C3 convertase inhibitors are expressed on the surfaces of endothelial cells (EC) to ensure 
that C activation is properly regulated, but they are not present on the surface of the extracorporeal 
circuit. This allows both the coagulation and C (via the alternative pathway) systems to become 
activated in an unregulated manner when blood comes into contact with this non-physiological surface. 
C3a and C5a are released, attracting and activating neutrophils via the C3a and C5a receptors 
respectively 145*146. C3a and C3adesArg also induce the synthesis of the pro-inflammatory cytokines 
TNF-a, IL-1 p and IL-6 606-607, which in turn exert their own effects, mainly by stimulating transcription 
factor NF-kB 608.
Neutrophils are initially recruited to injured tissue through low affinity interactions with EC and platelets 
through L-, E- and P-selectins respectively. Once activated, the expression of CR3 (integrin 
CD11b/CD18) on the neutrophil cell surface is upregulated 609 and binds to various adhesion molecules 
including intercellular adhesion molecule (ICAM), vascular cell adhesion molecule (VCAM) and platelet- 
endothelial cell adhesion molecule (PECAM) on the EC surface. As a result of these interactions, the 
neutrophils migrate into the interstitial fluid phase whereupon the contents of their lysosomes, such as
Figure 6.1 Schematic representation of the inflammatory response to 
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proteolytic enzymes, leukotrienes and oxygen free radicals, are released. These components can 
cause lipid peroxidation of EC and myocyte membranes, ultimately resulting in cellular dysfunction, 
oedema and cell death610.
Circulating levels of endotoxin rise during and after CPB 270,611-514. jh e gut is likely to be the main 
source of this, as changes in intestinal permeability occur during CPB615^ 19 due to ischemia- 
reperfusion (l/R) injury and might lead to the release of endotoxin into the circulation. Once in the 
circulation, endotoxin can bind to EC, inducing IL-6 secretion 620 and to LPS-binding protein in the 
circulation, forming a complex. This complex binds to CD14 expressed on the surface of 
macrophages, stimulating their production of TNF-a270-621. Endotoxin will also activate the C system 
via the alternative pathway32.
Nitric oxide (NO) production can increase significantly during and after CPB 622, leading to vasodilation 
and increased vascular permeability. This is mediated by inducible nitric oxide synthase (iNOS) which 
is activated by pro-inflammatory cytokines and endotoxin released during and after CPB 623-625 
However, NO produced by constitutive (c)NOS is believed to play a protective role and its release is 
impaired after CPB 626,627. clearly, the inflammatory response in patients undergoing CPB is very 
complex.
Therapeutic strategies to reduce systemic inflammation during and following CPB can be split into 
two broad scopes: a pharmacological-based approach and technical strategies. Steroids have a 
proven track record in reducing inflammation 628. The pre-operative administration of 
methylprednisolone significantly reduces the levels of pro-inflammatory cytokines and increases 
the anti-inflammatory cytokine IL-10629-630. Other studies have shown that steroid pre-treatment 
decreases endotoxin release631 and expression of neutrophil integrins632. Steroids exert these 
effects by suppressing the induction of pro-inflammatory protein expression through the inhibition 
of several transcriptional pathways in different cell types 633-635.
Aprotinin (section 1.9.3.) was routinely used in the early 1980s, although it emerged that at high 
doses it increased the risk of patients suffering myocardial infarction and other complications 
during cardiac surgery 32°. However, it has continued to remain in use and a recent extensive 
meta-analysis demonstrated that aprotinin decreases mortality by up to 50%; the risk of peri­
operative myocardial infarction is not increased, whilst the proportion of patients receiving blood 
components is reduced as is the frequency of surgical re-exploration 636. Aprotinin can also 
reduce the expression of various inflammatory mediators by the same mechanisms as steroids in 
in vitro experiments 637-639. However, there was no decrease in pro-inflammatory cytokine release 
or neutrophil activation in clinical trials 64°.
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Pexelizumab™the anti-C5 antibody (section 1.9.8.) is currently being tested in phase III clinical 
trials of patients requiring CPB during coronary artery bypass graft surgery. Pexelizumab™ 
inhibits C5a and soluble C5b-9 generation and leukocyte accumulation, but does not affect C3a 
generation 520. Its effectiveness in this context indicates that some of the harmful effects of CPB 
may be due to either C5a or SC5b-9 generation or both.
The routinely used technical strategy to lessen inflammation during and following CPB is the use 
of heparin-coated circuits. This reduces the direct contact of blood cells with foreign material, 
thereby decreasing C activation wi.642 cytokine release643, kallikrein 644 and leukocyte activation 
645. However, there are conflicting reports as to the success of this strategy, with some 
publications demonstrating little benefit646 whilst others show that high risk patients undergoing 
CPB with heparin-coated circuits have better clinical outcomes647. Some of the variability may 
be due to different coating techniques, for example, Duraflo II (Baxter Healthcare Corporation, 
California, USA) and Carmeda BioActive Surface (CBAS; Anaheim, California, USA) heparin 
coatings are used clinically. When compared against each other and an uncoated surface in 
trials, both coatings reduced C activation and neutrophil activation, although the CBAS system 
was more effective than the Duraflo II system 648.
Other technical strategies include ultrafiltration, maintaining a pulsatile flow during CPB and 
reducing temperature at which the surgery is carried out. Ultrafiltration is used during open-heart 
surgery to reduce excess body water accumulated during CPB and improve hemodynamic 
parameters m . Pro-inflammatory cytokine release is reduced in both paediatric and adult 
patients, but is not associated with improved clinical outcome in adults 6so. In paediatric patients 
there is decreased C activation and hemodynamic, pulmonary and hemostatic improvements 
have been demonstrated651.
Blood flow occurs in a pulsatile manner under physiological conditions 626. NO production is 
increased as a result of CPB, but it also modulates vasomotor tone in response to physiologic 
stimuli such as pulsatile flow and shear stress 652. By ensuring that a pulsatile flow is maintained 
during CPB, this might minimise any systemic responses. Although some studies have reported 
a reduction of endotoxin and other pro-inflammatory mediators 653,654 others have not 655.
Various studies have been conducted comparing the clinical outcome of patients who have 
experienced normothermic (33 - 37°C) and hypothermic (26 - 28°C) CPB. The results are 
difficult to interpret due to the range of temperatures that CPB can be carried out at. Hypothermic 
CPB may provide better neuroprotection 656,657 but otherwise overall, the temperature at which 
CPB is carried out seems to make little difference 658-661, as hypothermic CPB delays but does not 
completely prevent neutrophil activation 662-664,
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A study to discern which C components are responsible for mediating damage following l/R injury in the 
kidney, a side effect of CPB, was carried out in mice deficient in C3, C4, C5 or C6. All of the mice, 
apart from the C4-deficient mice, were protected, suggesting that C activation occurred via the 
alternative pathway and that the damage was mediated mainly by MAC formation. Inhibition of C5a 
activity in the C6-deficient mice did not provide them with further protection against l/R injury, 
confirming that the harmful aspects of C in this model were mainly due to C5b-9 production513. These 
data give strong justification for the development of an agent that specifically inhibits C5b-9 formation 
that could be used therapeutically in CPB.
The aims of this chapter were first to develop and characterise an ex vivo model of CPB based upon 
published methods 665>666 and second, to test the therapeutic potential of two of the inhibitory anti-C6 
antibodies, 23D1 and 27B1 in this ex vivo model of CPB.
6.2. Specific methods and protocols
6.2.1. Ex vivo model of Cardiopulmonary Bypass (CPB)
An ex vivo model of CPB was set up based on published methods 665-666 to investigate the 
potential of anti-C6 blocking antibodies to inhibit C activation in a therapeutic setting. In the 
published methods, low density polyethylene tubing (I.D. 1.6 mm, O.D. 3.2 mm, Nalgene) was 
used. In this study, for comparative purposes and to add further clinical relevance, Tygon® S-50- 
HL hospital and surgical tubing (I.D. 3.2 mm, O.D. 4.8 mm) was also used. This medical grade 
tubing is used in CPB.
6.2.1.1. Collection of human blood and serum preparation
Blood was collected from volunteers by an appropriately qualified person and allowed to 
coagulate in a glass collection tube at room temperature for 30 minutes. The clotted blood was 
centrifuged at 2000 rpm for 10 minutes. The serum fraction was removed and used immediately.
Serum was used rather than plasma as C activation occurs more readily in serum.
6.2.1.2. Tubing loop model
Human serum (3 ml) was placed in tubing (length 74 cm -  to fit around the rotor). The two ends 
of the tubing length were joined together to make a continuous and enclosed loop using an 
additional piece of tubing. An air space was left in the tubing loop giving a gas volume of 2.23 ml 
air. The tubing loop was then attached to the rotor with tape and placed in an incubator pre­
warmed to 37’C. The rotor was switched on and left to rotate the tubing at 60 rpm for 120 
minutes. A schematic diagram is shown in Figure 6.2. After incubation, the tubing loops were
Figure 6.2 The ex vivo model of cardiopulmonary bypass (CPB)
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A diagram of the ex vivo cardiopulmonary bypass model. Tubing (polyethylene or Tygon™) was 
filled with 3 ml of serum, closed into a circuit and attached to a rotor. The tubing loop was rotated 
for 2 hours in a 37°C incubator at 60 rpm.
122
removed, opened and the serum samples poured into 5 ml tubes containing 0.2 M EDTA, giving a 
final concentration of 10 mM EDTA. A 0 minute sample was passed through the tube briefly and 
added to EDTA. The samples were stored at -70°C until analysis for the formation of soluble 
C5b-9 by ELISA. To test the inhibitory activity of the antibodies, these were added to the serum 
at a range of concentrations prior to being placed in the tubing and then treated in the same way 
as normal serum.
6.2.2. Soluble C5b-9 ELISA
The commercial ELISA kit for measuring sC5b-9 (Quidel, California, USA; Catalogue number 
A009) was used according to the manufacturer’s instructions. Microassay strips were selected, 
determined by the number of blanks, standards and samples to be tested, and rehydrated by 
adding 300 pi wash buffer (0.05% Tween-20™, PBS, 0.01% Thimerosal) to each well, incubating 
for 2 minutes at room temperature and removing the liquid from each well. The microassay strips 
were supplied coated with a mouse monoclonal antibody specific for human sC5b-9. One 
hundred microlitres of blank, standard, control or sample diluted to the manufacturer’s 
recommended dilution in specimen diluent (0.05% Tween-20 ™, Protein Stabilizers, PBS, 0.01% 
Thimerosal) were added to assigned microassay wells and incubated for 1 hour at room 
temperature. The wells were washed by adding 300 pi wash buffer to each well, incubated for 1 
minute at room temperature and the liquid from each well removed. These steps were carried out 
a further four times, so that the wells were washed a total of five times. Fifty microlitres of sC5b-9 
conjugate (HRPO-conjugated goat antibodies to antigens of sC5b-9) was added to each well and 
incubated for 1 hour at room temperature. The microassay strips were washed five times as 
described above and 100 pi prepared substrate solution (0.7% 2-2’-Azino-di-(3- 
ethylbenzthiazoline sulfonic acid) diammonium salt, diluted in 0.1 M citrate buffer and 0.05% H2O2 
added immediately prior to use) was added to each well and incubated at room temperature for 
30 minutes. Fifty microlitres of stop solution was then added to each well and the absorbance 
read at 415 nm. The standard curve was plotted and the concentration of sC5b-9 in the samples 
calculated.
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6.3. Results
6.3.1. The ex vivo model of CPB
Soluble C5b-9 formation occurred in serum after incubation for 2 hours in either the Tygon™ or 
polyethylene tubing in the CPB ex vivo model in comparison to 0 hours incubation in tubing 
(Figure 6.3). After 2 hours in the medical grade Tygon™ tubing in the CPB model, C activation in 
the serum had occurred, causing an increase from 254 ng/ml SC5b-9 before incubation, to 2012 
ng/ml, which is a 7.92 fold increase. After being passed through the polyethylene tubing, the 
concentration of SC5b-9 in the serum was 345.2 ng/ml. After 2 hours in the CPB model, this had 
risen to 9443.5 ng/ml, which is a 27.36 fold increase in SC5b-9. In all of these conditions, results 
are means of duplicate measurements in the assay from single loops for each point. The 
physiological concentration of SC5b-9 in normal human serum is typically 100 -  250 ng/ml667.
6.3.2. Characterisation of the ex vivo CPB model with the C inhibitor, soluble CR1 (sCR1)
Soluble CR1 (sCR1) (described in section 1.9.6.1.) inhibits the formation of the C3 and C5 
convertases, ultimately preventing SC5b-9 formation 372-373. In order to gain information about the 
degree of inhibition of SC5b-9 formation that could be expected to occur in this model, escalating 
doses of sCR1 (1,2 and 5 pig/ml) were added to the serum being placed in the tubing at the start 
of the experiment.
The samples collected from the polyethylene or Tygon™ tubing were assayed for SC5b-9 (Figure 
6.4). In the polyethylene tubing, there was a baseline reading of 8748.6 ng/ml SC5b-9 when no 
sCR1 was added. The baseline reading of SC5b-9 in the Tygon™ tubing in the absence of sCR1 
was 4697.0 ng/ml. The addition of sCR1 at a dose of 1 pg/ml had no effect on the concentration 
of SC5b-9 in the polyethylene or Tygon™ tubing loops (SC5b-9 concentration was 9574.3 ng/ml 
and 4540.0 ng/ml, respectively). When sCR1 was added at a dose of 2 pg/ml, SC5b-9 formation 
was inhibited in the polyethylene and Tygon™ tubing by approximately 50% (4341.8 ng/ml and 
2362.9 ng/ml sC5b-9 respectively) in comparison to control. In the presence of 5 pg/ml sCR1, 
SC5b-9 formation was inhibited in both types of loop by approximately 50% (4480 ng/ml and 
1768.6 ng/ml SC5b-9 respectively) in comparison to control. For all of these conditions, results 
are the means of duplicate measurements in the assay from single loops for each data point.
Figure 6.3 Characterising an ex vivo model of CPB
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To determine whether medical grade Tygon™ tubing or polyethylene (PE) tubing could cause C 
activation 3 ml freshly prepared serum was placed in either tubing being tested; this was closed up 
and attached to a rotating device that rotated at 60 rpm and incubated at 37°C for 2 hours. At the 
end of this time, the tubing was removed, opened up and the serum drained out. To stop any 
further C activation, EDTA was added, making a final concentration of 10 mM and stored at -70°C 
until testing. For the 0 hours timepoint, fresh serum was passed through tubing and quenched and 
frozen as described. Soluble C5b-9 formation was measured by commercial ELISA and the 
measurements are presented graphically here. For experimental conditions, results are means of 
duplicate measurements in the assay from single loops for each data point. Error bars are standard 
deviation of the mean.
Figure 6.4 Inhibition of sC5b-9 formation by sCR1
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To determine whether the C inhibitor sCR1 inhibited C activation in this ex vivo model of CPB, 
escalating doses of sCR1 (1,2 and 5 (jg/ml) were added to freshly prepared serum and placed in 
either Tygon™ or polyethylene (PE) tubing. The tubing was closed up by joining them together 
and then attached to the rotating device for 2 hours at 37°C. The serum was removed and any 
potential C activation prevented by the addition of 10 mM EDTA (final concentration) and stored at 
-70°C until the concentration of sC5b-9 was assayed. As a control, serum without sCR1 added 
was also included in the experiment. Soluble C5b-9 formation was measured by ELISA and the 
measurements are shown on the graph above. For experimental conditions results are means of 
duplicate measurements in the assay from single loops for each data point. Error bars are 
standard deviation of the mean.
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6.3.3. Testing the activities of the anti-C6 antibodies 7A2,27B1 and 23D1 in the CPB 
model
The therapeutic potential of the two inhibitory anti-C6 antibodies 27B1 and 23D1 were tested in 
Tygon™ tubing at three doses over the concentration range (1 -  25 pg/ml). As a means of 
comparison, the same experiment was carried out in parallel using the non-inhibitory anti-C6 
antibody 7A2. Each dose of antibody was added to the serum samples immediately prior to 
being placed into the tubing. The samples were assayed for SC5b-9 after the end of the 
experiment (Figure 6.5). There are two findings: firstly, that for each of the three antibodies, as 
the amount of antibody added was increased, the apparent amount of SC5b-9 measured at the 
end of the experiment increased in a dose-dependent manner. Secondly, the amount of SC5b-9 
detected seemed to be dependent on the amount of antibody added, not on the antibody clone. 
For example, when no antibody was present, there was 5588.6 ng/ml SC5b-9 after 2 hours. After 
2 hours incubation in the presence of 1 pg/ml of either mAb 23D1 or 7A2, the amount of SC5b-9 
detected was approximately 5550 ng/ml, whilst 12331.4 ng/ml SC5b-9 was detected in serum to 
which 1 pg/ml mAb 27B1 had been added. After 2 hours incubation with 10 pg/ml of mAb 23D1, 
27B1 or 7A2, the amount of SC5b-9 detected was approximately 12200 ng/ml. Similarly, when 
25 ng/ml of any of the three mAbs was added, approximately 13700 ng/ml SC5b-9 was 
measured.
6.3.4. Investigations to determine whether the anti-C6 antibodies 7A2,27B1 and 23D1 
were interfering in the SC5b-9 ELISA
The preliminary data in section 6.3.3. were suggestive of the mAbs 7A2,27B1 and 23D1 
interfering in the SC5b-9 ELISA because the amount of SC5b-9 measured seemed to be 
dependent on the amount of mAb the serum was incubated with. These mAb preparations also 
contained bovine Ig (section 4.3.8.) as a result of the way in which they had been prepared. To 
test whether bovine Ig might be the agent interfering in the ELISA, as opposed to the mAbs 
themselves, mouse Ig prepared from mouse serum and two different preparations of a purified 
mAb clone TLD1C11, which was raised against an irrelevant rat antigen: one of which was pure; 
the other containing bovine Ig were added to freshly prepared serum. The mAb TLD1C11 has 
the same isotype as mAbs 7A2,23D1 and 27B1 and is not raised against C6. The mAbs 7A2, 
23D1 and 27B1 were also included in the experiment to determine whether they themselves were 
interfering in the SC5b-9 ELISA. Several concentrations of each antibody were added to the 
serum (1 -  25 pg/ml) in triplicate. Soluble C5b-9 in each sample was immediately measured.
Figure 6.5 Assessment of the inhibitory properties of antibody 
clones 27B1 and 23D1
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To investigate the C blocking properties of the inhibitory anti-C6 antibodies 23D1 and 27B1 in the ex 
vivo CPB model, fresh serum, together with either mAb 23D1 or 27B1 over the concentration range 
1 -  25 fig/ml was placed in Tygon™ tubing. The ends of the tubing were closed and then each 
tubing loop was attached to the rotating device and rotated for 2 hours at 37°C. The serum was 
removed and further C activation prevented by the addition of 10 mM EDTA (final concentration) 
and stored at -70°C until the concentration of sC5b-9 was measured. The mAb clone 7A2 was 
included as an antigen specific isotype matched control which had had no inhibitory activity in 
previous tests. Serum without antibody present was also included in the experiment as a baseline 
measurement. Soluble C5b-9 formation was measured by ELISA and is shown on the graph above. 
Results are means of duplicate measurements in the assay from single loops for each point. The 
error bars are the standard deviation from the mean.
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The samples contained no detectable SC5b-9 above serum background. These data show firstly, 
that under these conditions, bovine Ig does not interfere with the SC5b-9 ELISA. Secondly, these 
results indicate that the mAbs were not directly interfering with the ELISA under these 
experimental conditions.
6.4 Discussion
This chapter describes the development of an ex vivo model of CPB in two types of tubing. This 
model was initially characterised in terms of C activation leading to SC5b-9 formation. The ex 
vivo model of CPB was further characterised to define whether SC5b-9 formation could be 
inhibited and if so, the degree of inhibition that could be achieved, using the C inhibitor sCR1. 
After this, the ability of the two anti-C6 inhibitory mAbs, clones 27B1 and 23D1 to inhibit SC5b-9 
formation in this model was tested.
The two types of tubing used in this ex vivo model of CPB were polyethylene tubing and clinical 
grade Tygon™. Soluble C5b-9 formation occurred in both types of tubing, but this was 
approximately 3.5 times greater in the polyethylene tubing, confirming that some surfaces have 
greater C activating properties than others.
The C inhibitor sCR1 was tested in the CPB model over a range of doses ( 1 -5  pg/ml) to 
determine the extent of inhibition of SC5b-9 formation that could be achieved. Soluble C5b-9 
formation was inhibited in both types of tubing by approximately 50% when 5 pg/ml sCR1 was 
added to serum. In retrospect, it would have been interesting to use a wider range of doses of 
sCR1 to fully inhibit SC5b-9 formation. Other groups have carried out in vivo in studies of CPB 
using sCR1. Soluble CR1 (TP10™, AVANT Immunotherapeutics, Needham, Massachusetts, 
USA) was administered to pigs (10 mg/kg i.v., which is equivalent to 100 -  200 pg/ml in plasma) 
undergoing CPB. At this dose, SC5b-9 formation was almost completely inhibited in comparison 
to the control group receiving no sCR1 668. Nevertheless, the ex vivo model of CPB set up in this 
chapter is sufficient to demonstrate the activity of a C inhibitor in a highly sensitive manner.
The C6 inhibitory antibodies 27B1 and 23D1 were tested in this CPB model and compared with 
the non-inhibitory anti-C6 isotype-matched mAb, 7A2. Surprisingly, the amount of SC5b-9 
measured by ELISA did not decrease in response to any of the doses used. In fact, the higher 
the dose of antibody added the more sC5b-9 was detected. The amount of SC5b-9 detected in 
serum after being incubated with 10 pg/ml mAb for example, was very similar, irrespective of 
which clone had been used. This observation broadly applied to the three concentrations of mAb 
tested. However, mAbs 23D1 and 27B1 inhibited C-mediated haemolysis (Section 4.3.4.), a cell
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based assay which measures MAC formation. Therefore, these data were suggestive that the 
mAbs might be interfering in the ELISA. All of the mAbs had been prepared in house and had 
been co-purified with bovine Ig (section 4.3.8.). To investigate if the bovine Ig and the mAbs 
themselves were interfering in the SC5b-9 ELISA, these mAbs, along with preparations of an 
irrelevant isotype matched mAb, clone TLD1C11, lacking or containing bovine Ig were added to 
freshly prepared serum and SC5b-9 measured in each sample immediately by ELISA. Soluble 
C5b-9 was barely detectable in any of the samples, demonstrating that neither the bovine Ig nor 
mAbs were directly interfering in the SC5b-9 ELISA. Therefore, the observed increases in the 
amount of SC5b-9 in the CPB model in the presence of the anti-C6 mAbs must either have been 
due to the presence of antibody or a phenomenon specific to these anti-C6 antibodies. One way 
of determining this would be to incubate serum in the CPB model with pure TLD1C11 and 
TLD1C11 containing bovine Ig and mouse Ig for 2 hours and measure SC5b-9. If the amount of 
SC5b-9 measured did not increase, then this would show that the observed increase in SC5b-9 in 
the presence of the mAbs 23D1,27B1 and 7A2 were due specifically to these anti-C6 antibodies. 
This would indicate that these mAbs do not inhibit the fluid-phase generation of SC5b-9 and may 
even enhance its generation by cross-linking the complexes and causing C activation via the 
classical pathway, as opposed to the haemoiytic assays used to establish the inhibitory activity of 
mAbs 23D1 and 27B1 which are a measure of MAC formation on the erythrocyte cell surface. 
This may suggest that mAbs 23D1 and 27B1 are inhibiting C6 by interfering with it embedding in 
the cell surface during MAC formation.
If the amount of SC5b-9 measured in serum did increase after incubation with irrelevant 
antibodies in the CPB model, this would suggest that the presence of antibodies is causing C 
activation via the classical pathway, resulting in increased levels of SC5b-9 formation. There are 
two ways around this problem: one is to make F(ab’)2  fragments of mAbs 23D1 and 27B1, so that 
they cannot activate the classical pathway; the other is to make scFv versions of these 
antibodies, which would also have less C activating properties than the parent molecules. 
Currently, there are two examples in the literature of inhibitory antibodies raised against C 
components being tested either in vivo or in an ex vivo model of CPB for their ability to block 
sC5b-9 formation. These are Pexelizumab™ (section 1.9.8.), the humanised scFV anti-C5 
antibody470, and F(ab’)2  fragments of an anti-properdin blocking mAb669. Both of these agents 
inhibited SC5b-9 formation in a dose-dependent manner. However, neither of them were tested 
as intact Ig molecules either in an ex vivo model of CPB or in vivo.
To summarise, an ex vivo model of CPB has been set up and C activation took place, because 
SC5b-9 formation occurred in the presence of serum in the Tygon™ and polyethylene tubing
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used. The C inhibitor, sCR1 inhibited SC5b-9 formation in this model in a dose-dependent 
manner in both types of tubing, by up to approximately 50% at the maximal dose of sCR1 added 
(5 pg/ml). This was an important experiment that helped characterise this model in terms of the 
degree of inhibition of SC5b-9 formation that could be achieved with a previously defined C 
inhibitor 372,373. The inhibitory anti-C6 mAbs 27B1 and 23D1 were tested for their ability to inhibit 
SC5b-9 in this model, along with the non-inhibitory anti-C6 mAb 7A2 as an isotype control. The 
incubation of the mAbs with serum resulted in an increase in SC5b-9 measured and this was 
dose dependent. Given the C6 inhibitory properties of the mAbs, these results were suggestive 
of some kind of assay interference. However, experiments designed to investigate this 
demonstrated that the mAb preparations were not interfering in the SC5b-9 ELISA. Nonetheless, 
this ex vivo CPB model will be useful as a preliminary tool in assessing the activities of C 
inhibitors of the human alternative and terminal C pathways before testing them in animal models 
of disease.
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Chapter 7: General Discussion
7.1. Overview
The MAC is implicated in mediating the development of pathology in several autoimmune 
diseases such as rheumatoid arthritis and multiple sclerosis as well as due to clinical 
interventions, such as cardiopulmonary bypass (CPB). Currently, there are no drugs available 
that specifically inhibit MAC assembly. The advantage of blocking MAC formation as opposed to 
inhibiting the C cascade earlier on in the pathway is that there are many beneficial effects of C in 
the activation pathways, including the clearance of immune complexes and the chemattraction of 
neutrophils to areas of inflammation, ensuring that patients are not left vulnerable to infections. 
C6, a component of the MAC represents an ideal target for inhibition as it occurs early on in the 
terminal pathway and the complex it forms with C5b is not known to induce signalling cascades 
within cells or have any other effects outside the terminal pathway. Fortuitously, C6 deficient 
mice, rats and rabbits were available in house. The work described in this thesis sought to 
develop and characterise a panel of reagents that block C6 activity, with the ultimate aim of 
investigating their therapeutic potential in animal models of MAC mediated disease. To maximise 
the possibility of generating the greatest number of inhibitors, two approaches were used; one 
was to raise antibodies against C6 and the other was to pan a library of phage expressing 
peptides on their surface against C6.
Prior to the commencement of this project, attempts at making C inhibitory therapeutics had 
targeted the activating pathways and utilised recombinant technology to make soluble forms of 
membrane-associated C regulators. As a result of the successes achieved with these 
methodologies, similar approaches have been applied to making terminal pathway inhibitors. 
Soluble recombinant forms of the GPI-anchored membrane inhibitor, CD59 were made (sCD59) 
with a view to developing them as potential therapeutics 385,670,67^  but were poor inhibitors of 
MAC formation when tested in vitro and in vivo 385*672. To generate more active forms of sCD59, 
investigators have used a variety of techniques, including making chimeras, fusion proteins and 
attaching membrane-associating tags 4oo.404.673_ These measures improved the activity of the 
sCD59 in vitro in haemolytic assays. In vivo, attachment of a membrane-associating targeting 
moiety to soluble rat CD59 suppressed the development of disease in a rat model of rheumatoid 
arthritis. None of these agents have yet successfully been developed further for clinical use. 
Phage display is a young field and far fewer peptide inhibitors identified through this technique 
(excluding scFV) have been licensed for clinical use. With respect to C inhibitors, no peptides 
identified have been successfully developed for clinical use. Compstatin, which binds C3
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inhibiting its cleavage, is the most famous example of using phage display to develop a C 
inhibitor, but is limited in its applications and has not been developed as a therapeutic 361-363 
One of the advantages of phage display is that phage-peptides that bind to the protein of interest 
can be rapidly identified and sequenced. In this project, after three rounds of panning, the phage- 
peptides were selected for sequencing on the basis of their ability to inhibit C-mediated 
haemolysis, but the corresponding synthetic peptides lost that ability, even though they still 
recognised C6. This is suggestive of the observed inhibitory properties of the phage-peptides 
being due to steric hindrance or possibly an avidity effect. This loss of function is not uncommon 
^  but was a frustrating outcome and is a disadvantage of this type of approach to generating a 
peptide inhibitor. For this reason, this technique was probably not as good an approach to 
generating an inhibitor of C6 activity as making anti-C6 mAbs. There are many phage-peptide 
libraries commercially available and this is an important parameter that should be considered.
The main variations between different phage-peptide libraries are the lengths of the presented 
peptides and also whether these are constrained by disulphide bonds. The amino acids in 
constrained sequences show more stringent sequence specificity than linear peptides selected 
for binding to the same targets 570. Consequently, the library chosen for use in this study 
presented constrained peptides seven amino acids long. It may have been better to use a library 
displaying longer constrained peptides, or several libraries for comparison. In other studies in 
which inhibitory peptides of C components have been identified, the libraries used have displayed 
much longer peptide sequences than the 7-mer sequences used in this work 359-361. The greater 
success might be due to the longer length of the peptide, as it is likely that for the peptide to bind, 
more of the residues interact with the target protein to allow binding to occur during panning. For 
this reason, such a peptide would likely have a greater affinity for the protein it was panned 
against than a shorter peptide.
A positive outcome from using this technique was that three amino acid motifs were identified 
within the C6 binding peptides that were found to share homology with regions of C5 and C7. Of 
particular interest were two motifs identified from different peptides that matched residues close 
together in the C5b sequence. Therefore phage display might provide an opportunity to study the 
interactions of the molecular domains of C5b and C6 with each other in detail, as C5b6 complex 
formation happens so fast that it isn’t possible to study this in real time. If a particular sequence 
was found to bind to C6, this could in principal be made into an Fc fusion protein or attached to 
some other targeting molecule and tested for its ability to inhibit C6 activity. Mutation studies of 
the C6-binding peptide could be performed to determine sequences with a higher binding affinity.
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Potentially, this could lead to the development of an efficient inhibitor of C6 suitable for clinical 
use.
An alternative to modifying C regulatory proteins was to generate monoclonal and scFv 
antibodies against the C protein of interest. Monoclonal and scFV antibodies are highly specific 
and tend to have a far higher affinity for the protein they recognise than peptides or other 
molecules. They are also retained in the circulation for some time, minimising the dose required 
for therapeutic benefit. Such reagents already have a proven track record in the treatment of 
various conditions, including cancer w8-444*445-447-449, and rheumatoid arthritis 674.675 a  precedent 
for inhibiting the C system has been set with the anti-C5 mAb Eculizumab™ approved to treat 
PNH 472.676 and its scFv analogue, Pexelizumab™ approved for use during CPB to inhibit 
systemic C activation and to treat myocardial infarction Both agents inhibit C-mediated
haemolysis and C5a generation, but they are not terminal pathway specific and the loss of C5a 
with consequent inhibition of the beneficial chemattraction of neutrophils to the area of 
inflammation may have a deleterious effect on the patient’s health.
Given the success of the mAbs developed for clinical use, raising mAbs against C6 was a logical 
approach to developing an agent that inhibited MAC formation. More than twenty different mAbs 
were raised against rat, mouse or human C6, and they all recognised human C6. Many also 
inhibited C-mediated haemolysis in the presence of human serum. All of the mAbs raised against 
rat or mouse C6 had IgM isotypes, an efficient C activating isotype and were therefore not further 
investigated30-31. Nevertheless, these mAbs are potentially useful as they were raised against 
and recognise mouse C6 and there are no commercially available anti-mouse C6 mAbs at 
present. Some, for example, might be suitable for use in immunocytochemistry for following the 
deposition of C6 in the MAC in histological specimens and would enable the assessment of MAC 
deposition in tissues in disease models in mice such as EAE. The fact that all of the mAbs raised 
against rat and mouse C6 had an IgM isotype was suggestive of the antigen challenge not being 
great enough to induce class switching in the B cells to secreting an IgG isotype antibody s31-532. 
There are two ways of increasing the chances of this happening: one would have been to 
immunise the mice and rats with C6-enriched sera; the other to immunise with purified mouse 
and rat C6 respectively. It would have been relatively straightforward to enrich mouse and rat 
sera by performing PEG cuts and with hindsight, this simple approach would likely have been 
advantageous. To purify C6 from mouse and rat serum, classical methods would have needed to 
be used, as no anti-mouse C6 or anti-rat C6 antibodies were available at the start of this project 
for affinity purification. Classical purification methods were initially used to purify human C6 in
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this study, but proved inefficient and time consuming. At least 100 ml serum as starting material 
would have been required to purify rat or mouse C6 and it would have been practical to collect 
this volume of rat serum. This would not have been so for mouse serum, as in excess of 200 
mice would have had to be sacrificed to obtain this volume. Many anti-human C6 mAbs were 
made during the course of this study and as a consequence, some were used to affinity purify 
human C6. The yield and functional activity of the purified protein was much greater than using 
classical methods, because there were fewer steps making it much faster, so that C6 was less 
likely to be lost between steps and this also made the protein less prone to degradation. As a 
result of the work carried out during this project, anti-rat C6 and anti-mouse C6 mAbs are now 
available, making it possible to affinity purify rat and mouse C6 from small volumes of serum in 
the future.
The affinity purified human C6 was also used to determine its functional cross-species activity by 
being added to haemolytic assays using genetically C6-deficient rat, mouse and rabbit serum. 
These results clearly demonstrated that C6 is functionally conserved between these species, 
underlining the evolutionary importance of C proteins. Human C6 is a larger protein than rat or 
mouse C6, which share an 82% and 75% sequence homology with human C6 respectively 485-504. 
Even so, it was surprising that the anti-human C6 mAbs, clones 23D1,27B1 and 7A2 did not 
recognise other species C6, considering that they had been isolated from C6 deficient mice. It 
had originally been decided to immunise C6 deficient mice with normal mouse or purified human 
C6 to maximise the possibility of generating cross-species reactive mAbs. It is perhaps less 
unexpected that the inhibitory anti-human C6 mAbs, 23D1 and 27B1 do not recognise other 
species C6, as human C6 is a larger molecule than mouse and rat C6 because it contains two 
FIMS domains which enhance, but are not critical for its activity. An alternative approach to 
generating cross-species reactive anti-C6 mAbs with an IgG isotype would have been to be make 
recombinant proteins based upon regions of sequence similarity of C6 common to human, mouse 
and rat C6 and immunise mice and rats with these.
The species specificity of mAbs 23D1 and 27B1 for human C6 meant that it was not possible to 
test their inhibitory activity in vivo in animal models of C-mediated disease as had initially been 
anticipated. However, I wanted to test their therapeutic potential in a setting resembling a more 
clinical application than in vitro haemolytic assays. The activities of other C inhibitors have 
previously been investigated in ex vivo models of cardiopulmonary bypass (CBP) during which a 
complex inflammatory response is induced, including systemic C activation. The formation of 
C5b-9 is upregulated 267>270 mediating damage by causing cell lysis and can ultimately lead to 
multiple organ failure. For these reasons, an ex vivo model of CPB was established to test the
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inhibitory anti-C6 mAbs. The model was initially characterised by determining that more soluble 
SC5b-9 was present in human serum after 2 hours circulation in comparison to serum not 
circulated in the model. The amount of sC5b-9 detected was also dependent on the type of 
tubing used. To demonstrate SC5b-9 formation could be inhibited, the inhibitor soluble (s)CR1 
was added at various doses. The amount of SC5b-9 detected decreased dose-dependently to 
approximately 50% of that in the absence of sCR1 as the concentration of sCR1 added 
increased.
The abilities of mAbs 23D1 and 27B1 to inhibit MAC formation, together with a relevant isotype- 
matched control, were tested in the CPB model over a range of concentrations. Unexpectedly, 
for all of the mAbs, at each concentration of mAb incubated in the CPB model the concentration 
of SC5b-9 measured increased. In addition, the concentration of SC5b-9 measured in response 
to the same dose of different mAb was very similar, suggesting that the antibodies were 
interfering with the method used to measure SC5b-9; ELISA. This hypothesis was investigated 
and demonstrated that the mAbs were not directly interfering with the SC5b-9 ELISA. Therefore 
a logical interpretation of this data, in conjunction with the haemolytic assay data, is that mAbs 
23D1 and 27B1 do not inhibit sC5b-9 formation in the fluid phase, but they do inhibit MAC 
formation at the cell surface, raising important implications for their mechanism of inhibition of C6 
activity. These findings suggest that when either of these two mAbs bind to C6 they are not 
blocking its ability to bind to C5b to form the C5b6 complex; neither are they blocking the ability of 
C7 to bind to C5b6, but they are blocking the ability of this complex to insert into the cell 
membrane. The ex vivo CPB model happened to be very informative about the inhibitory action 
of mAbs 23D1 and 27B1, but as a model to test the therapeutic potential of agents, is probably 
more suited to testing the activity of fluid phase C inhibitors. These results also highlight the 
functional differences between cell-based assays and fluid-phase assays and the importance of 
carefully choosing a model to test an agent for the purpose it was intended. For example, the aim 
of this PhD was to generate inhibitors of C6 to block MAC formation in the cell membrane in order 
to prevent or stop the development of pathology in disease. It was of secondary consequence to 
inhibit sC5b-9 formation.
7.2. Future Directions
As a result of this work, many anti-C6 antibody secreting hybridoma cell lines have been created. 
Many had an IgM isotype, which meant that they were not further investigated, even though they 
functionally inhibited C6 activity. However, there are ways that these mAbs could be developed
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further and investigated for their therapeutic potential; either by inducing ‘class switching' so that 
they secrete mAbs with an IgG isotype, or by cloning the variable regions of the mAbs and 
ligating them to plasmids coding the Fc region of an IgG antibody to make a fusion protein. These 
would be interesting areas of research to pursue. Both of these approaches would also 
determine whether the observed inhibition of the intact antibody was due to a specific interaction 
with C6 at a region crucial for its activity, or whether this was due to steric hindrance. The 
advantage of developing these antibodies further is that they should recognise both mouse and 
human C6, so that their therapeutic potential can be tested in well-established animal models of 
MAC mediated disease.
Apart from generating mAbs and peptides that inhibit C6 activity an alternative approach would 
be to modifiy C inhibitory proteins made by infectious organisms. For example, bacteria and 
other parasitic organisms have evolved various strategies to evade the host immune system. 
These include making proteins that inhibit the activity of C components. The Schistosoma 
parasite makes at least two C inhibitory proteins during its lifecycle -  one, complement C2 
receptor inhibitor trispanning (CRIT) protein binds to C2 preventing it binding to C4b677-678. The 
other, schistosome C inhibitory protein type 1 (SCIP-1), is an analogue of CD59 and binds to C8 
and C9679. Apart from the specific targets that these proteins have evolved to inhibit, what is 
interesting about them is their sequence similarity with the host proteins they are mimicking. The 
region of CRIT that binds to C2 is homologous with a region within C4b 68°, likewise, SCIP-1 is 
recognised by anti-human CD59 antibodies. These proteins yield important information about the 
regions of C2 and CD59 that interact with C4b and C8 and C9 respectively and represent an 
opportunity for the development of C-blocking therapeutics, specific against these regions. CRIT 
is currently being investigated for this purpose681. Similarly, there is also a bacterial protein that 
binds C6 and C7, made by some virulent strains of Streptococcus pyogenes called streptococcal 
inhibitor of complement (SIC) 682. SIC inhibits C-mediated haemolysis, acting before the 
incorporation of fluid phase C5b-7 into cell membranes 683. As the sequence of SIC has been 
determined 682, it would be possible to make recombinant truncated forms of it, determine the 
region of the protein that inhibits C-mediated haemolysis and use this as a basis for developing 
inhibitory peptides of sC5b-9 formation. It is likely that such studies would also yield important 
information about the regions of C6 that are important for its activity in forming MAC.
The two most promising C6 inhibitors, mAbs 23D1 and 27B1 were not tested in animal models of 
disease in which the MAC is implicated in playing a role, because they did not recognise other 
species C6. However, it may be possible to test these mAbs in an animal model of disease 
mediated by the MAC in C6 deficient animals reconstituted with human C6. A study investigating
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the contribution of the MAC to disease progression in animal models of multiple sclerosis using 
normal and C6 deficient rats showed that the MAC formation mediates much of the pathology498. 
Upon reconstitution of the deficiency with human C6, the observed clinical disease and pathology 
in the C6 deficient rats became indistinguishable from that of the normal rats. This represents an 
opportunity to test the therapeutic potential of mAbs 23D1 and 27B1 to inhibit C6 activity. 
Following induction of disease in C6 deficient rats, when reconstituting the deficiency with human 
C6, the test mAb could be administered at the same time. If the rats did not develop disease or 
developed a milder pathology and disease than the relevant control groups, this would 
demonstrate the therapeutic potential of these mAbs as a proof of principle. Several disease 
models of multiple sclerosis and Guillan-Barre syndrome have been set up in house and C6 
deficient rats and mice are available in house to carry this out.
The field of developing C inhibitors as potential therapies is continuing to expand and as 
knowledge grows, our understanding of the essential properties of a good inhibitor is also 
furthered. Despite the advances that have been made here and elsewhere, there are still no 
inhibitors available that inhibit MAC formation for the therapy of human diseases. The work 
described in this thesis contributes towards the development of such an inhibitor, demonstrating 
that it is possible to specifically inhibit MAC formation and helping to elucidate the best 
approaches to take when initially generating inhibitors. It is also clear from this work that 
determining the co-associating molecular domains of C5b and C6 that interact with each other 
and the sequence of events that occur during C5b6 formation will be essential for developing a 
rational and targeted strategy for inhibiting MAC assembly.
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